

ESMO 20th World Congress on Gastrointestinal Cancer

Late-breaking Abstracts

LBA-001

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH)

A Zhu¹, R Finn², P Galle³, J Llovet⁴, J Blanc⁵, T Okusaka⁶, I Chau⁷, P Abada⁸, Y Hsu⁹, M Kudo¹⁰

¹Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA, Boston, Massachusetts, USA, ²University of California, Los Angeles Medical Center, Los Angeles, California, USA, ³University Medical Center Mainz, Mainz, Germany, ⁴Mount Sinai School of Medicine, New York, New York, USA, ⁵Hôpital Haut-Lévêque, Bordeaux, France, ⁶Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Japan, ⁷Royal Marsden Hospital, London and Surrey, UK, ⁸Eli Lilly and Company, Indianapolis, USA, ⁹Eli Lilly and Company, Bridgewater, New Jersey, USA, ¹⁰Kindai University School of Medicine, Osaka, Japan

LBA-002

Overall survival results from a Phase III trial of trifluridine/tipiracil vs. placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS)

J Tabernero¹, K Shitara², M Dvorkin³, W Mansoor⁴, H Arkenau⁵, A Prokharau⁶, M Alsina¹, M Ghidini⁷, C Faustino⁸, V Gorbunova⁹, E Zhavrid¹⁰, K Nishikawa¹¹, A Hosokawa¹², D Ganea¹³, ŞYalçın¹⁴, K Fujitani¹⁵, G Beretta¹⁶, R Winkler¹⁷, L Makris¹⁸, T Doi¹⁹, D Ilson²⁰

¹Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain, ²National Cancer Center Hospital East, Kashiwa-city, Japan, ³Omsk Regional Clinical Centre of Oncology, Omsk, Russian Federation, ⁴The Christie NHS Foundation Trust, Manchester, UK, ⁵Sarah Cannon Research Institute, HCA Healthcare, London, UK, ⁶Minsk City Clinical Oncology Dispensary, Minsk, Belarus, ⁷Azienda Ospedaliera di Cremona, Cremona, Italy, ⁸Instituto Português de Oncologia do Porto, Porto, Portugal, ⁹N.N.Blokhin Russian Cancer Research Center, Moscow, Russian Federation, ¹⁰Alexandrov National Cancer Centre of Belarus, Minsk, Belarus, ¹¹Osaka National Hospital, Osaka, Japan, ¹²University of Toyoma, Toyoma, Japan, ¹³Spitalul Judetean de Urgenta Sfântul Ioan cel Nou Suceava, Suceava, Romania, ¹⁴Hacettepe University, Ankara, Turkey, ¹⁵Osaka General Medical Center, Osaka, Japan, ¹⁶Humanitas Gavazzeni, Bergamo, Italy, ¹⁷Taiho Oncology, Inc., Princeton, New Jersey, USA, ¹⁸Stathmi Inc., New Hope, Pennsylvania, USA, ¹⁹National Cancer Center Hospital East, Kashiwa, Japan, ²⁰Memorial Sloan Kettering Cancer Center, New York, New York, USA

LBA-003 - Withdrawn

LBA-004

Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab plus cobimetinib and atezolizumab monotherapy vs. regorafenib in chemotherapy-refractory metastatic colorectal cancer

J Bendell¹, F Ciardiello², J Tabernero³, N Tebbutt⁴, C Eng⁵, M Di Bartolomeo⁶, A Falcone⁷, M Fakih⁸, M Kozloff⁹, N Segal¹⁰, A Sobrero¹¹, Y Shi¹², L Roberts¹², Y Yan¹², I Chang¹², A Uyei¹², T Kim¹³

¹Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee, USA,

²University of Campania, Naples, Italy, ³Vall d'Hebron University Hospital and Vall

d'Hebron Institute of Oncology, Barcelona, Spain, ⁴Olivia Newton-John Cancer &

Wellness Centre, Austin Health, Melbourne, Australia, ⁵The University of Texas MD

Anderson Cancer Center, Houston, Texas, USA, ⁶Department of Oncology, Fondazione

IRCCS Istituto Nazionale dei Tumori, Milan, Italy, ⁷Unit of Medical Oncology 2, Azienda

Ospedaliera-Universitaria Pisana, Department of Translational Research and New

Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy, ⁸City of Hope,

Duarte, California, USA, ⁹University of Chicago, Chicago, Illinois, USA, ¹⁰Memorial

Sloan Kettering Cancer Center, New York, New York, USA, ¹¹Medical Oncology Unit

IRCCS Ospedale San Martino IST, Genova, Italy, ¹²Genentech, Inc., South San Francisco,

California, USA, ¹³Asan Medical Center, Seoul, Republic of Korea

LBA-005

KEYNOTE-061: phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer

K Shitara¹, M Özgüroğlu², Y Bang³, M Di Bartolomeo⁴, M Mandalà⁵, M Ryu⁶, L Fornaro⁷, T Olesiński⁸, C Caglevic⁹, H Chung¹⁰, K Muro¹¹, E Gökkurt¹², W Mansoor¹³, R. McDermott¹⁴, E Schacham-Shmueli¹⁵, X Chen¹⁶, S Kang¹⁶, C Mayo¹⁶, A Ohtsu¹, C Fuchs¹⁷

¹National Cancer Center Hospital East, Kashiwa, Japan; ²Istanbul University, Cerrahpaşa

School of Medicine, Istanbul, Turkey; ³Seoul National University College of Medicine,

Seoul, South Korea; ⁴Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy;

⁵Papa Giovanni XXIII Hospital, Bergamo, Italy; ⁶Asan Medical Center, Seoul, South

Korea; ⁷Azienda Ospedaliera-Universitaria Pisana, Pisa, Italy; ⁸Maria Skłodowska-Curie

Memorial Cancer Center, Warsaw, Poland; ⁹Instituto Oncológico Fundación Arturo López

Pérez, Santiago, Chile; ¹⁰Yonsei Cancer Center, Yonsei University College of Medicine,

Seoul, South Korea; ¹¹Aichi Cancer Center Hospital, Nagoya, Japan; ¹²Hematology

Oncology Practice Eppendorf (HOPE), Hamburg, Germany; ¹³Christie Hospital NHS

Foundation Trust, Manchester, UK; ¹⁴Adelaide and Meath Hospital, Dublin, Ireland;

¹⁵Sheba Medical Center, Ramat Gan, Israel; ¹⁶Merck & Co., Inc., Kenilworth, New Jersey,

USA; ¹⁷Yale Cancer Center, New Haven, Connecticut, USA

Orals

O-001

Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors

F Meric-Bernstam¹, H Arkenau², B Tran³, R Bahleda⁴, R Kelley⁵, C Hierro⁶, D Ahn⁷, A Zhu⁸, M Javle⁹, R Winkler¹⁰, H He¹⁰, J Huang¹⁰, L Goyal¹¹

¹University of Texas MD Anderson Cancer Center, Houston, Texas, USA, ²Sarah Cannon Research Institute, HCA Healthcare, London, UK, ³Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia, ⁴Gustave Roussy Cancer Center, Villejuif, France, ⁵Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA, ⁶Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain, ⁷Mayo Clinic, Scottsdale, Arizona, USA, ⁸Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA, Boston, Massachusetts, USA, ⁹University of Texas, Anderson Cancer Center, Houston, Texas, USA, ¹⁰Taiho Oncology, Inc., Princeton, New Jersey, USA, ¹¹Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA

O-002

Geographic variation in systemic treatment of metastatic pancreatic adenocarcinoma (mPAC) patients in real world across Europe

J Taieb¹, A Carrato², àMellbring³, G Prager⁴, D Melisi⁵, B Westphalen⁶, T Macarulla Mercadé⁷, N D'Esquermes⁸, A Ferreras⁹, F de Jong¹⁰

¹Sorbonne Paris Cité, Paris Descartes University, Hôpital Europeen Georges Pompidou, Paris, France, ²IRYCIS, CIBERONC, Alcalá University, Hospital Universitario Ramón y Cajal, Madrid, Spain, ³Shire Sweden AB, Kista, Sweden, ⁴Clinical Division of Medical Oncology, Department of Medicine I, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria, ⁵Medical Oncology, University of Verona, Verona, Italy, ⁶Comprehensive Cancer Center München, Klinikum der Universität München, Munich, Germany, ⁷Vall d'Hebron University Hospital (HUVH) and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, ⁸Genactis, Chateaufort, France, ⁹Genactis, Antibes, France, ¹⁰Shire International GmbH, Glattbrunn, Switzerland

O-003

Gemcitabine with nab-paclitaxel in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): a quality of life randomized cross-over study (QOLINPAC)

G Chiritescu¹, K Dumon¹, C Verslype², H Prenen³, G Houbiers⁴, M Peeters⁵, J Janssens⁶, D Van Daele⁷, S Laurent⁸, J Arts⁹, K Hendrickx¹⁰, I Borbath¹¹, M Ferrante¹², F Bastin¹³, J Goeminne¹⁴, J Van Laethem¹⁵, E Vanderstraeten¹⁶, J Decaestecker¹⁷, W Van Vaerenbergh¹⁸, B Delhougne¹⁹, E Van Cutsem²⁰

¹University Hospitals Leuven, Leuven, Belgium, ²Division of Digestive Oncology, University Hospitals Leuven and Department of Oncology, Leuven, Belgium, ³University

Hospital Gasthuisberg, Leuven, Belgium, ⁴Clin Saint Joseph Liège Belgium, Liege, Belgium, ⁵Antwerp University Hospital, Edegem, Belgium, ⁶AZ Turnhout, Turnhout, Belgium, ⁷CHU Sart-Tilman Liege, Liege, Belgium, ⁸University Hospital Ghent, Gent, Belgium, ⁹A.Z. Sint Lucas Brugge, Brugge, Belgium, ¹⁰OLV Aalst, Aalst, Belgium, ¹¹Cliniques Universitaires Saint-Luc, Brussels, Belgium, ¹²A.Z. Sint Maarten Mechelen, Mechelen, Belgium, ¹³CHU Charleroi Belgium, Montigny-le-Tilleul, Belgium, ¹⁴Clinique Sainte Elisabeth Namur, Namur, Belgium, ¹⁵Hôpital Universitaire Erasme, Brussels, Belgium, ¹⁶A.Z. Maria Middelaes Gent, Gent, Belgium, ¹⁷AZ Delta Roeselare, Roeselare, Belgium, ¹⁸Heilig Hartziekenhuis Lier Belgium, Lier, Belgium, ¹⁹CHR Citadelle Belgium, Liege, Belgium, ²⁰University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium

O-004

Selected subgroup analyses of liposomal irinotecan (nal-IRI) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the global NAPOLI-1 phase III trial

T Macarulla Mercadé¹, K Lee², G Lakatos³, A Wang-Gillam⁴, L Chen⁵, B Mirakhur⁶, F de Jong⁷

¹Vall d'Hebron University Hospital (HUVH) and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, ²Seoul National University Hospital, Seoul, Republic of Korea, ³Department of Oncology, St. István and St. László Hospital, Budapest, Hungary, ⁴Washington University in St.Louis, St Louis, Missouri, USA, ⁵National Institute of Cancer Research, National Health Research Institutes, Miaoli, Republic of Taiwan, ⁶Ipsen Biopharmaceuticals, Inc., Basking Ridge, New Jersey, USA, ⁷Shire International GmbH, Glattpark-Opfikon, Switzerland

O-005

A multicentre, prospective clinical evaluation study for analyzing RAS mutational status utilizing plasma circulating tumor DNA in patients with metastatic colorectal cancer

Y Kagawa¹, T Kato², H Bando³, K Akagi⁴, T Denda⁵, T Nishina⁶, Y Komatsu⁷, E Oki⁸, T Kudo⁹, T Yamanaka¹⁰, T Yoshino¹¹

¹Department of Gastrointestinal Surgery, Kansai Rosai Hospital, Amagasaki, Japan, ²Department of Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan, ³Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan, ⁴Saitama Cancer Center, Kitaadachi-Gun, Japan, ⁵Chiba Cancer Center, Chiba, Japan, ⁶Shikoku Cancer Center, Matsuyama, Japan, ⁷Digestive Internal Medicine, Division of Cancer Center, Hokkaido University Hospital, Sapporo, Japan, ⁸Department of Surgery, Graduate School of Medical Sciences, Kyushu University, Higashi-ku, Japan, ⁹Osaka University Graduate School of Medicine, Suita, Japan, ¹⁰Yokohama City University School of Medicine, Yokohama, Japan, ¹¹National Cancer Center Hospital East, Kashiwa, Japan

O-006

Ultra-selection of metastatic colorectal cancer patients using next generation sequencing platform to improve clinical efficacy of anti-EGFR therapy

J Vidal¹, A Dalmases², C Santos Vivas³, R Garcia-Carbonero⁴, P García-Alfonso⁵, A Carrato⁶, E Elez⁷, M Ortiz⁸, F Losa⁹, B Massutí¹⁰, M Valladares-Ayerbes¹¹, J Manzano¹², J Vieitez de Prado¹³, J Gallego¹⁴, C Grávalos¹⁵, M Varela¹⁶, D Azuara¹⁷, J Tabernero¹⁸, R Salazar¹⁹, E Aranda²⁰, B Bellosillo²¹, C Montagut²²

¹Hospital del Mar, Barcelona, Spain, ²Molecular Biology Laboratory Hospital del Mar, Barcelona, Spain, ³Translational Research Laboratory and Department of Medical Oncology, Institut Català d'Oncologia-IDIBELL, L'Hospitalet de Llobregat, Spain, ⁴Hospital Universitario Virgen del Rocío, Sevilla, Spain, ⁵Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁶IRYCIS, CIBERONC, Alcalá University, Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁷Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, ⁸IMIBIC, Reina Sofía Hospital, University of Córdoba, CIBERONC, Instituto de Salud Carlos III, Córdoba, Spain, ⁹Hospital Sant Joan Despí - Moisès Broggi, Hospitalet de Llobregat, Spain, ¹⁰H. General Universitario de Alicante, Alicante, Spain, ¹¹Complejo Hospitalario Universitario La Coruña, La Coruña, Spain, ¹²H. Germans Trias i Pujol, Badalona, Spain, ¹³Asturias Central University Hospital, Oviedo, Spain, ¹⁴Hospital General Universitario de Elche, Elche, Spain, ¹⁵Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁶Pathological Anatomy Laboratory, Institut Català d'Oncologia, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain, ¹⁷Translational Research Laboratory, Institut Català d'Oncologia-IDIBELL, L'Hospitalet de Llobregat, Spain, ¹⁸Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain, ¹⁹Medical Oncology Department and IDIBELL, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Spain, ²⁰IMIBIC, Reina Sofía Hospital, University of Córdoba, CIBERONC, Instituto de Salud Carlos III, Córdoba, Spain, ²¹Department of Pathology, Hospital Universitari del Mar, Barcelona, Spain, ²²Department of Medical Oncology, Hospital Universitari del Mar, Barcelona, Spain

O-007

Liquid biopsy allows predicting benefit from rechallenge with cetuximab(cet)+irinotecan(iri) in RAS/BRAF wild-type mCRC patients(pts) with resistance to 1st-line cet+iri: Final results and translational analyses of the CRICKET study by GONO

D Rossini¹, C Cremolini¹, E Conca², M Del Re³, A Busico², F Pietrantonio⁴, F Bergamo⁵, R Danesi³, G Cardellino⁶, E Tamburini⁷, E Dell'Aquila⁸, A Strippoli⁹, G Masi¹, G Tonini⁸, F Negri¹⁰, D Corsi¹¹, N Pella⁶, R Intini¹², A Falcone¹³, D Santini⁸

¹Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy, ²Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, ³Clinical Pharmacology and Pharmacogenetics Unit, Department of Clinical and Experimental Medicine, Pisa, Italy, ⁴Department of Medical Oncology, IRCCS Fondazione Istituto Nazionale dei Tumori, Milan, Italy, ⁵Veneto Institute of Oncology IOV-IRCCS, Padua, Italy, ⁶Department of Oncology, Azienda Sanitaria Universitaria Integrata S. Maria della

Misericordia, Udine, Italy, ⁷Department of Medical Oncology, Infermi Hospital, Rimini, Italy, ⁸Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy, ⁹Unit of Clinical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy, ¹⁰Medical Oncology, University Hospital, Parma, Italy, ¹¹Medical Oncology Unit, Fatebenefratelli-Isola Tiberina Hospital, Rome, Italy, ¹²Medical Oncology Unit 1, Clinical and Experimental Oncology Department, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy, ¹³University of Pisa, Pisa, Italy

O-008

The prognostic role of microsatellite status, tumor mutational burden and protein expression in CRC

J Lam¹, Y Kim², F Cecchi³, S Woo³, A Chambers², I Tan¹, C Chua Wei Ling¹, K Si-Lin⁴, L Wei Qiang¹, T Lim Kiat Hon¹, S Anders Martin Jacobsen¹, T Hembrough⁵

¹National Cancer Centre Singapore, Singapore, ²NantOmics, Rockville, Maryland, USA, ³Nantomics, Rockville, Maryland, USA, ⁴National Cancer Centre Singapore, Singapore, ⁵NantOmics, Rockville, Maryland, USA

O-009

A Phase II multi institutional study of nivolumab in patients with advanced refractory biliary tract cancers (BTC)

R Kim¹, D Kim², O Alese³, D Li⁴, B El-Rayes⁵, N Shah¹, M Schell¹, J Zhou¹, V Chung⁴

¹Moffitt Cancer Center, Tampa, Florida, USA, ²Moffitt Cancer Center, Tampa, Florida, USA, ³Emory University, Atlanta, Georgia, USA, ⁴City of Hope, Duarte, California, USA, ⁵Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA

O-010

Cisplatin/5-fluorouracil +/- panitumumab for patients with non-resectable, advanced or metastatic esophageal squamous cell cancer: A randomized phase III AIO/EORTC trial with an extensive biomarker program

M Moehler¹, A Maderer², P Thuss-Patience³, B Brenner⁴, J Hecker⁵, F Longo Muñoz⁶, J Meiler⁷, T Ettrich⁸, R Hofheinz⁹, S Al-Batran¹⁰, A Vogel¹¹, L Mueller¹², M Lutz¹³, K Borchert¹⁴, R Greil¹⁵, M Alsina¹⁶, A Karatas¹⁷, E Van Cutsem¹⁸, R Keller¹⁷, J Larcher-Senn¹⁹, S Lorenzen⁵

¹Johannes-Gutenberg University Mainz, Mainz, Germany, ²University Medical Center Mainz, Berlin, Germany, ³Medizinische Klinik Hämatologie, Onkologie und Tumorimmunologie, Berlin, Germany, ⁴Rabin Medical Center – Tel Aviv University, Petah Tiqva, Israel, ⁵Klinikum rechts der Isar der TU München, Munich, Germany, ⁶Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁷Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany, ⁸Department of Internal Medicine I, University of Ulm, Ulm, Germany, ⁹University Hospital Mannheim, Mannheim, Germany, ¹⁰Krankenhaus Nordwest, Frankfurt, Germany, ¹¹Hannover Medical School, Hannover, Germany, ¹²Oncological Practice, Leer, Germany, ¹³EORTC, Saarbrücken, Germany, ¹⁴University Hospital Rostock, Rostock, Germany, ¹⁵III Medizinische Universitätsklinik Salzburg, Salzburg, Austria, ¹⁶Vall d'Hebron Institute of

Oncology, Barcelona, Spain, ¹⁷AIO-Studien-gmbH, Berlin, Germany, ¹⁸University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium, ¹⁹Assign Data Management and Biostatistics GmbH, Innsbruck, Austria

O-011

Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma (HCC)

P Merle¹, L Rimassa², B Ryoo³, I Cicin⁴, W Harris⁵, E Banu⁶, D Sarker⁷, B Tan⁸, H Van Vlierberghe⁹, S Sen¹⁰, C Love¹⁰, A Cheng¹¹, T Meyer¹², R Kelley¹³, G Abou-Alfa¹⁴

¹Hepatology Unit, Groupement Hospitalier Lyon Nord, Lyon, France, ²Humanitas Research Hospital – IRCCS, Rozzano, Italy, ³Asan Medical Center, Ulsan University College of Medicine, Seoul, Republic of Korea, ⁴Trakya University, Erdirne, Turkey, ⁵Department of Medicine, University of Washington, Seattle, Washington, USA, ⁶Medical Oncology Department, Teo Health SA, St. Constantin Hospital, Brasov, Romania, ⁷Department of Oncology, King's College Hospital, London, UK, ⁸Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA, ⁹Department of Gastroenterology and Hepatology, Ghent University Hospital, Gent, Belgium, ¹⁰Exelixis, Inc., San Francisco, California, USA, ¹¹Department of Oncology and Internal Medicine, National Taiwan University Hospital, Taipei, Republic of Taiwan, ¹²Royal Free Hospital, University College London, London, UK, ¹³Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA, ¹⁴Memorial Sloan Kettering Cancer Center, New York, New York, USA

O-012

Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer (mCRC) in routine clinical practice: Final analysis from the prospective, observational CORRELATE study

M Ducreux¹, L Petersen², L Öhler³, F Bergamo⁴, J Metges⁵, J de Groot⁶, J Wang⁷, B García Paredes⁸, N Kumar⁹, S Fiala-Buskies¹⁰, A Cervantes¹¹, J O'Connor¹², A Falcone¹³, on behalf of the CORRELATE Investigators¹⁴

¹Gustave Roussy Cancer Campus Grand Paris, Villejuif, France, ²Rigshospitalet, Copenhagen, Denmark, ³St. Josef Krankenhaus, Vienna, Austria, ⁴Veneto Institute of Oncology IOV-IRCCS, Padua, Italy, ⁵CHU de Brest – Hôpital Morvan, Brest, France, ⁶Isala, Zwolle, Netherlands, ⁷Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Republic of Taiwan, ⁸Hospital Clínico San Carlos, Madrid, Spain, ⁹Bayer HealthCare Pharmaceuticals, Whippany, New Jersey, USA, ¹⁰Bayer AG, Wuppertal, Germany, ¹¹University Hospital of Valencia, Valencia, Spain, ¹²Institute Alexander Fleming, Buenos Aires, Argentina, ¹³University of Pisa, Pisa, Italy, ¹⁴na, na, Alaska, USA

O-013

Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer (mCRC): Preliminary results from the phase IIIb, international, open-label, early-access PRECONNECT study

A Falcone¹, T André², J Edeline³, E François⁴, J Taieb⁵, J Phelip⁶, F Portales⁷, T Price⁸, M Becquart⁹, S Moreno Vera⁹, N Mounedji⁹, E Van Cutsem¹⁰, J Seitz¹¹

¹Unit of Medical Oncology 2, Azienda Ospedaliera-Universitaria Pisana, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy, ²Hôpital Saint Antoine, AP-HP, Paris, France, ³Centre Eugène Marquis, Rennes, France, ⁴Centre Antoine Lacassagne, Nice, France, ⁵Sorbonne Paris Cité, Paris Descartes University, Hôpital Europeen Georges Pompidou, Paris, France, ⁶CHU de St Etienne, St Etienne, France, ⁷Institut régional du Cancer, Montpellier, France, ⁸Queen Elizabeth Hospital and University of Adelaide, Woodville, Australia, ⁹Global Medical Affairs, Servier, Suresnes, Suresnes, France, ¹⁰University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium, ¹¹Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille, France

O-014

Regorafenib Dose Optimization Study (ReDOS): Randomized phase II trial to evaluate escalating dosing strategy and pre-emptive topical steroids for regorafenib in refractory metastatic colorectal cancer (mCRC) – An ACCRU Network study

T Bekaii-Saab¹, F Ou², D Anderson³, D Ahn⁴, P Boland⁵, K Ciombor⁶, N Jacobs⁷, R Desnoyers⁸, J Cleary⁹, J Meyers², E Chiorean¹⁰, K Pedersen¹¹, A Barzi¹², J Sloan¹³, J McCune¹⁴, M Lacouture¹⁵, H Lenz¹⁶, A Grothey¹¹

¹Mayo Clinic Cancer Center, Scottsdale, Arizona, USA, ²Mayo Clinic, Rochester, Minnesota, USA, ³Healthpartners Clinic, St Paul, Minnesota, USA, ⁴Mayo Clinic, Scottsdale, Arizona, USA, ⁵Roswell Park Cancer Institute, Buffalo, New York, USA, ⁶Vanderbilt University, Nashville, Tennessee, USA, ⁷Coon Rapids Clinic, Coon Rapids, Minnesota, USA, ⁸Wake Forrest, Winston-Salem, North Carolina, USA, ⁹Dana Farber Cancer Institute, Boston, Massachusetts, USA, ¹⁰University of Washington, Seattle, Washington, USA, ¹¹Mayo Clinic, Rochester, Minnesota, USA, ¹²University of Southern California, Los Angeles, California, USA, ¹³Mayo Clinic, Rochester, Minnesota, USA, ¹⁴City of Hope, Duarte, California, USA, ¹⁵Memorial Sloan Kettering, New York, New York, USA, ¹⁶USC Norris Comprehensive Cancer Center, Los Angeles, California, USA

O-015

A two arm phase II study of FOLFIRI in combination with standard or escalating dose of cetuximab as first line treatment for metastatic colorectal cancer: Everest 2 final results

Chiritescu Gabriela¹, Dumon Kristien¹, Macarulla Mercadé Teresa², Lang Istvan³, Santos Vivas Cristina⁴, Papai Zsuzsanna⁵, Janssens Jos⁶, Hendrickx Koen⁷, Pracht Marc⁸, Van den Eynde Marc⁹, Taïeb Julien¹⁰, Moons Veerle¹¹, Geboes Karen¹², Van Laethem Jean-Luc¹³,

Greil Richard¹⁴, Cervantes Andrés¹⁵, Vergauwe Philippe¹⁶, Ferrante Michel¹⁷, Vanderstraeten Erik¹⁸, Fridrik Michael¹⁹, Wöll Ewald²⁰, Limón Maria²¹, Rivera Fernando²², Sagaert Xavier¹, Tejpar Sabine¹, Van Cutsem Eric²⁵

¹University Hospitals Leuven, Leuven, Belgium, ²Vall d'Hebron University Hospital (HUVH) and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, ³National Institute of Oncology, Budapest, Hungary, ⁴Translational Research Laboratory and Department of Medical Oncology, Institut Català d'Oncologia-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain, ⁵State Health Center, Budapest, Hungary, ⁶AZ Turnhout, Turnhout, Belgium, ⁷OLV Aalst, Aalst, Belgium, ⁸Centre Eugène Marquis, Rennes, France, ⁹Clin. Univ. St-Luc Bruxelles, Brussels, Belgium, ¹⁰Georges Pompidou European Hospital, Paris, France, ¹¹Imelda Ziekenhuis Bonheiden, Bonheiden, Belgium, ¹²UZ Gent, Gent, Belgium, ¹³Hôpital Universitaire Erasme, Brussels, Belgium, ¹⁴III Medizinische Universitätsklinik Salzburg, Salzburg, Austria, ¹⁵University Hospital of Valencia, Valencia, Spain, ¹⁶A.Z. Groeninge Kortrijk, Kortrijk, Belgium, ¹⁷A.Z. Sint Maarten Mechelen, Mechelen, Belgium, ¹⁸A.Z. Maria Middelaers Gent, Gent, Belgium, ¹⁹Kepler Univ Hospital Linz, Linz, Austria, ²⁰Krankenhaus St. Vinzenz, Innere Medizin, Zams, Austria, ²¹H.U.V. del Rocío, Seville, Spain, ²²Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ²⁵University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium

O-016

First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study

F Pietrantonio¹, F Morano², S Corallo³, A Raimondi², F Loupakis⁴, C Cremolini⁵, V Smiroldo⁶, R Berenato⁷, A Sartore Bianchi⁸, M Tampellini⁹, S Bustreo¹⁰, M Clavarezza¹¹, R Murialdo¹², A Zaniboni¹³, G Tomasello¹⁴, G Peverelli³, C Antoniotti⁵, L Procaccio¹⁵, S Cinieri¹⁶, L Antonuzzo¹⁷, M Di Bartolomeo¹⁸, F de Braud²

¹Department of Medical Oncology, IRCCS Fondazione Istituto Nazionale dei Tumori, Milan, Italy, ²Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, ³Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, ⁴Medical Oncology Unit 1, Clinical and Experimental Oncology Department, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy, ⁵Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy, ⁶Istituto Clinico Humanitas, Rozzano, Italy, ⁷Department of Oncology, Fondazione I.R.C.C.S. Istituto Nazionale Tumori, Milan, Italy, ⁸Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, and Università degli Studi di Milano, Milan, Italy, ⁹AOU San Luigi Gonzaga, Orbassano, Italy, ¹⁰Città della Salute e della Scienza di Torino, Turin, Italy, ¹¹Ospedale Galliera, Genoa, Italy, ¹²Department of Oncology, Istituto di Ricerca a Carattere Clinico e Scientifico (IRCCS), Azienda Ospedaliera Universitaria San Martino - IST, Genoa, Italy, ¹³Fondazione Poliambulanza, Brescia, Italy, ¹⁴Department of Medical Oncology, Azienda Istituti Ospitalieri di Cremona, Cremona, Italy, ¹⁵Istituto Oncologico Veneto, Padua, Italy, ¹⁶Medical Oncology Unit, P.O. "A. Perrino" Hospital, Brindisi, Italy, ¹⁷Medical Oncology, Careggi University Hospital, Florence, Italy, ¹⁸Department of Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

O-017

FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in mCRC: Final results of the phase II randomized MOMA trial by GONO

F Marmorino¹, C Cremonini¹, F Bergamo², N Pella³, C Antoniotti¹, D Rossini¹, E Dell'Aquila⁴, G Masi¹, L Salvatore¹, F Loupakis⁵, L Marcucci⁶, D Gemma⁷, G Cardellino³, B Borelli¹, V Ricci⁸, S Delfanti⁹, E Mori¹⁰, G Tonini⁴, S Lonardi⁵, G Fontanini¹¹, L Boni¹², A Falcone¹³

¹Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy, ²Veneto Institute of Oncology IOV-IRCCS, Padua, Italy, ³Department of Oncology, Azienda Sanitaria Universitaria Integrata S. Maria della Misericordia, Udine, Italy, ⁴Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy, ⁵Medical Oncology Unit 1, Clinical and Experimental Oncology Department, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy, ⁶U.O. Oncologia Medica, Azienda USL-5 Istituto Toscano Tumori, Pontedera, Italy, ⁷Department of Medical Oncology, Hospital of Frosinone, Frosinone, Italy, ⁸Medical Oncology, Oncology Department, S. Croce & Carle Teaching Hospital Cuneo, Cuneo, Italy, ⁹Medical Oncology, Foundation IRCCS Policlinico San Matteo, Pavia, Italy, ¹⁰SOC Oncologia Medica- Nuovo Ospedale di Prato "Santo Stefano" Az.USL Toscana Centro, Prato, Italy, ¹¹Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy, ¹²Clinical Trials Coordinating Center, Istituto Toscano Tumori, University Hospital Careggi, Florence, Italy, ¹³University of Pisa, Pisa, Italy

O-018

Plasma miRNAs signature validation for early detection of colorectal cancer

M Herreros-Villanueva¹, S Durán-Sanchón², A Martín¹, R Pérez-Palacios¹, E Vila-Navarro², M Marcuello², M Díaz-Centeno³, J Cubiella⁴, M Diez⁵, L Bujanda⁶, A Lanas⁷, R Jover⁸, V Hernández⁹, E Quintero¹⁰, J Lozano², I Martínez¹¹, A Castells¹², M Gironella², R Arroyo¹
¹Amadix, Valladolid, Spain, ²CIBERehd, Barcelona, Spain, ³Hospital Clínic de Barcelona, Barcelona, Spain, ⁴Complexo Hospitalario Universitario de Ourense, Ourense, Spain, ⁵Hospital Universitario de Burgos, Burgos, Spain, ⁶Hospital Donostia, San Sebastián, Spain, ⁷Hospital Lozano Blesa, Zaragoza, Spain, ⁸Hospital General Universitario de Alicante, Alicante, Spain, ⁹Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ¹⁰Hospital Universitario de Canarias, La Laguna, Santa Cruz de Tenerife, Spain, ¹¹Owl Metabolomics, Derio, Spain, ¹²Hospital Clinic, Barcelona, Spain

O-019

PETACC-6: Preop chemoradiation and postop chemotherapy (capecitabine +/- oxaliplatin) in locally advanced rectal cancer: Overall survival after long term follow-up

H Schmoll¹, K Haustermans², T Price³, B Nordlinger⁴, R Hofheinz⁵, J Daisne⁶, J Janssens⁷, B Brenner⁸, P Schmidt⁹, H Reinel¹⁰, S Hollerbach¹¹, K Caca¹², F Fauth¹³, C Hannig¹⁴, J Zalcborg¹⁵, N Tebbutt¹⁶, M Mauer¹⁷, S Marreaud¹⁸, M Lutz¹⁹, E Van Cutsem²⁰
¹Martin Luther University Halle-Wittenberg, Halle, Germany, ²University Hospitals

Leuven, Leuven, Belgium, ³Queen Elizabeth Hospital and University of Adelaide, Woodville, Australia, ⁴Centre Hospitalier Universitaire Ambroise Paré, Assistance Publique Hôpitaux de Paris, Boulogne-Billancourt, France, ⁵University Hospital Mannheim, Mannheim, Germany, ⁶Université Catholique de Louvain, Namur, Belgium, ⁷AZ Turnhout, Turnhout, Belgium, ⁸Rabin Medical Center – Tel Aviv University, Petah Tiqva, Israel, ⁹Staedt. Klinikum Neunkirchen, Neunkirchen, Germany, ¹⁰Leopoldina-Krankenhaus der Stadt Schweinfurt GGMBH, Schweinfurt, Germany, ¹¹Allgemeines Krankenhaus Celle, Celle, Germany, ¹²Klinikum Ludwigsburg, Ludwigsburg, Germany, ¹³Onkologische Schwerpunktpraxis, Hanau, Germany, ¹⁴Gemeinschaftspraxis Haematologie und Onkologie, Bottrop, Germany, ¹⁵Peter MacCallum Cancer Centre, Melbourne, Australia, ¹⁶Austin Hospital, Melbourne, Australia, ¹⁷EORTC Headquarters, Brussels, Belgium, ¹⁸na, na, Belgium, ¹⁹Caritasklinik St. Theresa, Saarbruecken, Germany, ²⁰UZ Leuven-Campus Gasthuisberg, Leuven, Belgium

O-020

Activity of larotrectinib in patients with TRK fusion GI malignancies

M Nathenson¹, G Demetri², U Lassen³, D Hong⁴, V Boni⁵, J Deeken⁶, A Dowlati⁷, M Cox⁸, N Ku⁸, S Cruickshank⁸, H Qamoos⁸, A Drilon⁹

¹Dana-Farber Cancer Institute, Boston, Massachusetts, USA, ²Ludwig Center at Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA, ³Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark, ⁴UT MD Anderson Cancer Center, Houston, Texas, USA, ⁵START Madrid-CIOCC, Madrid, Spain, ⁶Inova Translational Medicine Institute, Falls Church, Virginia, USA, ⁷University Hospitals of Cleveland Medical Center, Cleveland, Ohio, USA, ⁸Loxo Oncology, South San Francisco, California, USA, ⁹Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York, USA

O-021

Safety and antitumor activity of pembrolizumab in patients with advanced microsatellite instability–high (MSI-H) colorectal cancer: KEYNOTE-164

D Le¹, P Kavan², T Kim³, M Burge⁴, E Van Cutsem⁵, H Hara⁶, P Boland⁷, J Van Laethem⁸, R Geva⁹, H Taniguchi¹⁰, T Crocenzi¹¹, M Sharma¹², C Atreya¹³, L Diaz¹⁴, L Liang¹⁵, P Marinello¹⁵, T Dai¹⁵, B O'Neill¹⁶

¹Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA, ²McGill University Health Center, Montreal, Quebec, Canada, ³Asan Medical Center, Seoul, Republic of Korea, ⁴Royal Brisbane and Women's Hospital, Herston, Australia, ⁵University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium, ⁶Saitama Cancer Center, Kitaadachi, Japan, ⁷Roswell Park Cancer Institute, Buffalo, New York, USA, ⁸Hôpital Universitaire Erasme, Brussels, Belgium, ⁹Sourasky Medical Center, Tel Aviv-Yafo, Israel, ¹⁰Aichi Cancer Center Hospital, Nagoya, Japan, ¹¹Providence Cancer Center, Portland, Oregon, USA, ¹²The University of Chicago Medicine, Chicago, Illinois, USA, ¹³UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA, ¹⁴Memorial Sloan Kettering Cancer Center, New York, New York, USA, ¹⁵Merck & Co., Inc., Kenilworth, New Jersey, USA, ¹⁶IU Health University Hospital, Indianapolis, Indiana, USA

O-022

Phase II study evaluating trifluridine/tipiracil+bevacizumab and capecitabine+bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysis

K Lesniewski-Kmak¹, V Moiseenko², M Saunders³, H Wasan⁴, G Argiles⁵, C Borg⁶, G Creemers⁷, M Fedyanin⁸, R Glynne-Jones⁹, P Pfeiffer¹⁰, C Punt¹¹, D Stroyakovskiy¹², A ten Tije¹³, A van de Wouw¹⁴, A Kanehisa¹⁵, R Fougerey¹⁵, N Lopez Busto¹⁵, N Amellal¹⁶; E Van Cutsem¹⁷

¹Szpitala Wojewodzkie w Gdyni/Gdansk Medical University, Gdynia, Poland, ²Saint-Petersburg Scientific Practical Center for Specialized Medical Care (oncological), St.Petersburg, Russian Federation, ³Christie Hospital NHS Foundation Trust, Manchester, UK, ⁴Hammersmith Hospital, Department of Cancer Medicine, London, UK, ⁵Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Barcelona, Spain, ⁶University Hospital Besançon, Besançon, France, ⁷Catharina Hospital, Eindhoven, Netherlands, ⁸N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russian Federation, ⁹Mount Vernon Centre for Cancer Treatment, London, UK, ¹⁰Department of Oncology, Odense University Hospital, Odense, Denmark, ¹¹Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ¹²Moscow City Oncology Hospital N62, Moscow, Russian Federation, ¹³Amphia Hospital Breda, Breda, Netherlands, ¹⁴VieCuri Medisch Centrum Noord-Limburg, Venlo, Netherlands, ¹⁵Institut de Recherches Internationales Servier, Suresnes, France, ¹⁶Servier Oncology, Suresnes, France, ¹⁷University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium

O-023

FOLFOX/bevacizumab +/- irinotecan in advanced colorectal cancer (CHARTA): Long term outcome

H Schmoll¹, B Garlipp², C Junghanß³, A Vogel⁴, U Kaiser⁵, A Florschütz⁶, S Kanzler⁷, C Hannig⁸, F Meinert¹, F Cygon¹, A Stein⁹

¹Martin Luther University Halle-Wittenberg, Halle, Germany, ²Uniklinik Magdeburg, Magdeburg, Germany, ³Universität Rostock, Rostock, Germany, ⁴Hannover Medical School, Hannover, Germany, ⁵Bernward Krankenhaus, Hildesheim, Germany, ⁶Städtisches Klinikum Dessau, Onkologie, Dessau, Germany, ⁷Leopoldina-Krankenhaus Schweinfurt, Med. Klinik II, Schweinfurt, Germany, ⁸Gemeinschaftspraxis Haematologie und Onkologie, Bottrop, Germany, ⁹University Medical Center Hamburg, Hamburg, Germany

O-024

mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer m(CRC): a randomized phase II VOLFI trial of the AIO (AIO- KRK0109)

M Geissler¹, T Klingler², J Riera-Knorrenschild³, A Tannapfel⁴, T Seufferlein⁵, S Held⁶, A Florschütz⁷, S Kanzler⁸, V Heinemann⁹, A Reinacher-Schick¹⁰, U Martens¹¹

¹Klinikum Esslingen, Cancer Center Esslingen, Esslingen, Germany, ²Klinikum Esslingen,

Hämatologie/Onkologie, Esslingen, Germany, ³Philips-Universität Marburg, Onkologie, Marburg, Germany, ⁴Department of Pathology, Ruhr-University Bochum, Bochum, Germany, ⁵Department of Internal Medicine I, University of Ulm, Ulm, Germany, ⁶Clinassess, Leverkusen, Germany, ⁷Städtisches Klinikum Dessau, Onkologie, Dessau, Germany, ⁸Leopoldina-Krankenhaus Schweinfurt, Med. Klinik II, Schweinfurt, Germany, ⁹Comprehensive Cancer Center, Krebszentrum München, Munich, Germany, ¹⁰Ruhr University, Bochum, Germany, ¹¹Dept. of Hematology/Oncology, Cancer Center Heilbronn-Franken, Heilbronn, Germany

O-025

Association between tumor mutation burden (TMB) and MLH1, PMS2, MSH2, and MSH6 alterations in 395 microsatellite instability-high (MSI-High) gastrointestinal (GI) tumors

M Salem¹, A Grothey², R Goldberg³, J Xiu⁴, W Korn⁴, A Shields⁵, J Hwang¹, P Philip⁶, H Lenz⁷, J Marshall¹

¹Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, USA, ²Mayo Clinic, Rochester, Minnesota, USA, ³Comprehensive Cancer Center at The Ohio State University, Columbus, Ohio, USA, ⁴Caris Life Sciences, Phoenix, Arizona, USA, ⁵Karmanos Cancer Center, Detroit, Michigan, USA, ⁶Karmanos Cancer Center, Detroit, Michigan, USA, ⁷USC Norris Comprehensive Cancer Center, Los Angeles, California, USA

O-026

Total circulating cell-free DNA (cfDNA) as a prognostic biomarker in metastatic colorectal cancer prior to first-line oxaliplatin-based chemotherapy

J Hamfjord¹, T Guren¹, O Dajani¹, B Glimelius², H Sorbye³, P Pfeiffer⁴, T Christoffersen⁵, O Lingjærde⁵, K Tveit¹, E Kure¹, N Pallisgaard⁶, K Spindler⁷

¹Oslo University Hospital, Oslo, Norway, ²Uppsala University, Uppsala, Sweden, ³Haukeland University Hospital, University of Bergen, Bergen, Norway, ⁴Department of Oncology, Odense University Hospital, Odense, Denmark, ⁵University of Oslo, Oslo, Norway, ⁶Zealand Hospital, Roskilde, Roskilde, Denmark, ⁷Department of Oncology, Aarhus University Hospital, Aarhus, Denmark

O-027

BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib + MEK inhibitor binimetinib + anti-epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer

E Van Cutsem¹, P Cuyle², S Huijberts³, J Schellens⁴, E Elez⁵, R Yaeger⁶, M Fakih⁷, C Montagut⁸, M Peeters⁹, J Desai¹⁰, T Yoshino¹¹, F Ciardiello¹², H Wasan¹³, K Maharry¹⁴, J Christy-Bittel¹⁴, A Gollerkeri¹⁴, S Kopetz¹⁵, A Grothey¹⁶, J Tabernero¹⁷

¹University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium, ²Imelda Ziekenhuis, Bonheiden, Belgium, ³Netherlands Cancer Institute, Amsterdam, Netherlands, ⁴The Netherlands Cancer Institute, Amsterdam, Netherlands, ⁵Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, ⁶Memorial Sloan-Kettering Cancer Center, New

York, New York, USA, ⁷City of Hope, Duarte, California, USA, ⁸Department of Medical Oncology, Hospital Universitari del Mar, Barcelona, Spain, ⁹Antwerp University Hospital, Edegem, Belgium, ¹⁰Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Walter and Eliza Hall Institute, Parkville, Australia, ¹¹National Cancer Center Hospital East, Kashiwa, Japan, ¹²University of Campania, Naples, Italy, ¹³Hammersmith Hospital, Department of Cancer Medicine, London, UK, ¹⁴Array BioPharma Inc., Boulder, Colorado, USA, ¹⁵UT MD Anderson Cancer Center, Houston, Texas, USA, ¹⁶Mayo Clinic, Rochester, Minnesota, USA, ¹⁷Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain

O-028

Long-term effect of peripheral sensory neuropathy (PSN) of 3 or 6 months oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: ACHIEVE as part of the IDEA collaboration

S Takeuchi¹, T Yoshino², T Yamanaka³, M Kotaka⁴, D Manaka⁵, T Eto⁶, J Hasegawa⁷, A Takagane⁸, M Nakamura⁹, T Kato¹⁰, Y Munemoto¹¹, H Bando¹², H Taniguchi¹³, M Gamoh¹⁴, M Shiozawa¹⁵, S Saji¹⁶, Y Maehara¹⁷, T Mizushima¹⁸, A Ohtsu², M Mori¹⁹
¹Teine-Keijinkai Hospital, Sapporo, Japan, ²National Cancer Center Hospital East, Kashiwa, Japan, ³Yokohama City University School of Medicine, Yokohama, Japan, ⁴Department of Gastrointestinal Cancer Center, Sano Hospital, Kobe, Japan, ⁵Department of Surgery, Gastrointestinal Center, Kyoto Katsura Hospital, Nishikyo-ku, Japan, ⁶Department of Gastroenterology, Tsuchiura Kodo General Hospital, Tsuchiura, Japan, ⁷Department of Surgery, Osaka Rosai Hospital, Sakai, Japan, ⁸Hakodate Goryoukaku Hospital, Hakodate, Japan, ⁹Aizawa Comprehensive Cancer Center, Aizawa Hospital, Matsumoto, Japan, ¹⁰Department of Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan, ¹¹Fukui-ken Saiseikai Hospital, Fukui, Japan, ¹²Ishikawa Prefectural Central Hospital, Kanazawa, Japan, ¹³Department of Surgery, Kyoto Second Red Cross Hospital, Kamigyo-ku, Japan, ¹⁴Department of Medical Oncology, Osaki Citizen Hospital, Osaki-shi, Japan, ¹⁵Kanagawa Cancer Center, Gastrointestinal Surgery, Asahi-ku, Japan, ¹⁶Japanese Foundation for Multidisciplinary Treatment of Cancer, Koto-ku, Japan, ¹⁷Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, ¹⁸Osaka University Graduate School of Medicine, Suita, Japan, ¹⁹Osaka University Graduate School of Medicine, Suita, Japan

O-029

The impact of combining Selective Internal Radiation Therapy (SIRT) with sorafenib on overall survival in patients with advanced hepatocellular carcinoma: the SORAMIC trial palliative cohort

J Ricke¹, B Sangro², H Amthauer³, I Bargellini⁴, P Bartenstein⁵, E Toni⁶, A Gasbarrini⁷, H Klumpen⁸, M Peck-Radosavljevic⁹, P Popovic¹⁰, O Rosmorduc¹¹, E Schott¹², C Verslype¹³, P Malfertheiner¹⁴
¹University Clinic Magdeburg, Magdeburg, Germany, ²Clinica Universidad de Navarra and CIBEREHD, Pamplona, Spain, ³Dept. of Nuclear Medicine, Charite University Hospital Berlin, Berlin, Germany, ⁴Dept. of Diagnostic and Interventional Radiology, University of Pisa, Pisa, Italy, ⁵Dept. of Nuclear medicine, Ludwig-Maximilians University

Munich, Munich, Germany, ⁶Dept. of Gastroenterology, Ludwig-Maximilians University, Munich, Germany, ⁷Dept. of Gastroenterology, Catholic University of Rome, Rome, Italy, ⁸Academic Medical Centre Amsterdam, Amsterdam, The Netherlands, ⁹Medizinische Universität Wien, Vienna, Austria, ¹⁰Dept. of Hepatogastroenterology, University hospital, Ljubljana, Slovenia, ¹¹Department of Hepatology, Hôpital de la Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris and Université Pierre et Marie Curie, Sorbonne Universités, Paris, France, Paris, France, ¹²Dept. of Gastroenterology, Charité University Hospital, Berlin, Germany, ¹³Dept. Of Hepatology, University Hospital Gasthuisberg, Leuven, Belgium, ¹⁴Dept. of Gastroenterology, University Hospital Magdeburg and Ludwig-Maximilians University, Munich, Germany

O-030

Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumab based therapy: Result of E7208

H Hochster¹, P Catalano², P O'Dwyer³, E Mitchell⁴, D Cohen⁵, B Faller⁶, J Kortmanský⁷, S Kircher⁸, J Lacy⁹, H Lenz¹⁰, U Verma¹¹, A Benson III¹²

¹Rutgers-Cancer Institute, New Brunswick, New Jersey, USA, ²Dana-Farber Cancer Institute, Boston, Massachusetts, USA, ³University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, USA, ⁴Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA, ⁵NYU Perlmutter Cancer Center, and ECOG-ACRIN, New York, New York, USA, ⁶Midwest Hem and Onc Assoc, Clayton, Missouri, USA, ⁷Medical Oncology and Hematology, Hamden, CT, USA, ⁸Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA, ⁹Smilow Cancer Hospital, Yale University, New Haven, Connecticut, USA, ¹⁰University of Southern California, Los Angeles, California, USA, ¹¹University of Texas Southwestern Medical Center, Dallas, Texas, USA, ¹²Northwestern Medicine, Chicago, Illinois, USA

Poster Discussions

PD-001

Endoscopic prediction of tumor invasion depth in early gastric signet ring cell carcinoma

H Moon¹, S Kang², J Sung², H Jeong³

¹Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Republic of Korea, ²Departments of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Republic of Korea, ³Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Republic of Korea

PD-002

A phase I/II trial of hafnium oxide nanoparticles activated by radiotherapy in hepatocellular carcinoma and liver metastasis

E Chajon¹, M Pracht¹, T De Baere², F Nguyen², J Bronowicki³, V Vendrely⁴, A Baumann⁵, V Croisé-Laurent⁶, E Rio⁷, Y Rolland⁸, S Le Sourd⁸, P Gustin², C Perret⁷, F Mornex⁹, D Peiffert¹⁰, P Merle¹¹, E Deutsch²

¹Centre Eugène Marquis, Rennes, France, ²Institut Gustave Roussy, Villejuif, France, ³INSERM 954, CHU de Nancy, Université de Lorraine, Nancy, France, ⁴Groupe Hospitalier Sud - Hôpital Haut-Lévêque, Pessac, France, ⁵Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France, ⁶Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France, ⁷ICO - Site René Gauducheau, Saint Herblain, France, ⁸Centre Eugène-Marquis, Rennes, France, ⁹Centre Hospitalier de la Croix Rousse, Lyon, France, ¹⁰Institut de Cancérologie de Lorraine, Vandœuvre les Nancy Cedex, France, ¹¹Hepatology Unit, Groupement Hospitalier Lyon Nord, Lyon, France

PD-003

Comparison of prognosis after hepatic resection of hepatocellular carcinoma between intermediate stage tumor and early stage tumor

*J Arita, T Kokudo, N Akamatsu, J Kaneko, T Ishizawa, K Hasegawa
University of Tokyo, Bunkyo-ku, Japan*

PD-004

Baseline characteristics and second-line treatment for metastatic pancreatic adenocarcinoma (mPAC) patients receiving first-line FOLFIRINOX, gemcitabine+nab-paclitaxel or gemcitabine-monootherapy in routine clinical practice across Europe

G Prager¹, T Macarulla Mercadé², àMellbring³, J Taieb⁴, A Carrato⁵, D Melisi⁶, B Westphalen⁷, N D'Esquermes⁸, A Ferreras⁹, F de Jong¹⁰

¹Clinical Division of Medical Oncology, Department of Medicine I, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria, ²Vall d'Hebron University Hospital (HUVH) and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, ³Shire Sweden AB, Kista, Sweden, ⁴Sorbonne Paris Cité, Paris Descartes University,

Hôpital Europeen Georges Pompidou, Paris, France, ⁵IRYCIS, CIBERONC, Alcalá University, Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁶Medical Oncology, University of Verona, Verona, Italy, ⁷Comprehensive Cancer Center München, Klinikum der Universität München, Munich, Germany, ⁸Genactis, Chateauneuf, France, ⁹Genactis, Antibes, France, ¹⁰Shire International GmbH, Glattpark-Opfikon, Switzerland

PD-005

Post-operative venous thromboembolism increased mortality in patients with either adenocarcinoma or non-adenocarcinoma pancreatic cancer

*K Majmudar¹, L Diaz Quintero¹, H Fuentes², S Stocker¹, A Tafur¹, M Talamonti¹
¹NorthShore University HealthSystem, Evanston, Illinois, USA, ²John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, USA*

PD-006

Characterizations of DNA copy number variations and spatio-temporal intra tumor heterogeneity in liver metastasis from colorectal cancer patients

M Marques¹, K Gambaro², M Couetoux du Tertre², M Witcher³, B Samson⁴, B Lesperance⁵, Y Ko⁶, R Dalfen⁷, E St-Hilaire⁸, L Sideris⁹, F Couture¹⁰, S Tejpar¹¹, R Burkes¹², M Harb¹³, T Alcindor¹⁴, E Camlioglu¹⁵, A Gologan¹⁵, V Pelsser¹⁵, S McNamara², P Kavan¹⁶, C Kleinman³, G Batist¹⁷

¹The Lady Davis Institute of the Jewish General Hospital, Departments of Oncology and Experimental Medicine, McGill University, Montréal, Quebec, Canada, ²Exactis Innovation, Montréal, Quebec, Canada, ³Segal Cancer Centre-Jewish General Hospital, Montréal, Quebec, Canada, ⁴Centre de Santé et de Services Sociaux Champlain Charles-Lemoyne, Greenfield Park, Quebec, Canada, ⁵Hospital Sacre-Coeur de Montreal, Montréal, Quebec, Canada, ⁶Sunnybrook Research Institute (SRI), Toronto, Ontario, Canada, ⁷St. Mary's Hospital, Montréal, Quebec, Canada, ⁸Georges Dumont Hospital, Moncton, New Brunswick, Canada, ⁹Hôpital Maisonneuve Rosemont, Montréal, Quebec, Canada, ¹⁰CHAU Lévis, Lévis, Quebec, Canada, ¹¹University of Leuven, Leuven, Belgium, ¹²Mount Sinai Hospital, Toronto, Ontario, Canada, ¹³Moncton Hospital, Moncton, New Brunswick, Canada, ¹⁴McGill University Health Centre, Montréal, Quebec, Canada, ¹⁵Jewish General Hospital, Montréal, Quebec, Canada, ¹⁶McGill University, Montréal, Quebec, Canada, ¹⁷Department of Oncology, McGill University and the Segal Cancer Center, Sir Mortimer B. Davis, Jewish General Hospital, Montréal, Quebec, Canada

PD-007

Network analysis of colon cancer invasiveness using gene expression data

*S Choi¹, E Kim², J Lee³, J Lee³, S Kim³, H Choi⁴, B Keum³, Y Jeon⁵, H Chun², H Lee⁶, C Kim³
¹Korea University Anam Hospital, Seoul, Republic of Korea, ²Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea, ³Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea, ⁴Division of Gastroenterology and Hepatology, Department of Internal Medicine, Institute of Gastrointestinal Medical Instrument Research, Korea University College of Medicine, Seoul, Republic of Korea,*

⁵*Division of Gastroenterology and Hepatology, Department of Internal Medicine, Seoul, Republic of Korea,* ⁶*Korea University College of Medicine, Seoul, Republic of Korea*

PD-008

Molecular characterization of immune microenvironment in colorectal cancers with microsatellite instability by digital RNA counting

M Giordano¹, R Moretto², R Giannini³, G Zucchelli², F Pietrantonio⁴, C Antoniotti², C Ugolini⁵, F Morano⁶, F Marmorino², E Sensi¹, A Belfiore⁷, D Rossini², C Lupi¹, G Masi², B Borelli², E Ongaro⁸, A Boccaccino², A Falcone³, C Cremolini², G Fontanini⁹

¹*Divisione di Anatomia Patologica, Dipartimento di Chirurgia, Università di Pisa, Pisa, Italy,* ²*Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy,* ³*University of Pisa, Pisa, Italy,* ⁴*Department of Medical Oncology, IRCCS Fondazione Istituto Nazionale dei Tumori, Milan, Italy,* ⁵*Department of Laboratory Medicine, Section of Pathology, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy,* ⁶*Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy,* ⁷*Istituto Nazionale dei Tumori Foundation, Milan, Italy,* ⁸*Department of Oncology, Azienda Sanitaria Universitaria Integrata S. Maria della Misericordia, Udine, Italy,* ⁹*Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy*

PD-009

Emergence of KRAS mutation may play a major role in the secondary resistance to EGFR blockade

T Yamada¹, G Takahashi¹, T Iwai¹, K Takeda¹, H Furuki², M Koizumi¹, S Shinji¹, A Matsuda³, Y Yokoyama¹, M Hotta¹, K Hara¹, H Yoshida¹

¹*Nippon Medical School Department of Digestive Surgery, Bunkyo-ku, Japan,* ²*Nippon Medical School, Bunkyo-ku, Japan,* ³*Nippon Medical School, Inzai, Japan*

PD-010

REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan: Quality of life analysis

T Yoshino¹, T Yamanaka², T Denda³, Y Tsuji⁴, K Shinozaki⁵, Y Komatsu⁶, Y Kobayashi⁷, J Furuse⁸, H Okuda⁹, M Asayama¹⁰, K Akiyoshi¹¹, Y Kagawa¹², T Kato¹³, E Oki¹⁴, T Ando¹⁵, Y Hagiwara¹⁶, Y Ohashi¹⁷, K Shitara¹⁸

¹*National Cancer Center Hospital East, Kashiwa, Japan,* ²*Yokohama City University School of Medicine, Yokohama, Japan,* ³*Chiba Cancer Center, Chiba, Japan,* ⁴*Department of Medical Oncology, Tonan Hospital, Sapporo, Japan,* ⁵*Hiroshima Prefectural Hospital, Hiroshima, Japan,* ⁶*Digestive Internal Medicine, Division of Cancer Center, Hokkaido University Hospital, Sapporo, Japan,* ⁷*Department of Medical Oncology, Kushiro Rosai Hospital, Kushiro, Japan,* ⁸*Kyorin University Hospital, Tokyo, Japan,* ⁹*Department of Medical Oncology, Keiyukai Sapporo Hospital, Sapporo, Japan,* ¹⁰*Saitama Cancer Center, Saitama, Japan,* ¹¹*Osaka City General Hospital, Osaka, Japan,* ¹²*Department of*

Gastrointestinal Surgery, Kansai Rosai Hospital, Amagasaki, Japan, ¹³Department of Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan, ¹⁴Department of Surgery, Graduate School of Medical Sciences, Kyushu University, Higashi-ku, Japan, ¹⁵University of Tsukuba, Tsukuba-shi, Japan, ¹⁶University of Tokyo, Bunkyo-ku, Japan, ¹⁷Chuo University, Tokyo, Japan, ¹⁸National Cancer Center Hospital East, Kashiwa-city, Japan

PD-011

SAPPHIRE: A randomized phase II study of oxaliplatin discontinuation after 6 cycles of mFOLFOX6 + panitumumab therapy in patients with colorectal cancer: Final analysis of efficacy and safety results

M Takahashi¹, Y Munemoto², M Nakamura³, M Kotaka⁴, H Kuroda⁵, T Kato⁶, N Minagawa⁷, S Noura⁸, M Fukunaga⁹, H Kuramochi¹⁰, T Touyama¹¹, T Takahashi¹², Y Akagi¹³, H Satake¹⁴, S Kurosawa¹⁵, T Miura¹⁵, H Mishima¹⁶, J Sakamoto¹⁷, K Oba¹⁸, N Nagata¹⁹

¹Yokohama Municipal Citizen's Hospital, Yokohama, Japan, ²Fukui-ken Saiseikai Hospital, Fukui, Japan, ³Aizawa Comprehensive Cancer Center, Aizawa Hospital, Matsumoto, Japan, ⁴Department of Gastrointestinal Cancer Center, Sano Hospital, Kobe, Japan, ⁵Kitakyushu General Hospital, Kitakyushu, Japan, ⁶Department of Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan, ⁷Department of Surgery I, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁸Osaka Rosai Hospital, Sakai, Japan, ⁹Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan, ¹⁰Tokyo Woman's Medical University Yachiyo Medical Center, Yachiyo, Japan, ¹¹Nakagami Hospital, Okinawa, Japan, ¹²Gifu University Hospital, Gifu, Japan, ¹³Kurume University Hospital, Kurume, Japan, ¹⁴Kobe City Medical Center General Hospital, Kansai Medical University Hospital, Kobe, Japan, ¹⁵Takeda Pharmaceutical Company Limited, Chuo-ku, Japan, ¹⁶Division of Cancer Center, Aichi Medical University, Nagakute, Japan, ¹⁷Tokai Central Hospital, Kakamigahara, Japan, ¹⁸Department of Biostatistics, The University of Tokyo, Tokyo, Japan, ¹⁹Department of Surgery, Kitakyushu General Hospital, Kitakyushu, Japan

PD-012

Early tumour shrinkage (ETS) and its impact on tumour-related symptoms in patients with previously untreated RAS wild-type metastatic colorectal cancer (mCRC): A retrospective analysis of three panitumumab studies

J Taieb¹, M Geissler², F Rivera³, M Karthaus⁴, R Wilson⁵, F Loupakis⁶, T Price⁷, M Tracy⁸, P Burdon⁹, M Peeters¹⁰

¹Sorbonne Paris Cité, Paris Descartes University, Georges Pompidou European Hospital, Paris, France, ²Klinikum Esslingen, Cancer Center Esslingen, Esslingen, Germany, ³Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Department of Hematology and Oncology, Städtisches Klinikum München, Klinikum Neuperlach, Munich, Germany, ⁵Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, UK, ⁶Medical Oncology Unit 1, Clinical and Experimental Oncology Department, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy, ⁷Queen Elizabeth Hospital and University of Adelaide, Woodville, Australia, ⁸Amgen Ltd., Milton, UK, ⁹European Medical, Amgen (Europe) GmbH, Zug, Switzerland, ¹⁰Antwerp University Hospital, Edegem, Belgium

PD-013

Usefulness of colonic tattooing using ICG in patients with colorectal tumors

J Park¹, H Moon², I Kwon³, J Kim⁴, S Kang⁵, E Lee², S Kim², J Sung⁵, B Lee², H Jeong⁵
¹Division of Gastroenterology, Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University School of Medicine, Daejeon, Republic of Korea, ²Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Republic of Korea, ³Clinical Trials Center, Chungnam National University Hospital, Daejeon, Republic of Korea, ⁴Departments of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea, Daejeon, Republic of Korea, ⁵Departments of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Republic of Korea

PD-014

Survival following curative indented treatment of brain metastases from colorectal cancer: A Danish population-based cohort study

A Boysen¹, A Ording², A Astradsson³, M Høyer⁴, K Spindler⁵
¹Aarhus University Hospital, Dep. of Oncology, Aarhus, Denmark, ²Aarhus University Hospital, Dep. of Clinical Epidemiology, Aarhus, Denmark, ³Aarhus University Hospital, Dep. of Neurosurgery, Aarhus, Denmark, ⁴Danish Center for Particle Therapy, Aarhus, Denmark, ⁵Department of Oncology, Aarhus University Hospital, Aarhus, Denmark

PD-015

Optimizing the use of first-line chemotherapy in metastatic colorectal cancer patients with mucinous histology. A multicenter, retrospective, combined analysis on 897 patients

V Catalano¹, F Bergamo², C Cremolini³, B Vincenzi⁴, F Negri⁵, P Giordani¹, D Santini⁴, D Sarti¹, U Torresi⁶, R Bisonni⁷, R Silva⁸, M Rocchi⁹, S Lonardi¹⁰, A Falcone¹¹, R Mattioli¹², F Graziano¹
¹A.O. Ospedali Riuniti Marche Nord, Pesaro, Italy, ²Veneto Institute of Oncology IOV-IRCCS, Padua, Italy, ³Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy, ⁴Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy, ⁵Medical Oncology, University Hospital, Parma, Italy, ⁶Ospedale di Macerata, Macerata, Italy, ⁷UOC Oncologia Medica - Ospedale Murri, Fermo, Italy, ⁸UO Oncologia Medica - Ospedale Profili, Fabriano, Italy, ⁹University of Urbino Carlo Bo, Urbino, Italy, ¹⁰Medical Oncology Unit 1, Clinical and Experimental Oncology Department, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy, ¹¹University of Pisa, Pisa, Italy, ¹²A.O. Ospedali Riuniti Marche Nord, Pesaro, Italy

PD-016

Safety of self-expandable metal stents (SEMS) or emergency surgery for acute colonic obstruction in metastatic colon cancer patients treated with bevacizumab

V Pacheco-Barcia¹, R Mondéjar Solís¹, O Martínez Saez², F Longo Muñoz³, E Bermejo⁴, J Moreno Monteagudo⁵, C Marin⁴, A Correa⁴, R Maqueda⁶, J Rogado¹, A Garcia de Paredes⁷, E Rodriguez de Santiago⁸, V Pachón Olmos⁹, R Ferreiro Monteagudo⁹, M Rodriguez Garrote⁹, A Carrato¹⁰, O Donnay¹, E Martin⁴, C Santander⁴, R Colomer¹

¹Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria La Princesa, Madrid, Spain, ²Ramón y Cajal University Hospital, Madrid, Spain, ³Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁴Hospital Universitario La Princesa, Madrid, Spain, ⁵Hospital La Princesa, Madrid, Spain, ⁶Hospital Universitario La Princesa, Madrid, Spain, ⁷Hospital Universitario Ramon y Cajal, Madrid, Spain, ⁸Hospital Universitario Ramon y Cajal, Madrid, Spain, ⁹Ramón y Cajal University Hospital, Madrid, Spain, ¹⁰IRYCIS, CIBERONC, Alcalá University, Hospital Universitario Ramón y Cajal, Madrid, Spain

PD-017

Clinical and molecular determinants of extrahepatic disease progression (ePD) in initially unresectable, liver-limited metastatic colorectal cancer (mCRC)

E Ongaro¹, D Rossini², F Pietrantonio³, F Morano⁴, F de Braud⁴, V Mazzaferro⁵, F Corti⁴, G Randon⁴, A Raimondi⁴, L Battaglia⁶, L Morelli⁷, L Urbani⁸, G Masi², R Moretto², C Antoniotti², F Marmorino², B Borelli², G Zucchelli², A Boccaccino², C Cremolini², A Falcone⁹

¹Department of Oncology, Azienda Sanitaria Universitaria Integrata S. Maria della Misericordia, Udine, Italy, ²Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy, ³Department of Medical Oncology, IRCCS Fondazione Istituto Nazionale dei Tumori, Milan, Italy, ⁴Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, ⁵Gastrointestinal and Hepatobilio-Pancreatic Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, ⁶Peritoneal Surface Malignancies Unit, Colon and Rectal Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, ⁷Department of Translational Research and New Technologies in Medicine and Surgery, General Surgery Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy, ⁸General Surgery Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy, ⁹University of Pisa, Pisa, Italy

PD-018

Comparing survival in left-sided and right-sided colorectal carcinoma: A Belgian population-based study

K Janssens¹, N Boeckx², G Van Camp³, K Op de Beek⁴, E Franssen⁵, F Calay⁶, N Van Damme⁶, M Peeters⁷

¹University of Antwerp, Antwerp, Belgium, ²Center of Oncological Research (CORE), University of Antwerp, Wilrijk, Belgium, ³Center of Medical Genetics, University of Antwerp and Antwerp University Hospital, Edegem, Belgium, ⁴a Center of Oncological

Research (CORE), University of Antwerp, Wilrijk, Belgium, ⁵StatUa Center for Statistics, University of Antwerp, Antwerp, Belgium, ⁶Belgian Cancer Registry, Sint-Joost-ten-Node, Belgium, ⁷Antwerp University Hospital, Edegem, Belgium

PD-019

RMB (RENCA Macro bead) therapy in advanced mCRC: Phase IIb preliminary multi-site survival findings; correlation & combination with Phase I and IIa data including imaging and lab profiles [U.S.FDA BB-IND 10091]

A Nazarian¹, Z Andrada², J Thomas², S Sureshbabu², N Berman², D Wolf³, L Gazda⁴, T Fahey⁵, A Ocean⁶, B Smith²

¹The Rogosin Institute, New York, New York, USA, ²The Rogosin Institute / Weill Cornell Medical Center, New York, New York, USA, ³Weill Cornell Medical Center, New York, New York, USA, ⁴The Rogosin Institute, Xenia, Ohio, USA, ⁵Weill Cornell Medical Center, New York, New York, USA, ⁶Weill Cornell Medical College, New York, New York, USA

PD-020

Age and RAS status to select patients with metastatic colorectal cancer (mCRC) for initial sequential versus combination therapy including fluoropyrimidines (FP), irinotecan (Iri) and bevacizumab (Bev): XELAVIRI- study

D Modest¹, L Fischer von Weikersthal², T Decker³, U Vehling-Kaiser⁴, J Uhlig⁵, M Schenk⁶, J Freiberg-Richter⁷, B Peuser⁸, C Denzlinger⁹, C Peveling genannt Reddemann¹⁰, U Graeven¹¹, G Schuch¹², I Schwaner¹³, A Stahler¹⁴, A Jung¹⁵, T Kirchner¹⁵, S Held¹⁶, S Stintzing¹⁷, C Giessen-Jung¹⁸, V Heinemann¹⁹, f AIO KKK0110 investigators²⁰

¹Department of Medical Oncology & Comprehensive Cancer Center, University Hospital Grosshadern, Munich, Germany, Munich, Germany, ²Department of Oncology, Gesundheitszentrum St. Marien GmbH, Amberg, Amberg, Germany, ³Onkologie Ravensburg, Germany, Ravensburg, Germany, ⁴Onkologische Praxis, Landshut, Germany, Landshut, Germany, ⁵Onkologie Muldentel, Naunhof, Germany, ⁶Krankenhaus Barmherzige Brüder Regensburg, Regensburg, Germany, ⁷Gemeinschaftspraxis Freiberg-Richter, Jacobasch, Illmer, Wolf, Dresden, Germany, ⁸Onkologische Praxis am Diakonissinnenhaus, Leipzig, Germany, ⁹Marienhospital Stuttgart, Stuttgart, Germany, ¹⁰Onkologische Praxis, Leverkusen, Germany, ¹¹German Rectal Cancer Study Group; Kliniken Maria Hilf, Mönchengladbach, Germany, ¹²Ilpa Hamburg, Hamburg, Germany, ¹³ONkologie Kurfürstendamm, Berlin, Germany, ¹⁴LMU Großhadern, München, Germany, ¹⁵Department of Pathology, Ludwig-Maximilians University of Munich, Munich, Germany, ¹⁶Clinassess, Leverkusen, Germany, ¹⁷Department of Oncology, Klinikum Grosshadern and Comprehensive Cancer Center, LMU, Munich, Germany, ¹⁸Department of Medical Oncology, Klinikum Grosshadern, University of Munich, Munich, Germany, ¹⁹Comprehensive Cancer Center, Krebszentrum München, Munich, Germany, ²⁰na, na, Germany

Posters

P-001

Factors influencing late presentation for health care among men with cancer esophagus attending Hospice Africa Uganda (HAU)

N Bandese

Hospice Africa Uganda, Kampala, Uganda

P-002

A novel patient derived orthotopic xenograft model of gastro-esophageal junction cancer: Key platform for translational discoveries

O Veeranki, Z Tong, A Mejia, R Katkhuda, B Mino, J Canales, A Garcia, W Lang, R Bassett, J Ajani, J Wu, S Kopetz, M Blum, W Hofstetter, C Kingsley, W Norton, D Maru
UT MD Anderson Cancer Center, Houston, Texas, USA

P-003

Targeted-sequencing and comprehensive molecular profiling of gastric signet ring cell carcinoma

J Wei¹, N Wu¹, Y Wang², B Xu², Y Yang¹, J Du¹, L Yu¹, Z Zou¹, Y Shao³, S Zhu⁴, B Liu⁵
¹The Comprehensive Cancer Center of Drum-Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, China, ²The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, China, ³Nanjing Shihe Gene Bio-Technology Co.,Ltd., Nanjing, China, ⁴The Beijing Genomics Institute, ShenZhen, China, ⁵The Comprehensive Cancer Center of Drum-Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, China

P-004

MicroRNAs and CDH1 regulation in intestinal-type gastric cancer

C Molinari¹, T Rossi², R Abou Khouzam³, G Ranzani³, G Tedaldi², P Ulivi⁴, P Morgagni⁵, L Saragoni⁵, M Monti², D Calistri⁶
¹Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, ²Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, ³University of Pavia, Pavia, Italy, ⁴Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, ⁵Morgagni-Pierantoni Hospital, Forli, Italy, ⁶Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Meldola, Italy

P-005

Retrospective analysis of the frequency of the ALK translocation obtained by immunohistochemistry in gastric adenocarcinomas in a single Costa Rican hospital

*L Corrales-Rodriguez¹, J Porras¹, M Araya¹, A van der Laet², P Khanna³, M Juárez¹
¹Hospital San Juan de Dios, San José, Costa Rica, ²Centro de Investigación y Manejo del Cancer / CCSS, San José, Costa Rica, ³Centro de Investigación y Manejo del Cáncer, San José, Costa Rica*

P-006

Personalization of treatment for patients with stomach cancer using molecular genetic markers

*I Bykov¹, M Mikerova¹, M Nemtsova², T Kchorobryh²
¹Sechenov University, Moscow, Russian Federation, ²First Moscow Medical University, Moscow, Russian Federation*

P-007

Neoadjuvant FLOT: Real world toxicity from a specialist UK centre

*Z Kordatou¹, G Papaxoinis², T Waddell¹, V Owen-Holt¹, J Weaver¹, R Hubner¹, W Mansoor¹
¹The Christie NHS Foundation Trust, Manchester, UK, ²Laiko General Hospital, Athina, Greece*

P-008

Treatment decisions in adolescents and young adults with gastric cancer in North Estonia Medical Centre from 2007-2016

*M Lõhmus¹, K Lepik¹, T Kütt², T Seufferlein³, K Oselin¹
¹North Estonia Medical Centre, Tallinn, Estonia, ²Tartu University Hospital, Tartu, Estonia, ³Department of Internal Medicine I, University of Ulm, Ulm, Germany*

P-009

Epidemiology and overall survival of gastric carcinoma patients (about 210 cases) experience of medical oncology department of CHU Hassan II Fez

*H Erraichi¹, Z Benbrahim², S Berrad³, K Darif⁴, L Nouikh³, L Amaadour², K Oualla², F Lmraber⁵, S Arifi⁶, N Mellas⁶
¹Hassan II University Hospital, Fez, Morocco, ²Medical Oncology Department, Hassan II University Hospital, Fez, Morocco, ³Fez, Fez, Morocco, ⁴Hassan II University Hospital Fez, Fez, Morocco, ⁵Medical Oncology Unit, University Hospital of Hassan II, Fez, Morocco, ⁶Department of Medical Oncology, Hassan II University Hospital, Fez, Morocco*

P-010

Berberine inhibits the migration and invasion depending on HNF4α via Wnt/beta-catenin pathway in gastric cancer

Q Hu, P Yi

Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China

P-011

Estrone and prolactin can be markers of risk of metastasis and pre-metastatic niche in patients with stomach cancer

O Kit; E Frantsiyants, V Bandovkina, Y Pogorelova, Y Gevorkyan, N Soldatkina, N Samoylenko

Rostov Research Institute of Oncology, Rostov-on-Don, Russian Federation

P-013

Redox forms of glutathione mark the aggressiveness of stomach cancer

I Goroshinskaya, E Surikova; E Frantsiyants, I Neskubina, Y Pogorelova, D Medvedeva, A Maslov, O Kit

Rostov Research Institute of Oncology, Rostov-on-Don, Russian Federation

P-014

Diagnostic and therapeutic efficacy of endoscopic enucleation for subepithelial tumors originating from muscularis propria layer

B Bang, E Ko, K Kwon, Y Shin, H Kim

Inha University College of Medicine, Incheon, Republic of Korea

P-015

Patient derived xenografts from American minority gastric cancer patients

S Wang¹, M Zhu¹, S Hammer¹, J Shen², I Nassour¹, J Mansour¹, D Agarwal¹, H Zhu¹, M Porembka¹

¹UT Southwestern Medical Center, Dallas, Texas, USA, ²Stanford University, Stanford, California, USA

P-016

Impact of HIF-1α and PKM1 expression on acquisition of paclitaxel resistance in gastric cancer

S Fushida, M Okazaki, J Kinoshita, T Yamaguchi, T Ohta

Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan, Kanazawa, Japan

P-017

Overall survival of patients with HCC treated with sorafenib versus patients treated with supportive therapy in evidence in Oncology Cabinet of Municipal Hospital of Pascani in session 2013-2018

E Bosteanu, V Hincu
Emergency Municipal Hospital, Pascani, Romania

P-018

The role of endothelial filtration for locoregional targeting of hepatic tumours with endothelium-specific antibodies and nanoparticles

N Winkler, F Strübing, D Kyuno, B Qian, Z Wang, W Groß, W Mier, E Ryschich
University Hospital Heidelberg, Heidelberg, Germany

P-019

Clinic-pathological pattern of hepatocellular carcinoma (HCC) in Egypt

H Elghazaly¹; A Gaballah², N Bahie Eldin³
¹Clinical Oncology Dept, Ain Shams University, Cairo, Egypt, ²Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt, ³Ain Shams University, Cairo, Egypt

P-020

Immunohistochemical study of KRAS, NRAS, BRAF and MSI phenotype in small bowel adenocarcinoma

V Michalaki¹, G Frangulidis², A Poydorou², T Theodosopoulos³, A Vezakis⁴, N Dafnios⁴, M Frangou⁵, E Karvouni⁶, C Papadimitriou⁷
¹Areteion Hospital University of Athens, Athens, Greece, ²Areteion Hospital 2nd Department of Surgery, Athens, Greece, ³Department of Surgery Areteion Hospital University of Athens, Athens, Greece, ⁴Department of Surgery Areteion Hospital, Athens, Greece, ⁵Areteion Hospital, Athens, Greece, ⁶Histopathology Department, Athens, Greece, ⁷Oncology Unit Areteion Hospital University of Athens, Athens, Greece

P-021

Molecular profiling of gastrointestinal cancer

P Apostolou, M Papadimitriou; P Parsonidis, A Iliopoulos, I Papasotiriou
Research Genetic Cancer Centre S.A., Florina, Greece

P-022

Clinico epidemiological and therapeutic profile of GIST: Oran center's experience

F Boudinar¹, Z Sara², B Larbaoui¹

¹Medical Oncology Department, EHSO Emir Abdelkader, Oran, Algeria, ²CAC ORAN, Oran, Algeria

P-023

Gastrointestinal stromal tumours: Retrospective review of an institution

*A Silva; H Magalhães, C Vieira, A Ferreira, J Dinis, M Soares
IPO-Porto, Porto, Portugal*

P-024

Varying Distribution Of Tissue Plasminogen Activators In Gastrointestinal Adenocarcinoma

*O Kit; E Frantsiyants, L Kozlova, A Maslov, E Kolesnikov, E Dzhenkova, N Samoylenko
Rostov Research Institute of Oncology, Rostov-on-Don, Russian Federation*

P-026

Tumor-associated universal inhibitors and free plasmin in adenocarcinoma of stomach and pancreatic head

*E Frantsiyants, O Kit, L Kozlova, A Maslov, E Kolesnikov, S Ilchenko
Rostov Research Institute of Oncology, Rostov-on-Don, Russian Federation*

P-027

Polymer hydrogels as innovative carriers for anticancer therapy

*M Kędzierska¹, A Drabczyk², S Kudłacik–Kramarczyk², P Potemski³, B Tyliszczak²
¹Medical University of Lodz, Department of Chemotherapy, WWCOiT Copernicus Hospital, Lodz, Poland, ²Cracow University of Technology, Krakow, Poland, ³Medical University of Lodz, Department of Chemotherapy, WWCOiT Copernicus Hospital, Lodz, Poland*

P-028

Lipoxin A4 inhibits the paracrine of Nodal in CAFs by suppressing FPRL1/ROS/NF-κB signaling to attenuate invasion and metastasis of gallbladder carcinoma

Y Shi¹, Y Fan², Y Hu³, J Jing³, E Li³

¹Department of Medical Oncology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China, ²Department of Medical Oncology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China, ³Department of Medical Oncology, First Affiliated

Hospital of Xi'an Jiaotong University, Xi'an, China

P-029

The therapeutic effect of newly developed endoscopic irreversible electroporation ablative device in gastrointestinal tract: Application to live porcine esophagus, stomach and rectum

J Lee¹, S Choi², S Kim¹, J Lee¹, H Choi³, E Kim⁴, B Keum¹, Y Jeon⁵, H Chun⁴, H Lee⁶, C Kim¹
¹Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea, ²Korea University Anam Hospital, Seoul, Republic of Korea, ³Division of Gastroenterology and Hepatology, Department of Internal Medicine, Institute of Gastrointestinal Medical Instrument Research, Korea University College of Medicine, Seoul, Republic of Korea, ⁴Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea, ⁵Division of Gastroenterology and Hepatology, Department of Internal Medicine, Seoul, Republic of Korea, ⁶Korea University College of Medicine, Seoul, Republic of Korea

P-030

Epidemiological profile and factors associated with mortality among patients with gastrointestinal cancers in a Haitian cancer program

J Bernard, V DeGennaro
Innovating Health International/St Luke Family Hospital, Tabarre, Haiti

P-031

Morbidity trends for selected gastrointestinal cancers in Poland and the costs of treatment

M Jarosz, E Rychlik
Institute of Food and Nutrition, Warsaw, Poland

P-032

FOLFIRINOX versus gemcitabine-cisplatin combination as first line therapy in treatment of pancreatic cancer

A Ozet¹, N Kayahan Satıř², H Satıř³
¹Ankara Gazi University Hospital, Ankara, Turkey, ²Gazi University Faculty of Medicine Hospital, Ankara, Turkey, ³Gazi University Faculty of Medicine Hospital, Ankara, Turkey

P-033

Longitudinal assessment of neutrophil-to-lymphocyte ratio (NLR) from diagnosis until death reveals a biphasic trend in metastatic pancreatic adenocarcinoma patients

C Morelli¹, V Formica², S Pellicori³, A Nardecchia¹, M Roselli¹

¹Medical Oncology Unit, Tor Vergata University Hospital, Rome, Italy, ²Medical Oncology Unit, University of Rome Tor Vergata, Rome, Italy, ³Unit of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, Milan, Italy

P-034

Austrian real world data in elderly and younger metastatic pancreatic cancer patients: Interim results of a multicenter non-interventional study with nab-paclitaxel/gemcitabine

W Eisterer¹, A Gerger², L Öhler³, B Mlineritsch⁴, T Sliwa⁵, K Wilthoner⁶, A Petzer⁷, P Pichler⁸, E Hubmann⁹, T Winder¹⁰, S Burgstaller¹¹, M Korger¹², J Andel¹³, E Wöll¹⁴, H Neumann¹⁵, M Pecherstorfer¹⁶, K Philipp-Abbrederis¹⁷, A Djanani¹⁷, B Gruenberger¹⁸, F Längle¹⁹, G Prager²⁰

¹Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria, ²Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria, ³St. Josef Krankenhaus, Vienna, Austria, ⁴Universitätsklinik Salzburg, Salzburg, Austria, ⁵Hanuschkrankenhaus Wien, Vienna, Austria, ⁶Landeskrankenhaus Vöcklabruck, Vöcklabruck, Austria, ⁷Ordensklinikum Linz BHS-EKH, Linz, Austria, ⁸Universitätsklinikum St. Pölten, St. Pölten, Austria, ⁹Krankenhaus der Barmherzigen Brüder Graz, Graz, Austria, ¹⁰Landeskrankenhaus Feldkirch, Feldkirch, Austria, ¹¹Klinikum Wels-Grieskirchen, Wels, Austria, ¹²Krankenhaus der Barmherzigen Brüder Eisenstadt, Eisenstadt, Austria, ¹³Landeskrankenhaus Steyr, Steyr, Austria, ¹⁴Krankenhaus St. Vinzenz, Innere Medizin, Zams, Austria, ¹⁵Krankenhaus der Elisabethinen Klagenfurt, Klagenfurt, Austria, ¹⁶Landesklinikum Krems, Krems, Austria, ¹⁷Medizinische Universität Innsbruck, Innsbruck, Austria, ¹⁸Barmherzige Brüder Wien, Dept Internal Med, Vienna, Austria, ¹⁹Dept Surgery, Wr Neustadt, Austria, ²⁰Clinical Division of Medical Oncology, Department of Medicine I, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria

P-035

Hepatic stellate cells (HSCs) activating HSF1-mediated COMP secretion promote liver metastasis of pancreatic cancer through CD36/AKT/FOXO1 signaling

L Sun¹, Y Wang², Q Li², L Wang², C Wang², B Yao², Z Liu², T Song², K Tu², Q Liu²
¹Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China, ²Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China

P-036

High proliferation is independently associated with disease progression in metastatic pancreatic adenocarcinoma

S Temraz¹, M Salim Hammoud¹, I Makki², S Nassif³, M Charafeddine⁴, D Mukherji¹, A Shamseddine¹
¹American University of Beirut Medical Center, Beirut, Lebanon, ²American University of Beirut, Beirut, Lebanon, ³American University of Beirut Medical Center, Beirut, Lebanon, ⁴American University of Beirut, Beirut, Lebanon

P-037

Pancreatic cancer in Morocco: A retrospective review

A Haimer¹, F Habib², A Soulaymani¹, A Mokhtari¹, H Hami¹

¹Laboratory of Genetics and Biometry, Faculty of Science, Ibn Tofail University, Kenitra, Morocco, ²Al Azhar Oncology Center, Rabat, Morocco

P-038

Stereotactic body radiation therapy (SBRT) for locally advanced pancreatic cancer (LAPC)

M Vera Merino, C Niño de Guzmán, D Angel Schutte, D Venencia, L Suarez Villasmil, S Zunino

Instituto Privado de Radioterapia, Cordoba, Argentina

P-039

Vascular endothelial growth factor (VEGF) splice isoforms may hold the key to targeting tumour angiogenesis in oesophageal cancer

F Mehedi

Kettering General Hospital NHS Foundation Trust, Kettering, UK

P-040

Biochemical and radiological inflammatory markers in oesophageal squamous cell carcinoma treated with radical chemoradiation

N Khin¹, W Peh², W Tham², W Lam², M Wang³, T Siow¹, F Lim¹, D Tan¹, F Chin¹, E Chua¹, F Wang¹, S Ho¹, C Yip¹

¹Radiation Oncology, National Cancer Centre, Singapore, ²Nuclear Medicine & Molecular Imaging, Singapore General Hospital, Singapore, ³Radiation Oncology, National Cancer Centre, Singapore

P-041

Prognostic impact of C-reactive protein/albumin ratio in locally advanced esophageal cancer

J Simões, N Tavares, M Ribeiro, C Borges, D Almeida, A Costa, L Águas, S Meireles
Hospital S. João, Porto, Portugal

P-042

**Definitive chemoradiation in esophageal squamous-cell carcinoma:
Carboplatin/paclitaxel versus cisplatin/5-FU**

N Tavares¹, M Ribeiro¹, S Meireles², D Almeida¹, L Águas¹, A Costa¹, P Fontes¹, M Damasceno²

¹Hospital S. João, Porto, Portugal, ²Hospital de S. João, Porto, Portugal

P-043

Oncologic outcomes of elderly patients with localized esophageal cancer who underwent curative surgery compared with younger patients

H Choi¹, S Sung²

¹The Catholic University of Korea, Uijeongbu-Si, Republic of Korea, ²Department of Radiation Oncology, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Su Won, Republic of Korea

P-044

Long term survival in advanced esophageal cancer, treated with a French modality of hypofractionated radiotherapy + chemotherapy with or without surgery, the experience at the Instituto Nacional de Cancerología, México

J Zamora Moreno¹, V Aiello-Crocifoglio², B García Pantoja¹, E Ruiz-García³, G Estrada⁴, F Baille⁵

¹Instituto Nacional de Cancerología, Mexico City, Mexico, ²Instituto Nacional de Cancerología, Mexico City, Mexico, ³Instituto Nacional de Cancerología, Tlalpan, Mexico, ⁴Instituto Mexicano del Seguro Social, Mexico City, Mexico, ⁵Hopitaux de Paris, Paris, France

P-045

Analysis of global factors associated with survival in esophageal squamous cell carcinoma: Our experience at Ramon y Cajal Hospital

A Barquín García¹, J Serrano Domingo², C Saavedra Serrano¹, V Albarrán Artahona¹, M Villamayor Delgado³, O Martínez Saez³, J Molina Cerrillo⁴, R Martín Huertas¹, E Corral de la Fuente¹, R Ferreiro Monteagudo⁴, M Rodríguez Garrote⁴, V Pachón Olmos⁴, M Vaz⁵, P Reguera Puertas⁴, C Guillén-Ponce⁶, A Carrato⁷, F Longo Muñoz⁵

¹Ramón y Cajal Hospital, Madrid, Spain, ², ³Ramón y Cajal University Hospital, Madrid, Spain, ⁴Ramón y Cajal University Hospital, Madrid, Spain, ⁵Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁶H. Universitario Ramón y Cajal, IRYCIS, Madrid, Spain, ⁷IRYCIS, CIBERONC, Alcalá University, Hospital Universitario Ramón y Cajal, Madrid, Spain

P-047

Feasibility of docetaxel, cisplatin and S-1 chemotherapy in elderly patients: Comparison with younger

Y Nakamura¹, T Nishimaki², H Shimoji¹, H Karimata¹

¹Digestive and General Surgery, University of the Ryukyus, Nishihara, Japan,

²Department of Surgery, University of the Ryukyus Faculty of Medicine, Nishihara-cho, Japan

P-048

Neoadjuvant chemotherapy for locally advanced squamous cell carcinoma of esophagus: Clinical profile and outcomes from tertiary care cancer centre

N Kumar¹, S Deo¹, N Shukla², S Bhorawal³, A Sharma⁴, R Pramanik¹, R Sahoo⁴, S Kumar⁵

¹All India Institute Of Medical Sciences, New Delhi, India, ²Dr B.R. Ambedkar Institute

Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India, ³All

India Institute of Medical Science, New Delhi, India, ⁴All India Institute Of Medical

Sciences, Delhi, India, ⁵All India Institute of Medical Science, Delhi, India

P-049

Liver metastases from esophageal carcinoma

D Kostov

Military Medical Academy, Varna, Bulgaria

P-050

Outcomes of minimal invasive three stage esophagectomy from a cancer centre in Pakistan

H Ali¹, I Ul Islam Nasir², A Wahid Anwer³

¹Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan,

²Shaukat Khanum Memorial Cancer Hospital And Research Center, Lahore, Pakistan,

³na, na, Pakistan

P-052

A phase 3 study of chemotherapy + pembrolizumab versus chemotherapy + placebo as first-line therapy for patients with advanced esophageal or esophagogastric junction (E/EGJ) cancer: KEYNOTE-590

K Kato¹, M Shah², P Enzinger³, J Bennouna⁴, L Shen⁵, A Adenis⁶, J Sun⁷, B Cho⁸, M

Ozguroglu⁹, T Kojima¹⁰, V Kostorov¹¹, C Hierro¹², Y Zhu¹³, S Shah¹³, P Bhagia¹³, T Doi¹⁰

¹National Cancer Center Hospital, Chuo-ku, Japan, ²Weill Cornell Medical College and

New York Presbyterian Hospital, New York, New York, USA, ³Dana-Farber Cancer

Institute, Boston, Massachusetts, USA, ⁴University Hospital of Nantes, Nantes, France,

⁵Beijing Cancer Hospital, Beijing, China, ⁶Institut du Cancer de Montpellier, Montpellier,

France, ⁷Samsung Medical Center, Seoul, Republic of Korea, ⁸Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea, ⁹Istanbul University, Cerrahpasa School of Medicine, Istanbul, Turkey, ¹⁰National Cancer Center Hospital East, Kashiwa, Japan, ¹¹Leningrad Regional Oncology Dispensary, Saint Petersburg, Russian Federation, ¹²Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain, ¹³Merck & Co., Inc., Kenilworth, New Jersey, USA

P-053

Pre-treatment peripheral neutrophil-lymphocyte ratio as a prognostic factor in gastric cancer

A Gaballah¹, T Hussein², A Ezzat², M Magdy²

¹*Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt,*

²*Department of Clinical Oncology, Ain Shams University, Cairo, Egypt*

P-054

Predicting HER2 status in esophagogastric cancer: Development and validation of an easy-to-use nomogram

L Fornaro¹, A Parnofiello², C Ugolini³, N Cardarelli⁴, G De Maglio⁵; I Pecora⁶, F Crivelli⁷, S Catanese⁸, G Cardellino⁹, G Musettini⁸, N Pella⁹, G Pasquini¹⁰, S Pizzolitto⁵, F Salani¹¹, M Clerico⁷, G Fontanini¹², G Fasola¹³, D Maurizio⁴, C Vivaldi⁸, F Montagnani⁷

¹*U.O. Oncologia Medica 2, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy,* ²*Department of Oncology, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy,* ³*Department of Laboratory Medicine, Section of Pathology, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy,* ⁴*Department of Oncology, San Bortolo General Hospital, AULSS8 East District, Vicenza, Italy,* ⁵*University Hospital Udine, Udine, Italy,* ⁶*Azienda Ospedaliero Universitaria Pisana, Pisa, Italy,* ⁷*Department of Oncology, Azienda Sanitaria Locale di Biella, Biella, Italy,* ⁸*Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy,* ⁹*Department of Oncology, Azienda Sanitaria Universitaria Integrata S. Maria della Misericordia, Udine, Italy,* ¹⁰*Department of Oncology, University Hospital, Pisa, Italy,* ¹¹*Unit of Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy,* ¹²*Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy,* ¹³*University Hospital Santa Maria della Misericordia, Udine, Italy*

P-055

Prolonged overall survival of metastatic gastric cancer patients with BRCA germline mutations

N Halpern¹, A Grinshpun², B Boursi¹, T Golan³, O Margalit⁴, D Aderka⁴, Y Laitman⁵, E Friedman⁵, A Hubert⁶, T Peretz⁶, T Hamburger⁶, I Kedar-Barnes⁷, Z Levi⁸, I Ben-Aharon⁹, Y Goldberg¹⁰, E Shacham-Shmueli³

¹*Department of Oncology, Sheba Medical Center, Ramat Gan, Israel,* ²*Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel,* ³*Sheba Medical Center, Ramat Gan, Israel,* ⁴*Sheba Medical Center, Ramat Gan, Israel,* ⁵*The Susanne Levy Gertner Oncogenetics Unit, The Danek Gertner Institute of Human Genetics, Ramat Gan, Israel,* ⁶*Sharett Institute of Oncology, Hadassah-Hebrew University*

Medical Center, Jerusalem, Israel, ⁷Recanati Genetics Institute, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel, ⁸Division of Gastroenterology, Rabin Medical Center, Early Detection and High Risk Unit, Petach Tikva, Israel, ⁹Institute of Oncology, Davidoff Center, Rabin Medical Center, Petach Tikva, Israel, ¹⁰ Recanati Genetics Institute, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel

P-056

Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are independent prognostic factors for overall survival in Hispanic patients with gastric adenocarcinoma

A Ramos-Esquivel¹, D Brenes², E Cordero³, W Alpizar-Alpizar³

¹University of Costa Rica, San José, Costa Rica, ²Universidad de Costa Rica, San Pedro, Costa Rica, ³University of Costa Rica, San Pedro, Costa Rica

P-057

Predicting survival benefit of capecitabine plus cisplatin in patients with metastatic gastric cancer patients using quantitative proteomics

E An¹, M Ryu², D Yan¹, Y Park², H Na², J Ma², Y Tian³; F Cecchi⁴, T Hembrough⁵, Y Kang²

¹NantOmics, Rockville, Maryland, USA, ²Asan Medical Center, Seoul, Republic of Korea, ³NantOmics, LLC, Rockville, Maryland, USA, ⁴Nantomics, Rockville, Maryland, USA, ⁵NantOmics, Rockville, Maryland, USA

P-058

The prognostic value of systemic inflammatory factors in patients with HER2-positive metastatic gastric cancer

N Martínez-Lago¹, R Lesta-Mellid¹, C Reboredo Rendo¹, M Reboredo-Lopez¹, L Antón Aparicio²

¹University Hospital of A Coruña, A Coruña, Spain, ²Medical Oncology Department - University Hospital of A Coruña, A Coruña, Spain

P-059

The overview of H. pylori prevalence in patients with dyspepsia and its association with gastric adenocarcinoma at different locations.

S Aghayeva

Azerbaijan Medical University, Baku, Azerbaijan

P-060

Comparison of efficacy and safety between redo-endoscopic treatment and surgery for recurrent gastric neoplasms at the scar of prior endoscopic submucosal dissection

D Kim¹, H Na¹, J Ahn¹, J Lee², K Jung¹, K Choi¹, H Song¹, G Lee¹, H Jung¹

¹Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical

Center, Seoul, Republic of Korea, ²Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

P-061

Immunocytochemical method for diagnosis of metastases of signet ring cell carcinoma of the stomach

*S Lukmonov¹, O Usmanov¹, M Ismailov², K Madatov¹, U Kurbankulov¹, U Allazarov¹
¹Tashkent Medical Academy, Tashkent, Uzbekistan, ²Tashkent Pediatric Medical Institute, Tashkent, Uzbekistan*

P-062

Radiation therapy in locally distributed inoperable cancer of the stomach without the symptoms of obstruction

*S Lukmonov¹, O Usmanov¹, K Madatov¹, M Ismailov², U Kurbankulov¹, U Allazarov¹
¹Tashkent Medical Academy, Tashkent, Uzbekistan, ²Tashkent Pediatric Medical Institute, Tashkent, Uzbekistan*

P-063

The clinical outcomes and the pathogenetic background of gastric MALT lymphoma in Korea

*S Lee¹, D Cheung²
¹Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea, ²Yeouido St. Mary Hospital, Seoul, Republic of Korea*

P-064

Early outcomes of a pilot study of neoadjuvant chemotherapy with S-1 plus oxaliplatin at dose of 130mg/m² (nacG-SOX130) in stage III gastric cancer

*S Konishi¹, D Manaka¹, H An², Y Nishikawa², T Ota¹, R Kudo¹, K Kawaguchi¹, S Hamasu¹, R Nishitai¹
¹Department of Surgery, Gastrointestinal Center, Kyoto Katsura Hospital, Nishikyo-ku, Japan, ²Department of Surgery, Gastrointestinal Center, Kyoto Katsura Hospital, Nishikyo-ku, Japan*

P-065

Patterns of care and clinical outcomes for gastric and gastro-oesophageal cancers in South Australian population: Initial results of a state-wide audit

*N Abbas¹, M Barnes², T Price³, C Karapetis⁴, T Bright¹, J Bull⁵, R Gowda⁶, N Rodgers⁷, D Watson¹, C Connell⁸, S Thompson⁶, J Shenfine⁵, N Singhal⁶, A Roy¹
¹Flinders Medical Centre, Bedford Park, Australia, ²Flinders University, Bedford Park, Australia, ³Queen Elizabeth Hospital and University of Adelaide, Woodville, Australia,*

⁴*Southern Adelaide Local Health Network, Adelaide, Australia,* ⁵*Finders Medical Centre, Bedford Park, Australia,* ⁶*Royal Adelaide Hospital, Adelaide, Australia,* ⁷*Clinpath Laboratories, Kent Town, Australia,* ⁸*Adelaide Radiotherapy Centre, Bedford Park, Australia*

P-066

Feasibility study of intraperitoneal docetaxel combined with intravenous cisplatin and oral S-1 for gastric cancer patients with peritoneal carcinomatosis

K Lam¹, B Law², W Chan², Y Wong³, K Chiu⁴, T So⁵, S Chan⁶, V Lee¹, K Chu³, D Kwong⁷, S Law⁷

¹*Department of Clinical Oncology, LKS Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China,* ²*Queen Mary Hospital, Hong Kong, China,* ³*Dept. of Surgery, The University of Hong Kong, Hong Kong, China,* ⁴*Dept. of Diagnostic Radiology, The University of Hong Kong, Hong Kong, China,* ⁵*Department of Clinical Oncology, LKS Faculty of Medicine, University of Hong Kong, Hong Kong, China,* ⁶*Queen Mary Hospital, Hong Kong, China,* ⁷*The University of Hong Kong, Hong Kong, China*

P-067

Neutrophil-to-lymphocyte ratio as a predictive or prognostic factor for gastric cancer treated with nivolumab: A retrospective study

T Ogata¹, H Satake², M Ogata¹, Y Hatachi³, H Yasui⁴

¹*Kobe City Medical Center General Hospital, Kobe, Japan,* ²*Department of Medical Oncology, Cancer Treatment Center, Kansai Medical University Hospital, Hirakata, Japan,* ³*Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan,* ⁴*Department of Oncology, Kobe City Medical Center General Hospital, Kobe, Japan*

P-068

Clinical outcomes of endoscopic submucosal dissection for lesions on the proximal location of the stomach

S Kim¹, C Choi¹, D Kang¹, H Kim¹, S Park¹, D Ryu¹, J Ko¹, H Kim¹, B Kwon¹, K Lee², J Lee²; J Lee², H Nam¹

¹*Pusan National University Yangsan Hospital, Yangsan, Republic of Korea,* ²*Pusan National University Yangsan Hospital, Yangsan-si, Republic of Korea*

P-069

Associated factors with overlooked multiple synchronous gastric epithelial neoplasia

D Kang¹, C Choi¹, H Kim¹, S Park¹, S Kim¹, D Ryu¹, J Ko¹; J Lee², J Lee², K Lee², B Kwon¹, H Kim¹, H Nam¹

¹Pusan National University Yangsan Hospital, Yangsan, Republic of Korea, ²Pusan National University Yangsan Hospital, Yangsan-si, Republic of Korea

P-070

A multicenter phase II study of TAS-114 in combination with S-1 in patients with pre-treated advanced gastric cancer (EPOC1604): Interim analysis in the first stage

A Kawazoe¹, D Takahari², Y Nakamura¹, M Suzuki¹, H Tamura¹, M Fukutani³, H Hasegawa⁴, M Yano¹, M Wakabayashi⁵, S Nomura⁶, A Sato⁷, K Shitara⁸

¹National Cancer Center Hospital East, Kashiwa-shi, Japan, ²Cancer Institute Hospital, Koto-ku, Japan, ³National Cancer Center, Kashiwa, Japan, ⁴National Cancer Center, Kashiwa, Japan, ⁵Clinical Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan, ⁶National Cancer Center, Kashiwa-city, Japan, ⁷Clinical Research Support Office, National Cancer Center, Kashiwa-city, Japan, ⁸National Cancer Center Hospital East, Kashiwa-city, Japan

P-071

Comparative effectiveness of preoperative, postoperative and perioperative treatments for resectable gastric cancer: A network meta-analysis for the literature of past 20 years

Z Cai¹, Y Yin², C Shen³, B Zhang⁴

¹Gastrointestinal Surgery, West China Hospital, Chengdu City, China, ²West China Hospital, Chengdu City, China, ³West China Hospital, Chengdu, China, ⁴West China Hospital, Sichuan University, Chengdu, China

P-072

Is the prognostic effect of etiologies in patients with gastric cardia cancer during a recent decade of Korea?

W Chung¹, Y Kim²; S Oh³

¹St. Vincent Hospital, the Catholic University of Korea, Suwon Si, Republic of Korea, ²St. Vincent Hospital, the Catholic University of Korea, Suwon Si, Republic of Korea, ³St. Vincent's Hospital, Suwon, Republic of Korea

P-073

Prognostic factors for gastric cancer after curative gastrectomy

S Karrit¹, I Belaid², F Ezzairi³, A El Ghali⁴, A Bedioui⁵, N Bouzid⁶, M Ben Mabrouk⁷, F Bouzaiene⁸, Y Ben Cheikh⁹, I Chabchoub³, M Hochlaf¹⁰, L Ben Fatma³, S Ben Ahmed³

¹Farhat Hached Sousse, Department of Medical Oncology, Sousse, Tunisia, ²Medical

Oncology Unit, Ibn El Jazzar Hospital, Kairouan, Tunisia, ³Department of Medical Oncology, Farhat Hached Hospital, Sousse, Tunisia, ⁴Department of General Surgery, Farhat Hached University Hospital, Sousse, Tunisia, ⁵Department of Pathology, Farhat Hached University Hospital, Sousse, Tunisia, ⁶Farhat Hached Sousse Hospital, Department of Radiotherapy, Sousse, Tunisia, ⁷Department of General Surgery, Sahloul University Hospital, Sousse, Tunisia, ⁸Department of Radiology, Farhat Hached University Hospital, Sousse, Tunisia, ⁹Sahloul University Hospital, Sousse, Tunisia, ¹⁰Department of Medical Oncology, Farhat Hached Hospital, Sousse, Tunisia

P-074

Outcome and prognostic factors of gastric cancer in Tunisia

S Karrit¹, I Belaid², F Ezzairi³, A El Ghali⁴, A Bedioui⁵, N Bouzid⁶, M Ben Mabrouk⁷, F Bouzaiene⁸, Y Ben Cheikh⁹, I Chabchoub³, M Hochlaf¹⁰, L Ben Fatma³, S Ben Ahmed³
¹Farhat Hached Sousse, Department of Medical Oncology, Sousse, Tunisia, ²Medical Oncology Unit, Ibn El Jazzar Hospital, Kairouan, Tunisia, ³Department of Medical Oncology, Farhat Hached Hospital, Sousse, Tunisia, ⁴Department of General Surgery, Farhat Hached University Hospital, Sousse, Tunisia, ⁵Department of Pathology, Farhat Hached University Hospital, Sousse, Tunisia, ⁶Farhat Hached Sousse Hospital, Department of Radiotherapy, Sousse, Tunisia, ⁷Department of General Surgery, Sahloul University Hospital, Sousse, Tunisia, ⁸Department of Radiology, Farhat Hached University Hospital, Sousse, Tunisia, ⁹Sahloul University Hospital, Sousse, Tunisia, ¹⁰Department of Medical Oncology, Farhat Hached Hospital, Sousse, Tunisia

P-075

Dendritic cell vaccine-based immunotherapy in combination with salvage chemotherapy for patients with advanced or relapsed gastric cancer

M Ogasawara
Sapporo Hokuyu Hospital, Sapporo, Japan

P-076

The correlation between RhoA, CDH1 expression and clinicopathological characteristics in Chinese gastric cancer patients

Q Wei, Q He, Q Xu, J Li, L Chen, C Luo, J Ying
Zhejiang Cancer Hospital, Hangzhou, China

P-077

Benefit of neoadjuvant chemotherapy for resectable gastric cancer

N Chorna¹, A Lukashenko², Y Ostapenko¹, O Kolesnik², A Boiko²
¹National Cancer Institute of Ukraine, Kiev, Ukraine, ²National Cancer Institute, Kiev, Ukraine

P-078

Management, outcome and prognostic factors of metastatic gastric cancer

S Karrit¹, I Belaid², F Ezzairi³, A El Ghali⁴, A Bedioui⁵, N Bouzid⁶, M Ben Mabrouk⁷, F Bouzaiene⁸, Y Ben Cheikh⁹, I Chabchoub³, M Hochlaf¹⁰, L Ben Fatma³, S Ben Ahmed³
¹Farhat Hached Sousse, Department of Medical Oncology, Sousse, Tunisia, ²Medical Oncology Unit, Ibn El Jazzar Hospital, Kairouan, Tunisia, ³Department of Medical Oncology, Farhat Hached Hospital, Sousse, Tunisia, ⁴Department of General Surgery, Farhat Hached University Hospital, Sousse, Tunisia, ⁵Department of Pathology, Farhat Hached University Hospital, Sousse, Tunisia, ⁶Farhat Hached Sousse Hospital, Department of Radiotherapy, Sousse, Tunisia, ⁷Department of General Surgery, Sahloul University Hospital, Sousse, Tunisia, ⁸Department of Radiology, Farhat Hached University Hospital, Sousse, Tunisia, ⁹Sahloul University Hospital, Sousse, Tunisia, ¹⁰Department of Medical Oncology, Farhat Hached Hospital, Sousse, Tunisia

P-079

Efficacy and safety of nivolumab monotherapy for metastatic gastric cancer

K Akiyoshi¹, Y Tsuboguchi¹, S Ueda¹, S Okazaki¹, A Tsuya¹, S Tokunaga¹, H Daga²
¹Osaka City General Hospital, Osaka, Japan, ²Osaka City General Hospital, Dept of Medical Oncology, Osaka, Japan

P-080

Gastric cancer in young patients under the age of 45 years old: A comparative study with older patients

S Karrit¹, I Belaid², F Ezzairi³, A Bedioui⁴, A El Ghali⁵, N Bouzid⁶, M Ben Mabrouk⁷, F Bouzaiene⁸, Y Ben Cheikh⁹, I Chabchoub³, M Hochlaf¹⁰, L Ben Fatma³, S Ben Ahmed³
¹Farhat Hached Sousse, Department of Medical Oncology, Sousse, Tunisia, ²Medical Oncology Unit, Ibn El Jazzar Hospital, Kairouan, Tunisia, ³Department of Medical Oncology, Farhat Hached Hospital, Sousse, Tunisia, ⁴Department of Pathology, Farhat Hached University Hospital, Sousse, Tunisia, ⁵Department of General Surgery, Farhat Hached University Hospital, Sousse, Tunisia, ⁶Farhat Hached Sousse Hospital, Department of Radiotherapy, Sousse, Tunisia, ⁷Department of General Surgery, Sahloul University Hospital, Sousse, Tunisia, ⁸Department of Radiology, Farhat Hached University Hospital, Sousse, Tunisia, ⁹Sahloul University Hospital, Sousse, Tunisia, ¹⁰Department of Medical Oncology, Farhat Hached Hospital, Sousse, Tunisia

P-081

Early experience on the histopathological response to perioperative docetaxel, oxaliplatin and 5-FU/Sodium levofolinate (FLOT) for patients with resectable gastric adenocarcinoma when compared to cisplatin/5-fluorouracil (CF)

A Rolo¹, S Campelos², P Carvalho³, L Oliveira¹, B Lima¹, A Teixeira¹, C Carvalho¹, I Faustino¹, C Coutinho¹
¹Department of Oncology, Hospital Senhora da Oliveira, Guimarães, Portugal,

²*Department of Pathologic Anatomy, Hospital Senhora da Oliveira, Guimarães, Portugal,*

³*Department of Gastroenterology, Hospital Senhora da Oliveira, Guimarães, Portugal*

P-082

Neoadjuvant chemotherapy in gastric cancer

A Bounedjar¹, R Yaici², A Melzi³, N Kechad⁴, M Abada⁵

¹*CHU Blida, Blida, Algeria,* ²*ONCOLOGY, ZABANA, Algeria,* ³*medical oncology societe, Blida, Algeria,* ⁴*EPH Medea Algeria, na, Algeria,* ⁵*EPH Aindefla Algeria, Blida, Algeria*

P-083

Impact of the length of the resection margin on local recurrence after curative endoscopic submucosal dissection for early gastric cancer

H Chung¹, J Park², S Shin², S Lee², Y Lee²

¹*Seoul National University, Seoul, Republic of Korea,* ²*Yonsei University College of Medicine, Seoul, Republic of Korea*

P-084

First-line mFOLFOX6 for peritoneally disseminated gastric cancer with massive ascites or inadequate oral intake

H Osumi¹, D Takahari², K Chin¹, M Ogura³, T Ichimura², T Wakatsuki⁴, I Nakayama⁵, Y Ota⁶, M Suenaga¹, E Shinozaki¹, K Yamaguchi⁷

¹*Department of Gastroenterology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Japan,* ²*Cancer Institute Hospital, Koto-ku, Japan,*

³*Department of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Japan,* ⁴*Cancer Institute Hospital Department of*

Gastroenterology, Koto-ku, Japan, ⁵*NTT Medical Center Tokyo, Shinagawa-ku, Japan,*

⁶*Cancer Institute Hospital, Japanese Foundation of Cancer Research, Tokyo, Japan,* ⁷*Department of Gastroenterology Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-ku, Japan*

P-085

The impact of the difference in total diameter of metastatic tumor as a prognostic factor for advanced gastric cancer treated with systemic chemotherapy

Y Sasaki¹, J Hirota², J Konno³

¹*Medical Oncology Division, Hakodate Central General Hospital, Hokkaido, Japan,*

²*Hakodate Central General Hospital, Hokkaido, Japan,* ³*Department of Internal Medicine, Hakodate Central General Hospital, Hakodate, Japan*

P-086

Treatment and testing patterns among patients with HER2+ advanced/metastatic gastric, esophageal or gastroesophageal junction (GEJ) adenocarcinoma in the United States

Y Janjigian¹, L Hess², Y Zhu³, Y Fang⁴, A Liepa³, C Kuder², S Chin³

¹Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA, ²Eli Lilly & Co, Indianapolis, Indiana, USA, ³Eli Lilly and Company, Indianapolis, Indiana, USA, ⁴InVentiv Health, Indianapolis, Indiana, USA

P-087

Hyperthermic intraperitoneal chemotherapy (HIPEC) in combined treatment of locally advanced and disseminated gastric cancer: Results of a single-centre study

R Yarema¹, M Ohorchak², Y Oliynyk¹, M Matusak³, M Zubarev¹, P Gyrya², Y Kovalchuk², V Safiyan², I Karelin⁴, T Semotuk², T Novicka², L Laba², M Yarysh², T Fetsych⁵

¹Danylo Halytsky Lviv National Medical University, Department of Oncology and Medical Radiology, Lviv, Ukraine, ²Lviv Regional Cancer Center, Lviv, Ukraine, ³Lviv Regional Oncology Center, Lviv, Ukraine, ⁴Lviv Oncological Regional Center, Lviv, Ukraine, ⁵Lviv Medical University, Lviv, Ukraine

P-088

Genetic polymorphisms and PG1/PG2 and G17 levels can predict gastric carcinoids in autoimmune atrophic chronic gastritis patients

R Cannizzaro¹, R Magris², S Maiero¹, M Fornasarig¹, M De Zorzi², G Zanette³, C Mazzon⁴, E Canton², A Steffan², V Canzonieri¹, V De Re⁵

¹Centro di Riferimento Oncologico, Aviano, Italy, ²Centro di Riferimento Oncologico, IRCCS, Aviano, Italy, ³Azienda per l'Assistenza Sanitaria n.5, Pordenone, Italy, ⁴Azienda per l'Assistenza Sanitaria n.5, Pordenone, Italy, ⁵Centro di Riferimento Oncologico, Aviano, Italy

P-089

Gastric cancer in Lynch Syndrome: Are precancerous conditions co- risk factors?

M Fornasarig¹, R Magris², S Maiero¹, A Viel², E Canton², V Canzonieri¹; R Cannizzaro¹

¹Centro di Riferimento Oncologico, Aviano, Italy, ²Centro di Riferimento Oncologico, IRCCS, Aviano, Italy

P-090

Ethnic and racial disparities among young patients with noncardia gastric cancer

*C Hester, A Yopp, P Polanco, J Mansour, S Wang, M Porembka
UT Southwestern Medical Center, Dallas, Texas, USA*

P-091

Influence of the visceral vessels structure variations on peculiarity of radical surgical treatment of stomach cancer

S Khoshimov, S Lukmonov
Tashkent Medical Academy, Tashkent, Uzbekistan

P-092

Multivisceral resections for locally advanced gastric cancer

Y Ostapenko¹, A Lukashenko², O Kolesnik², N Chorna¹, A Boiko²
¹National Cancer Institute of Ukraine, Kiev, Ukraine, ²National Cancer Institute, Kiev, Ukraine

P-094

A phase 3, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer that responded to platinum-based first-line chemotherapy

F Ciardiello¹, Y Bang², J Bendell³, A Cervantes⁴, R Brachmann⁵, Y Zhang⁵, M Raponi⁵, H Farin⁶, L Shen⁷
¹University of Campania, Naples, Italy, ²Seoul National University Hospital, Seoul, Republic of Korea, ³Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee, USA, ⁴University Hospital of Valencia, Valencia, Spain, ⁵BeiGene USA, Inc, Emeryville, California, USA, ⁶BeiGene USA, Inc, Cambridge, Massachusetts, USA, ⁷Beijing Cancer Hospital, Beijing, China

P-095

A randomized clinical trial of apatinib on an intermittent versus continuous dosing schedule in combination with docetaxel for advanced gastric cancer in second-line setting

Y He¹, Y Yan², L Ke², X Hu³, S Wu², J Niu², H Li¹, H Xu¹, H Luo¹, L Cao¹, W Chen¹, C Ji⁴, Y Sun⁴, G Wang⁴, T Xu⁴, B Hu⁴
¹Department of Oncology, Anhui Provincial Cancer Hospital, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China, ²Department of Oncology, Anhui Provincial Cancer Hospital, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China, ³Department of Oncology, Anhui Provincial Cancer Hospital, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China, ⁴The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China

P-096

A phase 3 study of chemotherapy + pembrolizumab vs chemotherapy + placebo as neoadjuvant/adjuvant treatment for patients with gastric or gastroesophageal junction (G/GEJ) cancer: KEYNOTE-585

Y Bang¹, E Van Cutsem², C Fuchs³, A Ohtsu⁴, J Tabernero⁵, D Ilson⁶, W Hyung⁷, V Strong⁶, T Goetze⁸, T Yoshikawa⁹, L Tang⁶, P Hwang¹⁰, K Shitara¹¹

¹Seoul National University Hospital, Seoul, Republic of Korea, ²University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium, ³Yale Cancer Center, New Haven, Connecticut, USA, ⁴National Cancer Center Hospital East, Kashiwa, Japan, ⁵Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain, ⁶Memorial Sloan Kettering Cancer Center, New York, New York, USA, ⁷Yonsei Cancer Hospital, Yonsei University Health System, Seoul, Republic of Korea, ⁸Institute of Clinical Cancer Research, UCT University Cancer Center, Frankfurt, Germany, ⁹Kanagawa Cancer Center, Yokohama, Japan, ¹⁰Merck & Co., Inc., Kenilworth, New Jersey, USA, ¹¹National Cancer Center Hospital East, Kashiwa-city, Japan

P-097

SIRT therapy with Yttrium-90 resin microspheres in patients with liver cirrhosis Child Pugh B7-9 and unresectable nonmetastatic hepatocellular cancer

J Eick¹, M Burbelko², M Plotkin³, J Steinberg⁴, W Ring⁴, C Schwertner⁴

¹Innere Medizin-Gastroenterologie, GI Onkologie und Infektiologie, Vivantes-Klinikum Am Urban, Berlin, Germany, ²Institut für Radiologie und Interventionelle Therapie, Vivantes-Klinikum Am Urban, Berlin, Germany, ³Institut für Nuklearmedizin, Vivantes-Klinikum Am Urban, Berlin, Germany, ⁴Innere Medizin-Gastroenterologie, GI Onkologie und Infektiologie, Vivantes-Klinikum Am Urban, Berlin, Germany

P-098

Treatment patterns and costs of care for patients diagnosed with hepatocellular carcinoma (HCC) in the United States (U.S.)

L Hess¹, Z Cui², X Li², Y Wu³, A Girvan², P Abada⁴

¹Eli Lilly & Co, Indianapolis, Indiana, USA, ²Eli Lilly and Company, Indianapolis, Indiana, USA, ³Syneos Health, Indianapolis, Indiana, USA, ⁴Eli Lilly and Company, Indianapolis, USA

P-099

Predictive factor for early recurrence of resected hepatocellular carcinoma

T Kato¹, H Noda², A Yoshizawa¹, N Kasahara¹, F Watanabe³, Y Endo¹, Y Kaneda¹, T Rikiyama⁴

¹Saitama Medical Center, Jichi Medical University, Saitama, Japan, ²Saitama Medical Center, Jichi Medical University, Saitama, Japan, ³Saitama Medical Center, Jichi Medical University, Saitama, Japan, ⁴Department of Surgery, Saitama Medical Center, Jichi Medical University, Saitama, Japan

P-100

Efficacy, safety, and pharmacokinetics of the anti-programmed cell death receptor-1 (PD-1) monoclonal antibody, tislelizumab (BGB-A317) in a phase 2, open-label, multicenter study to investigate in patients with unresectable hepatocellular carcinoma

A Cheng¹, G Abou-Alfa², Z Ren³, E Assenat⁴, A Cubillo⁵, S Pluntke⁶, L Rimassa⁷, P Ross⁸, L Wyrwicz⁹, J Hou¹⁰, C Li¹¹, J Wu¹², M Ducreux¹³

¹Department of Oncology and Internal Medicine, National Taiwan University Hospital, Taipei, Republic of Taiwan, ²Memorial Sloan Kettering Cancer Center, New York, New York, USA, ³Zhongshan Hospital, Fudan University, Shanghai, China, ⁴CHRU Saint Eloi, Montpellier, France, ⁵HM Universitario Sanchinarro, Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain, ⁶Kliniken Essen-Mitte, Essen, Germany, ⁷Humanitas Research Hospital – IRCCS, Rozzano, Italy, ⁸Guy's and St Thomas' NHS Foundation Trust, Great Maze Pond, UK, ⁹Centrum Onkologii-Instytut im. M. Skłodowskiej Curie, Warsaw, Poland, ¹⁰Beigene USA, Inc, Emeryville, California, USA, ¹¹BeiGene (Beijing) Co., Ltd., Beijing, China, ¹²BeiGene USA Inc., Fort Lee, New Jersey, USA, ¹³Gustave Roussy Cancer Campus Grand Paris, Villejuif, France

P-101

HEPANOVA: A phase 2 trial of tumor treating fields concomitant with sorafenib for advanced hepatocellular carcinoma

A Grosu¹, J Strouthos², T Brunner¹, U Weinberg³

¹Department of Radiation Oncology, University Hospital Freiburg, Freiburg, Germany, ²Medical Center – University of Freiburg, Freiburg, Germany, ³Novocure, Root D4, Switzerland

P-102

A retrospective review of neutrophil-lymphocyte ratio as a predictive prognostic marker in upper gastrointestinal cancers in three UK hospitals over a nine year period

N Wreglesworth¹, C Roberts², P Innominato¹

¹North Wales Cancer Centre, Bangor, UK, ²Betsi Cadwaladr University Health Board, University of Wales, Bangor, UK

P-103

The prospective multicenter study of relation between 5-HIAA / substance P plasma concentration transition and nausea/vomiting in patients with gastrointestinal cancer receiving moderately emetogenic chemotherapy

T Muranaka¹, Y Komatsu², S Ohnishi³, M Yagisawa¹, K Sawada¹, Y Kawamoto¹, H Nakatsumi¹, S Yuki³, M Dazai⁴, T Saiki⁵, A Ishiguro⁵, M Tateyama⁶, K Ono⁷, N Sakamoto⁸

¹Division of Cancer Center, Hokkaido University Hospital, Sapporo, Japan, ²Digestive Internal Medicine, Division of Cancer Center, Hokkaido University Hospital, Sapporo, Japan, ³Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan, ⁴Department of Gastroenterology, Sapporo Medical Center NTT EC,

Sapporo, Japan, ⁵Department of Medical Oncology, Teine Keijinkai Hospital, Sapporo, Japan, ⁶Department of Internal Medicine, Tomakomai Nisshou Hospital, Tomakomai, Japan, ⁷Department of Biostatistics, Hokkaido University Hospital Clinical Research and Medical Innovation Center, Sapporo, Japan, ⁸Department of Gastroenterology and Hepatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan

P-104

Amrubicin in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract

H Osumi¹, E Shinozaki¹, K Chin¹, D Takahari², M Ogura³, T Ichimura², T Wakatsuki⁴, Y Ota⁵, I Nakayama², M Suenaga¹, K Yamaguchi⁶

¹Department of Gastroenterology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Japan, ²Cancer Institute Hospital, Koto-ku, Japan, ³Department of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Japan, ⁴Cancer Institute Hospital Department of Gastroenterology, Koto-ku, Japan, ⁵Cancer Institute Hospital, Japanese Foundation of Cancer Research, Tokyo, Japan, ⁶Department of Gastroenterology Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-ku, Japan

P-105

Clinical outcomes and toxicity of chemoradiation with IMRT for anal cancer

*J Fonseca, N Ferreira, C Viveiros, G Fernandez, C Travancinha, L Mirones, S Esteves, I Rosa, M Limbert, J Freire, F Santos
Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal*

P-106

Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin chemotherapy: retrospective analysis of 142 patients

H Engin

Bulent Ecevit University School of Medicine Department of Medical Oncology , Zonguldak, Turkey

P-107

Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A single center experience

H Engin

Bulent Ecevit University School of Medicine Department of Medical Oncology , Zonguldak, Turkey

P-108

Effectiveness of radical radiochemotherapy (RCT) in patients with anal cancer managed at the Bank of Cyprus Oncology Centre: 15 years' experience

V Vassiliou¹, M Pittaka², A Gudenian³, K Michailidou⁴, L Michael⁵, I Constantinou⁶, P Kountourakis⁶, D Andreopoulos⁶, M Talias⁷, M Kantaris⁶, M Charalambous⁷

¹Bank of Cyprus Oncology Centre, Strovolos, Cyprus, ²Limassol General Hospital, Limassol, Cyprus, ³Larnaca General Hospital, Larnaca, Cyprus, ⁴Department of Electron Microscopy/Molecular Pathology, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus, ⁵University of Patras Medical School, Patras, Greece, ⁶Bank of Cyprus Oncology Centre, Nicosia, Cyprus, ⁷Open University Cyprus, Nicosia, Cyprus

P-109

Detection and management of hyperglycaemia in oncology patients receiving systemic anti-cancer therapy

L Morrison¹, R Gillmore², R Pierce³

¹The Royal Free Hospital, London, UK, ²Royal Free London NHS Foundation Trust, London, UK, ³Royal Free Hospital, London, UK

P-110

Squamous cell carcinoma of the anal canal and the results of radical treatment with intensity-modulated radiotherapy

I Oblak¹, V Velenik¹, F Anderluh¹, E Brecejlj¹, J But-Hadzic¹, A Secerov-Ermenc², A Jeromen¹

¹Institute of Oncology, Ljubljana, Slovenia, ²institute of oncology, Ljubljana, Slovenia

P-112

Prevalence and genotyping of HPV in anal squamous cell carcinoma

S Iseas¹, M Coraglio², J Gonzalez³, E Slutsky⁴, D Carvajal⁴, A Cabanne⁵, M Carballido¹, G Mendez¹, M Picconi³, E Roca¹

¹Hospital de Gastroenterología Bonorino Udaondo-Oncology Unit, Buenos Aires, Argentina, ²Hospital de Gastroenterología Bonorino Udaondo-Coloproctology Unit, Buenos Aires, Argentina, ³Oncogenic Virus Department, National Institute of Infectious Diseases, ANLIS "Dr. Malbrán", Caba, Argentina, ⁴Hospital de Gastroenterología Bonorino Udaondo-Oncology Unit, Caba, Argentina, ⁵Hospital de Gastroenterología Bonorino Udaondo-Pathology Unit, Buenos Aires, Argentina

P-113

Management of proteinuria with VEGF inhibitor in an academic hospital in Japan: A retrospective observational research

S Kataoka¹, Y Nishikawa¹, T Funakoshi¹, T Horimatsu¹, E Uchino², S Hiragi², T Matsubara², Y Ikemi³, K Matsubara³, M Yanagita², M Muto¹

¹Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Department of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ³Department of Pharmacy, Kyoto University Hospital, Kyoto, Japan

P-114

The prognostic values of tumor characteristics and clinical factors of neuroendocrine tumors: Two centers experience

E Sezer¹, K Eser², V Ercolak³, Y Acikgoz⁴; B Ozturk⁵

¹Mersin University Medical Faculty, Department of Medical Oncology, Mersin, Turkey,

²Mersin university Medical Faculty, Department of Medical Oncology, Mersin, Turkey,

³Mersin University Medical Faculty Dept. of Medical Oncology, Mersin, Turkey, ⁴Health Sciences University Ankara Numune Education and Research Hospital Dept. of Medical Oncology, Ankara, Turkey, ⁵Health Sciences University, Antalya Education and Research Hospital, Division of Medical Oncology, Antalya, Turkey

P-115

Starting a tumor board meeting at a public sector hospital – problems faced and its impact on patient care: A lower middle income country experience

A Malik¹, M Afzal²

¹Shaukat Khanum Memorial Cancer Hospital, Lahore, Pakistan, ²Lahore General Hospital, Lahore, Pakistan

P-116

A long-term analysis of imatinib palliative treatment in gastrointestinal stromal tumors

I Domingues¹, J Carvalho¹, E Pratas¹, S Pinheiro¹, S Amaral¹, N Bonito², E Jesus³, J Ribeiro³, A Chaves⁴, A Pais³, G Sousa³

¹Instituto Português de Oncologia de Coimbra, Coimbra, Portugal, ²Portuguese Oncology Institute of Coimbra, Coimbra, Portugal, ³Portuguese Institute of Oncology of Coimbra, Coimbra, Portugal, ⁴IPO Coimbra, Coimbra, Portugal

P-117

30-day mortality associated with systemic anti-cancer therapy (SACT) in gastrointestinal malignancies: The Christie experience

F Marti Marti¹, A McGurk¹, N Alam¹, L Bhatt², M Braun¹, R Hubner¹, W Mansoor¹, C McBain¹, M McNamara³, S Mullamitha⁴, M Saunders⁵, H Sheikh², F Thistlethwaite¹, J Valle⁶, G Wilson¹, J Hasan¹

¹The Christie NHS Foundation Trust, Manchester, UK, ²The Christie Hospital, Manchester, UK, ³The Christie NHS Foundation Trust/University of Manchester (Institute of Cancer Sciences), Manchester, UK, ⁴The Christie Hospital NHS Foundation Trust, Manchester, UK, ⁵Christie Hospital NHS Foundation Trust, Manchester, UK, ⁶University of Manchester, Dept. Medical Oncology, The Christie Hospital, NHS Foundation Trust, Manchester, UK

P-118

**Chemoradiation for anal canal carcinoma in a comprehensive cancer center:
Retrospective cohort study**

*J Dias, F Pereira, N Sousa, P Ferreira, D Gomes, O Sousa
Portuguese Institute of Oncology, Porto, Portugal*

P-119

**The feasibility study of short hydration with oral rehydration therapy in chemotherapy
with cisplatin plus gemcitabine for biliary tract cancer (KHBO-1302)**

*T Ioka¹, D Sakai², H Wada³, H Eguchi⁴, K Yanagihara⁵, H Satake⁶, J Shimizu⁷, M Kanai⁸, K Hashimoto⁹, T Ajiki¹⁰, M Nakamura¹¹, Y Takeda¹², K Yoshimura¹³, E Hatano¹⁴, H Nagano¹⁵
¹Osaka International Cancer Institute, Osaka, Japan, ²Osaka University Graduate School of Medicine, Dept of Gastroenterological Surgery, Suita, Japan, ³Osaka International Cancer Institute, Osaka, Japan, ⁴Department of Surgery, Graduate School of Medicine, Osaka University, Suita, Japan, ⁵Department of Medical Oncology, Kansai Electric Power Hospital, Osaka, Japan, ⁶Department of Medical Oncology, Cancer Treatment Center, Kansai Medical University Hospital, Hirakata, Japan, ⁷Department of Surgery, Osaka Rosai Hospital, Sakai, Japan, ⁸Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁹Department of Surgery, NTT West Osaka Hospital, Osaka, Japan, ¹⁰Kobe University Hospital Hepato-Biliary-Pancreatic Surgery, Kobe, Japan, ¹¹Aizawa Comprehensive Cancer Center, Aizawa Hospital, Matsumoto, Japan, ¹²Department of Surgery, Kansai Rosai Hospital, Amagasaki, Japan, ¹³Department of Biostatistics, Innovative Clinical Research Center, Kanazawa University, Kanazawa, Japan, ¹⁴Department of Surgery, Hyogo College of Medicine, Nishinomiya, Japan, ¹⁵Yamaguchi University Graduate School of Medicine, Department of Gastroenterological, Breast and Endocrine Surgery, Ube, Japan*

P-120

**Comparison of different risk classification systems in patients with high risk
gastrointestinal stromal tumors**

*Y Yin¹, Z Cai², B Zhang³, C Shen⁴
¹West China Hospital, Chengdu City, China, ²Gastrointestinal Surgery, West China Hospital, Chengdu City, China, ³West China Hospital, Sichuan University, Chengdu, China, ⁴West China Hospital, Chengdu, China*

P-121

**Impaired quality of life of caregivers of patients with gastrointestinal cancer undergoing
palliative chemotherapy**

*N Takeuchi¹, K Koike¹, S Yoshida¹, N Sekiguchi², T Noguchi²
¹Ina Central Hospital, Ina, Japan, ²Shinsyuu University, Matsumoto, Japan*

P-122

Primary gastric diffuse large B cell lymphoma: A single center experience from developing country

A Gogia, V Raina, M Sharma

All India Institute Of Medical Sciences, New Delhi, India

P-123

Quality of life by Karnofsky index in patients with gastrointestinal cancer subject to parenteral nutritional therapy

T Pessoa¹, A Pessoa², P Aguiar², F Moreira², R Pessoa³, C Silva²

¹Laboratory of Molecular Biology and Development, University of Fortaleza, Fortaleza, Brazil, ²University of Fortaleza, UNIFOR, Fortaleza, Brazil, ³Federal University of Ceará, Fortaleza, Brazil

P-124

De novo malignancies in patients after liver transplantation: A single centre experience

K Chmelova¹, J Spicak²

¹Institute for Clinical and Experimental Medicine, Prague 4, Czech Republic, ²Institute for Clinical and Experimental Medicine, Prague, Czech Republic

P-125

Laparoscopic liver resection for tumors in proximity to major vasculature and the impact of neo-adjuvant systemic therapy

M D'Hondt¹, E Willems¹, I Parmentier², H Pottel³, C Verslype⁴, C De Meyere¹, F Vansteenkiste¹, M Besselink⁵

¹Department of Digestive and Hepatobiliary/Pancreatic Surgery, Groeninge Hospital, Kortrijk, Belgium, ²AZ Groeninge Kortrijk, Oncology and Statistics, Kortrijk, Belgium, ³Interdisciplinary Research Center, Leuven University, Campus, Kortrijk, Belgium, ⁴Dept. Of Hepatology, University Hospital Gasthuisberg, Leuven, Belgium, ⁵Academic Medical Center Amsterdam, Amsterdam, Netherlands

P-126

Impact of revision surgery timing on overall survival in incidentally detected gall bladder cancer: An experience from tertiary care centre of Northern India

A Mishra¹, M Gowda², S Bhorival³, S Deo⁴, N Shukla¹, A Sharma⁵, S Pathy², S Kumar⁶

¹All India Institute of Medical Sciences, New Delhi, India, ²All India Institute of Medical Sciences, Delhi, India, ³All India Institute of Medical Science, New Delhi, India, ⁴All India Institute Of Medical Sciences, New Delhi, India, ⁵All India Institute Of Medical Sciences, Delhi, India, ⁶All India Institute of Medical Science, Delhi, India

P-127

Impact of lymph node positivity on overall survival in operable gall bladder cancer: An experience from tertiary cancer care centre from Northern India

A Mishra¹, M Gowda², S Bhorawal³, D Muduly⁴, N Shukla¹, S Deo⁵, A Sharma⁶, S Pathy², S Kumar⁷

¹All India Institute of Medical Sciences, New Delhi, India, ²All India Institute of Medical Sciences, Delhi, India, ³All India Institute of Medical Science, New Delhi, India, ⁴Dr B.R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India, ⁵All India Institute Of Medical Sciences, New Delhi, India, ⁶All India Institute Of Medical Sciences, Delhi, India, ⁷All India Institute of Medical Science, Delhi, India

P-128

Surgical resection of primary tumor site is associated with prolonged survival in metastatic pancreatic neuroendocrine carcinoma

T Feng¹, S Ling²

¹Zhejiang Cancer Hospital, Hangzhou, China, ²The First Affiliated Hospital of Zhejiang University, Hangzhou, China

P-129

Comparing efficacy of 1-L Peg-Asc with prucalopride versus 2-L Peg-Asc for bowel preparation

S Jang¹, Y Jeen², S Choi³, J Lee⁴, S Kim⁴, J Lee⁴, H Choi¹, E Kim⁵, B Keum⁴, H Lee⁶, H Chun⁵, C Kim⁴

¹Division of Gastroenterology and Hepatology, Department of Internal Medicine, Institute of Gastrointestinal Medical Instrument Research, Korea University College of Medicine, Seoul, Republic of Korea, ²Division of Gastroenterology and Hepatology, Department of Internal Medicine, Seoul, Republic of Korea, ³Korea University Anam Hospital, Seoul, Republic of Korea, ⁴Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea, ⁵Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea, ⁶Korea University College of Medicine, Seoul, Republic of Korea

P-130

A phase I/II Trial of CRISPR-Cas9-mediated PD-1 knockout Epstein-Barr virus cytotoxic lymphocytes (EBV-CTLs) for advanced stage EBV associated malignancies

J Wei¹, J Yan², S Su², J Shao², Y Zhao², Q Xu², Y Yang¹, Z Zou¹, X Huang³, B Liu⁴

¹The Comprehensive Cancer Center of Drum-Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, China, ²The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, China, ³School of Life Science and Technology, Shanghai Tech University, Shanghai, China, ⁴The

Comprehensive Cancer Center of Drum-Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing , China

P-131

Endoscopic detachable auxiliary manipulator in endoscopic submucosal dissection: Animal model study

H Jeon¹, H Chun², B Keum³, J Lee³, S Choi⁴, S Kim³, J Lee⁵, H Choi⁶, E Kim², Y Jeen⁷, H Lee⁸, C Kim³

¹Division of Gastroenterology and Hepatology, Department of Internal Medicine, Gastrointestinal Medical Instrument Research, Korea University College of Medicine, Seoul, Republic of Korea, ²Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea, ³Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea, ⁴Korea University Anam Hospital, Seoul, Republic of Korea, ⁵Korea University College of Medicine, Seoul, Korea, ⁶Division of Gastroenterology and Hepatology, Department of Internal Medicine, Institute of Gastrointestinal Medical Instrument Research, Korea University College of Medicine, Seoul, Republic of Korea, ⁷Division of Gastroenterology and Hepatology, Department of Internal Medicine, Seoul, Republic of Korea, ⁸Korea University College of Medicine, Seoul, Republic of Korea

P-132

Poly-Ligand Profiling differentiates pancreatic cancer patients according to treatment benefit from gemcitabine+placebo versus gemcitabine+evofosfamide and identifies candidate targets

V Domyuk¹, X Liu¹, D Magee¹, Z Gatalica¹, A Stark¹, P Kennedy¹, M Rosenow¹, A Barker², D Berry³, G Poste⁴, D Halbert¹, C Hart⁵, M Famulok⁶, G Mayer⁶, M Korn¹, M Miglarese¹, D Spetzler¹

¹Caris Life Sciences, Phoenix, Arizona, USA, ²Arizona State University, Tempe, Arizona, USA, ³Berry Consultants, Austin, Texas, USA, ⁴Arizona State University, Scottsdale, Arizona, USA, ⁵Threshold Pharmaceuticals, San Francisco, California, USA, ⁶University of Bonn, Bonn, Germany

P-133

The use of NLR, PLR and CA19.9 as prognostic markers for locally advanced pancreatic cancer

A Dean¹, D Higgs¹, A Das², S Fennessy², M Rogers-Seeley², C McGarvey², M McNulty²

¹St John of God Hospital Subiaco, Subiaco, Australia, ²St John of God Hospital Subiaco, Perth, Australia

P-134

Antibodies matter: A meta-analysis of the prognostic value of human equilibrative nucleoside transporter 1 (hENT1) antibodies in pancreatobiliary cancer

D Yusuf¹, L Vos¹, A Lui¹, Z Abdelaziz¹, S Ghosh², J Spratlin¹, J Mackey¹

¹Cross Cancer Institute, Edmonton, Alberta, Canada, ²Cross Cancer Institute, Edmonton, AB, Canada

P-135

The impact of inflammatory biomarkers on overall survival of patients with pancreatic cancer treated with chemoradiation

K Holub, C Conill

Hospital Clínic de Barcelona, Barcelona, Spain

P-136

Timed-flat infusion (TFI) 5-fluorouracil with irinotecan and oxaliplatin in pancreatic adenocarcinomas: A single institution experience with FIr/FOx regimen

A Cortellini¹; A Parisi², K Cannita³, O Venditti³, F Pavese¹, C D'Orazio⁴, P Lanfiuti Baldi³, V Vicentini⁵, R Vicentini⁵, G Porzio⁴, L Verna⁶, C Ficorella¹

¹Medical Oncology Unit, St. Salvatore Hospital, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy, ²Medical Oncology Unit, St. Salvatore Hospital, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy, ³Medical Oncology Unit, St. Salvatore Hospital, L'Aquila, Italy, ⁴Medical Oncology Unit, St. Salvatore Hospital, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy, ⁵Department of Hepatobiliar-Pancreatic Surgery, St. Salvatore Hospital, L'Aquila, Italy, ⁶Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy

P-137

Intraperitoneal chemotherapy for pancreatic cancer with peritoneal metastases: A single center retrospective analysis of 25 patients

Y Tsuji¹, T Takayama¹, N Okamura¹, J Sugiyama¹, S Oiwa², M Yoshida², Y Okagawa², M Hirayama², D Sato³, Y Suzuki³

¹Department of Medical Oncology, Tonan Hospital, Sapporo, Japan, ²Department of Gastroenterology, Tonan Hospital, Sapporo, Japan, ³Department of Surgery, Tonan Hospital, Sapporo, Japan

P-138

Predictive factors for early relapse and survival in resected pancreatic cancer: A single institution experience

C Saavedra Serrano¹, P Reguera Puertas², O Martínez Saez³, F Longo Muñoz⁴, A Barquín García¹, V Albarrán Artahona¹, M Villamayor Delgado³, J Molina Cerrillo², E Corral de la Fuente¹, R Martín Huertas¹, J Serrano Domingo⁵, V Pachón Olmos², R Ferreiro Monteagudo², M Rodríguez Garrote², M Vaz⁴, R Fuentes¹, C Guillén-Ponce⁶, A Carrato⁷

¹Ramón y Cajal Hospital, Madrid, Spain, ²Ramón y Cajal University Hospital, Madrid, Spain, ³Ramón y Cajal University Hospital, Madrid, Spain, ⁴Hospital Universitario

Ramón y Cajal, Madrid, Spain, ⁵, ⁶H. Universitario Ramón y Cajal, IRYCIS, Madrid, Spain, ⁷IRYCIS, CIBERONC, Alcalá University, Hospital Universitario Ramón y Cajal, Madrid, Spain

P-139

HGCSG 1403: Phase I trial of oxaliplatin / irinotecan / S-1 (OX-IRIS) as first line chemotherapy for unresectable pancreatic cancer

A Ishiguro¹, Y Kawamoto², S Yuki³, S Nakano³, M Yagisawa², K Sawada², T Muranaka², H Hayashi⁴, H Nakatsumi², T Saiki¹, K Harada⁵, Y Kobayashi⁵, I Iwanaga⁶, K Hatanaka⁷, Y Sakata⁸, Y Komatsu⁹

¹Department of Medical Oncology, Teine Keijinkai Hospital, Sapporo, Japan, ²Division of Cancer Center, Hokkaido University Hospital, Sapporo, Japan, ³Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan, ⁴Division of Clinical Cancer Genomics, Hokkaido University Hospital, Sapporo, Japan, ⁵Department of Medical Oncology, Kushiro Rosai Hospital, Kushiro, Japan, ⁶Department of Medical Oncology, Japanese Red Cross Kitami Hospital, Kitami, Japan, ⁷Department of Gastroenterology, Hakodate Municipal Hospital, Hakodate, Japan, ⁸CEO, Misawa City Hospital, Misawa, Japan, ⁹Digestive Internal Medicine, Division of Cancer Center, Hokkaido University Hospital, Sapporo, Japan

P-141

PanCO: An open-label, single-arm pilot study of Oncosil™ in patients with unresectable locally advanced pancreatic adenocarcinoma in combination with FOLFIRINOX or gemcitabine+nab-paclitaxel chemotherapies

M Harris¹, D Croagh², M Aghmesheh³, A Nagrial⁴, N Nguyen⁵, H Wasan⁶, T Ajithkumar⁷, A Kraszewski⁸, T Maher⁸, P Ross⁹

¹Monash Cancer Centre, Melbourne, Australia, ²Monash Medical Centre, Melbourne, Australia, ³Wollongong Hospital, Wollongong, Australia, ⁴Westmead Hospital, Sydney, Australia, ⁵Royal Adelaide Hospital, Adelaide, Australia, ⁶Hammersmith Hospital, London, UK, ⁷Addenbrooke's Hospital, Cambridge, UK, ⁸OncoSil Medical, Sydney, Australia, ⁹Guy's and St Thomas' NHS Foundation Trust, Great Maze Pond, UK

P-142

Updated results of biweekly gemcitabine/nab-paclitaxel as first-line treatment for advanced pancreatic cancer

S Kokkali¹; M Drizou¹, E Tripodaki¹, D Stefanou¹, E Magou¹, D Zylis², M Kapiris¹, D Nasi¹, C Georganta¹, A Ardavanis²

¹St Savvas Anticancer Hospital, Athens, Greece, ²First Department of Medical Oncology, Aghios Savvas Anticancer Hospital, Athens, Greece

P-143

Safety of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer patients presenting with hyperbilirubinemia secondary to bile duct obstruction

M Sasaki¹, H Imaoka², M Kan², Y Suzuki², G Kimura², K Umemoto², K Watanabe², H Takahashi², Y Hashimoto², I Ohno², S Mitsunaga², M Ikeda²

¹Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Japan, ²National Cancer Center Hospital East, Kashiwa, Japan

P-144

Pancreatic ductal adenocarcinoma (PDAC) and type 2 diabetes mellitus: Cause or consequence? Analysis of the prevalence of alterations in glucose metabolism (AGM) in a patients' cohort with PDAC

L Medina Rodriguez¹, C Sanchez Cendra², M Pantin Gonzalez², D Gutierrez Abad³, I Juez Martel³, M De Torres Olombrada³

¹Hospital de Fuenlabrada, Fuenlabrada, Spain, ²Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain, ³Hospital Universitario Fuenlabrada, Fuenlabrada, Spain

P-145

FOLFIRINOX in pancreatic cancer: A careful review

E Una Cidon¹, P Alonso²

¹Oncology Department, Royal Bournemouth Hospital, NHS Foundation Trust, Bournemouth, UK, ²Clinical University Hospital, Valladolid, Spain

P-146

Circulating tumor DNA (ctDNA) as a predictor of treatment for locally advanced pancreatic cancer

G Botiraliyeva

National Cancer Research Centre, Tashkent, Uzbekistan

P-147

Use of gemcitabine and nab-paclitaxel as a third-line treatment following failure of first line gemcitabine for advanced pancreatic adenocarcinoma

M McNulty¹, A Dean², A Das¹, M Gordon¹

¹St John of God Hospital Subiaco, Perth, Australia, ²St John of God Hospital Subiaco, Subiaco, Australia

P-148

Nimotuzumab bi-weekly/low dose combined to chemotherapy in advanced pancreatic cancer: A clinical study

M Lima¹, V Jennifer², C Dominguez³, G Robin², M Dunia², O Alexander⁴, G Giselle⁴, M Amparo⁵, R Ivan², B Noyde², J Soriano²

¹Clinical Oncology Department, Ameijeiras Hospital, Havana, Cuba, ²Ameijeiras Hospital, Havana, Cuba, ³Clinical Pathology Department, Ameijeiras Hospital, Havana, Cuba, ⁴Molecular Biology Department, Ameijeiras Hospital, Havana, Cuba, ⁵Center of Molecular Immunology, Havana, Cuba

P-149

Risk factors and epidemiological features of pancreatic cancer in Iran

A Pourshams

Digestive Diseases Research Institute, Tehran University of Medical Sciences., Tehran, Iran

P-150

Prognostic effect of primary tumor location in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC)

T Macarulla Mercadé¹, A Wang-Gillam², L Chen³, J Blanc⁴, K Lee⁵, G Bodoky⁶, A Dean⁷, J Siveke⁸, B Mirakhur⁹, J Chen¹⁰, F de Jong¹¹

¹Vall d'Hebron University Hospital (HUVH) and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, ²Division of Oncology, Washington University, St. Louis, Missouri, USA, ³National Institute of Cancer Research, National Health Research Institutes, Miaoli, Republic of Taiwan, ⁴Hôpital Haut-Lévêque, Bordeaux, France, ⁵Seoul National University Hospital, Seoul, Republic of Korea, ⁶Department of Oncology, Szent László Hospital, Budapest, Hungary, ⁷St John of God Hospital Subiaco, Subiaco, Australia, ⁸West German Cancer Center, University Hospital Essen, Essen, and German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Essen, Germany, ⁹Ipsen Biopharmaceuticals, Inc., Basking Ridge, New Jersey, USA, ¹⁰Shire plc, Cambridge, Massachusetts, USA, ¹¹Shire International GmbH, Glattbrugg-Opfikon, Switzerland

P-151

Prognostic value of baseline biliary stents on outcomes in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the NAPOLI-1 trial

G Lakatos¹, K Lee², J Siveke³, J Blanc⁴, T Macarulla Mercadé⁵, A Dean⁶, G Bodoky⁷, B Mirakhur⁸, J Chen⁹, A Wang-Gillam¹⁰, L Chen¹¹, F de Jong¹²

¹Department of Oncology, St. István and St. László Hospital, Budapest, Hungary, ²Seoul National University Hospital, Seoul, Republic of Korea, ³West German Cancer Center, University Hospital Essen, Essen, and German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Essen, Germany, ⁴Hôpital Haut-Lévêque,

Bordeaux, France, ⁵Vall d'Hebron University Hospital (HUVH) and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, ⁶St John of God Hospital Subiaco, Subiaco, Australia, ⁷Department of Oncology, Szent László Hospital, Budapest, Hungary, ⁸Ipsen Biopharmaceuticals, Inc., Basking Ridge, New Jersey, USA, ⁹Shire plc, Cambridge, Massachusetts, USA, ¹⁰Division of Oncology, Washington University, St. Louis, Missouri, USA, ¹¹National Institute of Cancer Research, National Health Research Institutes, Miaoli, Republic of Taiwan, ¹²Shire International GmbH, Glattpark-Opfikon, Switzerland

P-152

The effect of best response to prior anticancer therapy on efficacy outcomes in the NAPOLI-1 trial of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy

T Macarulla Mercadé¹, A Wang-Gillam², L Chen³, J Blanc⁴, K Lee⁵, G Bodoky⁶, A Dean⁷, J Chen⁸, B Mirakhur⁹, J Siveke¹⁰, F de Jong¹¹

¹Vall d'Hebron University Hospital (HUVH) and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, ²Division of Oncology, Washington University, St. Louis, Missouri, USA, ³National Institute of Cancer Research, National Health Research Institutes, Miaoli, Republic of Taiwan, ⁴Hôpital Haut-Lévêque, Bordeaux, France, ⁵Seoul National University Hospital, Seoul, Republic of Korea, ⁶Department of Oncology, Szent László Hospital, Budapest, Hungary, ⁷St John of God Hospital Subiaco, Subiaco, Australia, ⁸Shire plc, Cambridge, Massachusetts, USA, ⁹Ipsen Biopharmaceuticals, Inc., Basking Ridge, New Jersey, USA, ¹⁰West German Cancer Center, University Hospital Essen, Essen, and German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Essen, Germany, ¹¹Shire International GmbH, Glattpark-Opfikon, Switzerland

P-153

Decreased appetite (DA) at baseline impacts prognosis in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC)

K Lee¹, G Bodoky², J Blanc³, J Siveke⁴, T Macarulla Mercadé⁵, A Wang-Gillam⁶, L Chen⁷, B Mirakhur⁸, J Chen⁹, F de Jong¹⁰

¹Seoul National University Hospital, Seoul, Republic of Korea, ²Department of Oncology, Szent László Hospital, Budapest, Hungary, ³Hôpital Haut-Lévêque, Bordeaux, France, ⁴West German Cancer Center, University Hospital Essen, Essen, and German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Essen, Germany, ⁵Vall d'Hebron University Hospital (HUVH) and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, ⁶Division of Oncology, Washington University, St. Louis, Missouri, USA, ⁷National Institute of Cancer Research, National Health Research Institutes, Miaoli, Republic of Taiwan, ⁸Ipsen Biopharmaceuticals, Inc., Basking Ridge, New Jersey, USA, ⁹Shire plc, Cambridge, Massachusetts, USA, ¹⁰Shire International GmbH, Glattpark-Opfikon, Switzerland

P-154

Real life triplet FIr/FOx chemotherapy in first line metastatic pancreatic ductal adenocarcinoma: Recommended schedule for expected activity and safety and phase II study

G Bruera¹, S Massacese², R Manetta³, A Giordano³, S Carducci³, E Ciacco², E Ricevuto¹
¹Oncology Territorial Care, S. Salvatore Hospital, Oncology Network ASLI Abruzzo, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy, ²Pharmacy Unit, S. Salvatore Hospital, Oncology Network ASLI Abruzzo, L'Aquila, Italy, ³Radiology, S. Salvatore Hospital, Oncology Network ASLI Abruzzo, L'Aquila, Italy

P-155

Open-label, multicenter, single-arm study of FABLOx (metronomic 5-fluorouracil plus nab-paclitaxel, bevacizumab, leucovorin, and oxaliplatin) in patients with metastatic pancreatic cancer: Phase I results

V Sahai¹, W Saij², A Kalyan³, P Philip⁴, C Rocha-Lima⁵, A Ocean⁶; M Ondovik⁷, D Simeone⁸, M Karnoub⁷, C Louis⁷, V Picozzi⁹
¹University of Michigan, Ann Arbor, Michigan, USA, ²Tufts Medical Center, Boston, Massachusetts, USA, ³Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA, ⁴Karmanos Cancer Center, Detroit, Michigan, USA, ⁵Gibbs Cancer Center and Research Institute, Spartanburg, South Carolina, USA, ⁶Weill Cornell Medical College, New York, New York, USA, ⁷Celgene Corporation, Summit, New Jersey, USA, ⁸New York University Langone Perlmutter Cancer Center, New York, New York, USA, ⁹Virginia Mason, Seattle, Washington, USA

P-156

Effectiveness and costs of FOLFIRINOX in the treatment of advanced pancreatic cancer in a Portuguese oncology center

H Magalhães¹, J Lima², M Cassiano Neves¹, M Fontes e Sousa¹, M Machado¹
¹IPO-Porto, Porto, Portugal, ²Hospital de Braga, Braga, Portugal

P-157

Gemcitabine/nabpaclitaxel efficacy in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma

V Michalaki¹, A Poydorou², G Frangulidis², A Vezakis³, E Karvouni⁴, C Papadimitriou⁵
¹Areteion Hospital University of Athens, Athens, Greece, ²Areteion Hospital 2nd Department of Surgery, Athens, Greece, ³Department of Surgery Areteion Hospital, Athens, Greece, ⁴Histopathology Department, Athens, Greece, ⁵Oncology Unit Areteion Hospital University of Athens, Athens, Greece

P-158

Correlation of neutrophil lymphocyte ratio, platelet lymphocyte ratio and rate of change of CA 19.9 in predicting outcome for metastatic pancreatic cancer

*A Dean¹, D Higgs¹, A Das², M Rogers-Seeley², S Fennessy², C McGarvey², M McNulty²
¹St John of God Hospital Subiaco, Subiaco, Australia, ²St John of God Hospital Subiaco, Perth, Australia*

P-159

Analysis of early tumor shrinkage and depth of response in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX or gemcitabine + nab-paclitaxel

*C Vivaldi¹, C Cappelli², F Donati³, L Fornaro⁴, G Musettini¹, G Pasquini⁵, I Pecora², S Catanese¹, M Lencioni⁶, F Salani⁷, P Boraschi³, A Falcone⁸, E Vasile¹
¹Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, ²Azienda Ospedaliero Universitaria Pisana, Pisa, Italy, ³Department of Diagnostic Imaging - Pisa University Hospital, Pisa, Italy, ⁴U.O. Oncologia Medica 2, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy, ⁵Department of Oncology, University Hospital, Pisa, Italy, ⁶Azienda Ospedaliero-Universitaria di Pisa, Pisa, Italy, ⁷Unit of Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, ⁸University of Pisa, Pisa, Italy*

P-160

Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice

*A García Velasco¹, T Macarulla², C Bugés Sánchez³, M Martín⁴, C García⁵, C Pericay⁶, S Merino⁷, L Visa⁸, T Martín⁹, M Pedraza¹⁰, B Carnero¹¹, R Guardedeño¹, L Pellín¹², D Vilanova¹², B Laquente¹³
¹Institut Català d'Oncologia (ICO), Girona, Spain, ²Hospital Universitari Vall d'Hebrón, Barcelona, Spain, ³Institut Català d'Oncologia (ICO) – Hospital Germans Trias i Pujol, Badalona, Spain, ⁴Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁵Complejo Hospitalario de Burgos, Burgos, Spain, ⁶Corporació Sanitaria Parc Taulí, Sabadell, Spain, ⁷Hospital Sant Joan de Reus, Reus, Spain, ⁸Hospital del Mar, Barcelona, Spain, ⁹Hospital Universitario de Salamanca, Salamanca, Spain, ¹⁰Complejo Asistencial Universitario de León, León, Spain, ¹¹Hospital del Bierzo, Ponferrada, Spain, ¹²Celgene S.L.U., Madrid, Spain, ¹³Institut Català d'Oncologia, L'Hospitalet de Llobregat, Spain*

P-161

Folfirinox versus gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer: a single-center cohort study

*I Cho¹, H Kang², J Jo², H Lee³, M Chung⁴, J Park², S Park⁵, S Song⁴, M Park⁶, C An⁶, S Jung⁷, S Bang⁸
¹Department of Internal Medicine, International St. Mary's Hospital, Catholic Kwandong University, Incheon, Republic of Korea, ²Department of Internal medicine, Yonsei*

University College of Medicine, Seoul, Republic of Korea, ³Division of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea, ⁴Division of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea, ⁵Yonsei University College of Medicine, Seoul, Republic of Korea, ⁶Department of Radiology, Yonsei University College of Medicine, Seoul, Republic of Korea, ⁷Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea, ⁸Yonsei University, Seoul, Republic of Korea

P-162

Second line in pancreatic cancer: Resuming our experience and looking for prognostic factors

*B Anton¹, F Longo Muñoz², D Gutierrez Abad¹, M De Torres Olombrada¹, I Juez Martel¹, B LOSADA VILA³, J Letéllez¹, J Guerra Martínez¹, A Fernández Román¹
¹Hospital Universitario Fuenlabrada, Fuenlabrada, Spain, ²Hospital Universitario Ramón y Cajal, Madrid, Spain, ³Hospital de Fuenlabrada, Fuenlabrada, Spain*

P-163

Observational study of comparative effectiveness of nab-paclitaxel plus gemcitabine vs gemcitabine plus cisplatin or gemcitabine alone for the first-line treatment of metastatic pancreatic adenocarcinoma in the University Hospital Centre Zagreb

*J Prejac¹, I Goršič¹, M Vidović², H Golem¹, D Kekez¹, N Librenjak¹, S Pleština¹
¹University Hospital Center Zagreb, Zagreb, Croatia, ²University Hospital Centre Zagreb, Zagreb, Croatia*

P-164

Gemcitabine plus nab-paclitaxel versus modified FOLFIRINOX as first line chemotherapy in metastatic pancreatic cancer: A comparison of toxicity and survival

*V Pacheco-Barcia¹, T France², G Zogopoulos³, N Bouganim², O Donnay¹, T Alcindor⁴, R Mondéjar Solís¹, K Guo², E Martín⁵, R Colomer¹, J Asselah⁶
¹Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria La Princesa, Madrid, Spain, ²McGill University Health Center, Cedars Cancer Centre, Montreal, Quebec, Canada, ³McGill University Health Centre, Montreal, Quebec, Canada, ⁴McGill University Health Centre, Montréal, Quebec, Canada, ⁵Hospital Universitario La Princesa, Madrid, Spain, ⁶McGill University Royal Institution, Montreal, Quebec, Canada*

P-165

Clinical outcomes for modified FOLFIRINOX chemotherapy for pancreatic cancer

*D Holyoake¹, C Lo², H Stubbings¹, T Roques¹
¹Norfolk and Norwich University Hospital, Norwich, UK, ²Norfolk and Norwich University Hospital, Norwich, UK*

P-166

Questions of resolving cholestasis in metastatic cancer of the hepatobiliary system

S Khoshimov

Tashkent Medical Academy, Tashkent, Uzbekistan

P-167

Symptoms reported at initial diagnosis of (metastatic) pancreatic adenocarcinoma ([m]PAC) in routine clinical practice and variation in frequencies across Europe

D Melisi¹, B Westphalen², àMellbring³, A Carrato⁴, J Taieb⁵, G Prager⁶, T Macarulla Mercadé⁷, N D'Esquermes⁸, A Ferreras⁹, F de Jong¹⁰

¹Medical Oncology, University of Verona, Verona, Italy, ²Comprehensive Cancer Center München, Klinikum der Universität München, Munich, Germany, ³Shire Sweden AB, Kista, Sweden, ⁴IRYCIS, CIBERONC, Alcalá University, Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁵Sorbonne Paris Cité, Paris Descartes University, Hôpital Européen Georges Pompidou, Paris, France, ⁶Clinical Division of Medical Oncology, Department of Medicine I, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria, ⁷Vall d'Hebron University Hospital (HUVH) and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, ⁸Genactis, Chateaufort, France, ⁹Genactis, Antibes, France, ¹⁰Shire International GmbH, Glattbrugg, Switzerland

P-168

Multiple dose pharmacokinetics of erlotinib when combined with gastric acid reducing agents: A comparison with a physiologically based pharmacokinetic model

A Sahmanovic Hrgovic¹, A Gruber¹, C Dittrich², M Kitzmueller¹, P Buchner¹, N Kirchbaumer Baroian¹, M Czejka¹

¹Department of Clinical Pharmacy and Diagnostics, University of Vienna, Vienna, Austria, ²Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIENNA), Kaiser Franz Josef-Spital, 3rd Medical Department – Centre for Oncology and Haematology, Vienna, Austria

P-169

Gemcitabine induced hemolytic uremic syndrome: Underestimated?

E Una Cidon¹, P Alonso²

¹Oncology Department, Royal Bournemouth Hospital, NHS Foundation Trust, Bournemouth, UK, ²Clinical University Hospital, Valladolid, Spain

P-170

Management of patients with unresectable HCC: A simulation-based assessment of medical oncologists' practice choices

T Herrmann¹, A Carothers¹, G Littman¹, M Warters¹, C Cason¹, T Bekaii-Saab²

¹*Medscape Education, New York, New York, USA*, ²*The Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute, Columbus, Ohio, USA*

P-171

Analysis of echoendoscopic punctures of a solid pancreatic lesions in a private institution in Brazil

T Pessoa¹, A Pessoa², P Aguiar², R Pessoa³, A Moura⁴, D Ferreira⁵, F Távora³, F Pessoa⁶, R Pessoa⁵

¹*Laboratory of Molecular Biology and Development, University of Fortaleza, Fortaleza, Brazil*, ²*University of Fortaleza, UNIFOR, Fortaleza, Brazil*, ³*Federal University of Ceará, Fortaleza, Brazil*, ⁴*University of Fortaleza, UNIFOR, Fortaleza, Brazil*, ⁵*SOBED, São Paulo, Brazil*, ⁶*State University of Ceará, Fortaleza, Brazil*

P-172

Treatment modalities and prognostic factors of pancreatic cancer: A retrospective study

W Khechine¹; I Belaid², F Ezzairi¹, A El Ghali³, A Bedioui⁴, N Bouzid⁵, F Bouzaiene⁶, M Ben Mabrouk⁷, Y Bencheick⁸, I Chabchoub¹, M Hochlaf⁹, L Ben Fatma¹, S Ben Ahmed¹

¹*Department of Medical Oncology, Farhat Hached Hospital, Sousse, Tunisia*, ²*Medical Oncology Unit, Ibn El Jazzar Hospital, Kairouan, Tunisia*, ³*Department of General Surgery, Farhat Hached University Hospital, Sousse, Tunisia*, ⁴*Department of Pathology, Farhat Hached University Hospital, Sousse, Tunisia*, ⁵*Farhat Hached Sousse Hospital, Department of Radiotherapy, Sousse, Tunisia*, ⁶*Department of Radiology, Farhat Hached University Hospital, Sousse, Tunisia*, ⁷*Department of General Surgery, Sahloul University Hospital, Sousse, Tunisia*, ⁸*Department of Radiology, Sahloul University Hospital, Sousse, Tunisia*, ⁹*Department of Medical Oncology, Farhat Hached Hospital, Sousse, Tunisia*

P-175

Clinical implication of inflammation markers for identifying radiotherapy candidates in inoperable locally advanced pancreas cancer

W Cho¹, J Yu¹, H Park¹, D Lim¹, J Park², S Kim¹, Y Park¹

¹*Samsung Medical Center, Seoul, Republic of Korea*, ²*Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea*

P-176

Analysis of various clinical and pathological factors affecting survival in patients diagnosed with pancreatic adenocarcinoma: Single institute study

A Nagy

Ain Shams University, Cairo, Egypt

P-178

Clinical characteristic of pancreatic cancer

B Abdelkader El Hakim¹, N Caid², L Saoudi², R Benemla², R Ramoul², S Rekkache², F Smaili³

¹Saad Dahlab Univerity, Blida, Algeria, ²University of Blida, Blida, Algeria, ³Societe of Oncologie Medicale, Blida, Algeria

P-179

Surgical management of pancreatic tumors in children

A Lukashenko¹, Y Ostapenko², O Kolesnik¹, N Chorna²

¹National Cancer Institute, Kiev, Ukraine, ²National Cancer Institute of Ukraine, Kiev, Ukraine

P-180

Neo-adjuvant FOLFIRINOX in borderline-resectable/locally advanced pancreatic adenocarcinoma: An updated analysis

S Temraz¹, M Salim Hammoud¹, M Zorkot², W Albonji², H Dbouk³, F Farhat⁴, M Charafeddine², D Mukherji¹, A Shamseddine¹

¹American University of Beirut Medical Center, Beirut, Lebanon, ²American University of Beirut, Beirut, Lebanon, ³Nabih Berri Governmental University Hospital, Nabatieh, Lebanon, ⁴Hammoud Hospital University Medical Center, Saida, Lebanon

P-181

Pancreatic head resections: Impact factors, perioperative morbidity, mortality and long-term survival

B Iljavec, S Potrc

University Medical Center Maribor, Maribor, Slovenia

P-182

Efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma in a phase 3, randomized, open-label, multicenter study

S Qin¹, R Finn², M Kudo³, T Meyer⁴, A Vogel⁵, M Ducreux⁶, T Macarulla⁷, G Tomasello⁸, F Boisserie⁹, J Hou¹⁰, C Li¹¹, J Song¹², A Zhu¹³

¹People's Liberation Army (PLA) 81 Hospital, Nanjing, China, ²University of California, Los Angeles Medical Center, Los Angeles, California, USA, ³Kindai University School of Medicine, Osaka, Japan, ⁴Royal Free Hospital, University College London, London, UK, ⁵Hannover Medical School, Hannover, Germany, ⁶Gustave Roussy Cancer Campus Grand Paris, Villejuif, France, ⁷Vall d'Hebrón Institute of Oncology, Barcelona, Spain, ⁸Department of Medical Oncology, Azienda Istituti Ospitalieri di Cremona, Cremona, Italy,

⁹BeiGene USA, Inc, Fort Lee, New Jersey, USA, ¹⁰Beigene USA, Inc, Emeryville, California, USA, ¹¹BeiGene (Beijing) Co., Ltd., Beijing, China, ¹²Beigene USA, Inc., Fort Lee, New Jersey, USA, ¹³Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA, Boston, Massachusetts, USA

P-183

A pilot trial of PEGPH20 (Pegvorhialuronidase alfa) in combination with avelumab (anti-PD-L1 MSB0010718C) in chemotherapy resistant pancreatic cancer (PDAC)

L Medina Rodriguez¹, C Guillén-Ponce², J Feliu³, M Hidalgo⁴

¹Hospital de Fuenlabrada, Fuenlabrada, Spain, ²H. Universitario Ramón y Cajal, IRYCIS, Madrid, Spain, ³University Hospital La Paz, Madrid, Spain, ⁴Centro Nacional de Investigaciones Oncológicas, Madrid, Spain

P-184

CanStem111P trial: A Phase 3 Study of napabucasin (NAPA) plus nab-paclitaxel (nPTX) with gemcitabine (Gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC)

T Bekaii-Saab¹, T Okusaka², D Goldstein³, B O'Neill⁴, J Tabernero⁵, C Li⁶, M Reni⁷, B Jin⁸, C Oh⁸, L Borodyansky⁸, E Van Cutsem⁹

¹Mayo Clinic Cancer Center, Scottsdale, Arizona, USA, ²Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Japan, ³Prince of Wales Hospital, Sydney, Australia, ⁴IU Health University Hospital, Indianapolis, Indiana, USA, ⁵Vall d'Hebron University Hospital, Barcelona, Spain, ⁶Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Republic of Taiwan, ⁷Ospedale San Raffaele, Milan, Italy, ⁸Boston Biomedical, Cambridge, Massachusetts, USA, ⁹University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium

P-185

PANOVA-3: A phase 3 study of Tumor Treating Fields combined with nab-paclitaxel and gemcitabine for front-line treatment of locally-advanced pancreatic adenocarcinoma

U Weinberg¹, O Faber¹, M Giladi², Z Bomzon², G Lavy-Shahaf², E Kirson²

¹Novocure, Root D4, Switzerland, ²Novocure, Haifa, Israel

P-186

Chemotherapy for patients with advanced or metastatic pancreatic cancer (AMPC)

B Abdelkader El Hakim¹, F Braneci², N Caid², L Saoudi², R Ramoul², R Benemla², S Rekkache², F Smaili³

¹Saad Dahlab Univerity, Blida, Algeria, ²University of Blida, Blida, Algeria, ³Societe of Oncologie Medicale, Blida, Algeria

P-187

Erythrocyte membrane fatty acids as the potential biomarkers for detection of early-stage and progression of colorectal cancer

M Kruchinina¹, A Gromov¹, Y Prudnikova¹, M Shashkov², A Sokolova³, V Kruchinin⁴

¹Research Institute of Internal and Preventive Medicine - Branch of the Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russian Federation, ²Boreskov Institute of Catalysis Siberian Branch of Russian Academy of Sciences SB RAS, Novosibirsk, Russian Federation, ³N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry Of Siberian Branch of Russian Academy of Sciences, Novosibirsk, Russian Federation, ⁴Rzhanov's Institute of Semiconductor Physics Siberian Branch of Russian Academy of Sciences, Novosibirsk, Russian Federation

P-188

LncRNA-ZFAS1 contributes to colon cancer progression through the miR-150-5p/VEGFA axis

X Chen, S Wang

Medical College, Southeast University, Nanjing, China

P-189

Retinoic acid-induced 2 (RAI2) is a potential tumor suppressor and RAI2 promoter methylation is a poor prognostic marker in colorectal cancer

W Yan¹, K Wu², Y Yang¹, M Guo³, G Dai⁴

¹Department of Oncology, Chinese PLA General Hospital, Beijing, China, ²Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China, ³Chinese PLA General Hospital, Beijing, China, ⁴The General Hospital of the People's Liberation Army, Beijing, China

P-190

The influence of GSTM1-null, TS-del6bp, XRCC1-A751C gene polymorphisms on overall survival in colorectal cancer patients related to the TNM parameters: A Romanian single-center study

L Procopciuc¹, G Osian², M Iancu³

¹University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania, ²3rd Surgery Clinic, Cluj-Napoca, Romania, ³Department of Medical Informatics and Biostatistics, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania

P-191

Combined analysis of KRAS, NRAS, BRAF mutations and mismatch repair deficiency testing in Indian patients with metastatic colorectal carcinoma: A single centre experience

T Sood¹, A Rauthan², P Patil², S Kulkarni¹

¹Manipal Hospital, Bengaluru, India, ²Manipal Comprehensive Cancer Center, Manipal Hospital, Bangalore, India

P-192

Proteomic analysis and epigenetics alterations in patients with colorectal cancer treated at an oncology reference hospital in Manaus, Brazil

P Viapiana¹, S Chalub², F Almeida¹, J Gama Fischer¹, A Leão de Souza¹

¹Federal University of Amazonas, Manaus, Brazil, ²Fundação Centro de Controle de Oncologia do Amazonas, Manaus, Brazil

P-193

RAS status in Algerian metastatic colorectal cancer

A Bensalem

EH Didouche Mourad, Medecine Faculty, University 3 Constantine, Constantine, Algeria

P-194

Transcribed ultraconserved regions Uc160 and Uc346 in colon cancer progression

*A Kottorou, C Sirinian; F Dimitrakopoulos, A Antonacopoulou, T Makatsoris, H Kalofonos
Clinical and Molecular Oncology Laboratory, Division of Oncology, Medical School,
University of Patras, Patras, Greece*

P-195

Cost of illness for colorectal cancer at low middle income countries Egypt case

A Abotaleb

World Health Organization (WHO), Cairo, Egypt

P-196

Anti-angiogenic action of leukotriene-C4 induced 15-hydroxyprostaglandin dehydrogenase in colon cancer cells is a TNF- α dependent phenomenon

S Satapathy, A Sjolander

Lund University, Malmö, Sweden

P-197

Repurposing ponatinib for the treatment of colorectal cancer

F Tan¹, T Putoczki², F Hollande³; R Luwor⁴

¹Peter MacCallum Cancer Centre, Melbourne, Australia, ²Walter and Eliza Hall Institute for Medical Research, Parkville, Australia, ³The University of Melbourne, Melbourne, Australia, ⁴The University of Melbourne, Parkville, Australia

P-198

The management of locally advanced and metastatic colorectal cancer: A retrospective study of 77 cases

F Boudinar¹, G Bettache², K Wahiba³, B Larbaoui¹

¹Medical Oncology Department, EHSO Emir Abdelkader, Oran, Algeria, ²Oncology Department, Oran, Algeria, ³CHU Oran, Oran, Algeria

P-199

Colorectal cancer screening in Flanders: Advances in personalised screening

W van de Veerdonk¹, G Van Hal², M Peeters³, I De Brabander⁴, G Silversmit⁴, S Hoeck⁵

¹Faculty of Medicine and Health Sciences, Department of Social Epidemiology and Health Policy, University of Antwerp, Antwerp, Belgium, ²University of Antwerp, Antwerp, Belgium, ³Antwerp University Hospital, Edegem, Belgium, ⁴Belgian Cancer Registry, Brussels, Belgium, ⁵Centre for Cancer Detection, Antwerp, Belgium

P-200

Risk factors of colorectal cancer in Linxian, China: A nutrition intervention trial with 30 years follow-up

H Keskin¹, A Etemadi², P Taylor²

¹Istanbul Medeniyet Uni. , Istanbul, Turkey, ²Metabolic Epidemiology Branch, the National Cancer Institute (NCI), the National Institutes of Health (NIH), Bethesda, Maryland, USA

P-201

Evaluation of the prognostic value of lymph-node ratio in patients with colon cancer in the oxaliplatin era

B Bird¹; D Connell², D O' Connor¹

¹Bon Secours Hospital Cork, Cork, Ireland, ²University College Cork, Douglas, Ireland

P-202

Competing risks analysis of microsatellite instability as a prognostic factor in colorectal cancer

K Spring¹, J Toh², P Chapuis³, L Bokey⁴, C Chan³, O Dent⁵

¹Ingham Institute/University of Western Sydney, Sydney, Australia, ²Westmead Hospital, Sydney, Australia, ³Concord Hospital, Sydney, Australia, ⁴Liverpool Hospital, Sydney, Australia, ⁵University of Sydney, Sydney, Australia

P-203

Survival and prognostic factors of non metastatic rectal adenocarcinoma: Analytic multifactor review of 91 cases

K Darij¹, Z Benbrahim², M Benhami³, I Ahalli⁴, R Boujarnija⁴, H Erraichi⁴, R Elhazzaz⁵, H Ouahbi², L Amaadour⁶, K Oualla², F El M'rabet³, S Arifi⁷, N Mellas⁷

¹Hassan II University Hospital Fez, Fez, Morocco, ²Medical Oncology Department, Hassan II University Hospital, Fez, Morocco, ³Department of Medical Oncology, University Hospital Center Hassan II, Fez, Morocco, ⁴Hassan II University Hospital, Fez, Morocco, ⁵UHC Fez, Fez, Morocco, ⁶University Hospital of Hassan II Oujda, Fez, Morocco, ⁷Department of Medical Oncology, Hassan II University Hospital, Fez, Morocco

P-204

Prognostic value of neo-adjuvant treatment in localized rectal cancer about 78 cases

K Darij¹, Z Benbrahim², M Benhami³, I Ahalli⁴, R Boujarnija⁴, H Erraichi⁴, R Elhazzaz⁵, H Ouahbi², L Amaadour⁶, K Oualla², F El M'rabet³, S Arifi⁷, N Mellas⁷

¹Hassan II University Hospital Fez, Fez, Morocco, ²Medical Oncology Department, Hassan II University Hospital, Fez, Morocco, ³Department of Medical Oncology, University Hospital Center Hassan II, Fez, Morocco, ⁴Hassan II University Hospital, Fez, Morocco, ⁵UHC Fez, Fez, Morocco, ⁶University Hospital of Hassan II Oujda, Fez, Morocco, ⁷Department of Medical Oncology, Hassan II University Hospital, Fez, Morocco

P-205

Preoperative short course of radiotherapy in selected high risk patients

M Caro Gallarín¹, H Rosales González², J Jové Teixidó¹, E Luguera Sánchez¹, I Planas Toledano¹, Y Luis Dorta², G Antelo Redondo², E Baena González², A Álvarez Gracia¹, C Bugés Sánchez³, I Camps Ausàs², S Villà Freixa¹

¹ICO Badalona, HUGTiP, Badalona, Spain, ²Hospital Germans Trias I Pujol, Badalona, Spain, ³Institut Català d'Oncologia (ICO) – Hospital Germans Trias i Pujol, Badalona, Spain

P-206

Intensive first line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: Preliminary phase II data and individual limiting toxicity syndromes prediction by pharmacogenomic biomarkers

G Bruera¹, S Massacese², F Pepe³, U Malapelle³, A Dal Mas⁴, E Ciacco², G Calvisi⁴, P Marchetti⁵, G Troncone³, M Simmaco⁶, E Ricevuto¹

¹*Oncology Territorial Care, S. Salvatore Hospital, Oncology Network ASLI Abruzzo, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy,* ²*Pharmacy Unit, S. Salvatore Hospital, Oncology Network ASLI Abruzzo, L'Aquila, Italy,* ³*Department of Public Health, University Federico II, Naples, Italy,* ⁴*Pathology, S. Salvatore Hospital, Oncology Network ASLI Abruzzo, L'Aquila, Italy,* ⁵*La Sapienza University, Sant'Andrea Hospital, Rome, Italy,* ⁶*Advanced Molecular Diagnostics, S. Andrea Hospital, Rome, Italy*

P-207

Clinico-pathological and molecular characterization of BRAF mutant metastatic colorectal cancer (mCRC): Are all mutations created equal?

M Schirripa¹, P Biason², F Cortiula³, M Pino⁴, F Urbano⁵, C Antoniotti⁶, S Corallo⁷, F Gelsomino⁸, A Orlandi⁹, S Lonardi¹, F Bergamo¹⁰, G Munari¹¹, U Malapelle¹², M Rugge¹³, C Mescoli¹⁴, L Reggiani Bonetti¹⁵, G Lanza¹⁶, A Dei Tos¹⁷, G De Maglio¹⁸, V Zagonel¹⁹, F Loupakis¹, M Fassan¹⁴

¹*Medical Oncology Unit 1, Clinical and Experimental Oncology Department, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy,* ²*Oncologia Medica 1, Istituto Oncologico Veneto IRCCS, Padua, Italy,* ³*Oncologia, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy,* ⁴*Medical Oncology, Ospedale Santa Maria Annunziata, Bagno a Ripoli, Italy,* ⁵*Department of Radiological, Oncological and Anatomopathological Sciences, Sapienza University of Rome, Rome, Italy,* ⁶*Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy,* ⁷*Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy,* ⁸*Modena Cancer Centre, Department of Oncology/Haematology, University of Modena and Reggio Emilia, Modena, Italy,* ⁹*Università Cattolica del Sacro Cuore - Oncologia Medica, Rome, Italy,* ¹⁰*Veneto Institute of Oncology IOV-IRCCS, Padua, Italy,* ¹¹*Istituto Oncologico Veneto, IRCCS, Padua, Italy,* ¹²*Department of Public Health, University Federico II, Naples, Italy,* ¹³*Department of Medicine, Pathology and Cytopathology Unit, University of Padova, Padua, Italy,* ¹⁴*Department of Medicine (DIMED), Pathology Unit, University of Padua, Padua, Italy,* ¹⁵*Department of Laboratory Integrated Activities, Anatomic Pathology and Legal Medicine, University of Modena and Reggio Emilia, Modena, Italy,* ¹⁶*University of Ferrara, Ferrara, Italy,* ¹⁷*Department of Pathology, General Hospital of Treviso, Treviso, Italy,* ¹⁸*University Hospital Udine, Udine, Italy,* ¹⁹*Oncologia Medica 1, Istituto Oncologico Veneto - IRCCS, Padua, Italy*

P-208

Autophagy (A) related proteins evaluation represents an independent survival factor of colorectal cancer (CRC) patients (pts)

M Karamouzis¹, A Saetta², E Koustas¹, I Chatziandreou², I Giannopoulou², M Michelli², C Giaginis³, A Papavassiliou¹, S Theoharis²

¹*Molecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece,* ²*Department of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece,* ³*Department of Food Science & Nutrition, University of the Aegean, Lemnos, Greece*

P-209

P 53 abnormal expression might influence global outcome through EGFR modulation in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan cetuximab

M Puzzone¹, L Demurtas², P Ziranu², E Lai³, R Giampieri⁴, L Faloppi⁵, A Mandolesi⁶, C Cremolini⁷, G Masi⁷, F Gelsomino⁸, S Mariani², A Cubeddu², L Casula², N Liscia², V Pusceddu², C Antoniotti⁷, C Loretelli⁹, F Meriggi¹⁰, A Zaniboni¹¹, A Falcone¹², S Cascinu¹³, M Scartozzi¹⁴

¹Departments of Medical Oncology, University of Cagliari, University Hospital 'Duilio Casula', Monserrato, Italy, ²Departments of Medical Oncology, University of Cagliari, University Hospital 'Duilio Casula', Cagliari, Italy, ³Departments of Medical Oncology, University of Cagliari, University Hospital 'Duilio Casula', Cagliari, Italy, ⁴Clinica Oncologica, AOU Ospedali Riuniti, Ancona, Italy, ⁵Medical Oncology Unit, Macerata General Hospital, ASUR Marche AV3, Macerata, Italy, ⁶Departments of Institute of Pathology, AO Ospedali Riuniti-UNIVPM, Ancona, Italy, ⁷Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy, ⁸Modena Cancer Centre, Department of Oncology/Haematology, University of Modena and Reggio Emilia, Modena, Italy, ⁹Department of Biomedical and Clinical Sciences, Milan, Italy, ¹⁰Medical Oncology Unit, Fondazione Poliambulanza, Brescia, Italy, ¹¹Fondazione Poliambulanza, Brescia, Italy, ¹²University of Pisa, Pisa, Italy, ¹³Azienda Ospedaliera-Università di Modena, Modena, Italy, ¹⁴Medical Oncology, University of Cagliari, University Hospital, Cagliari, Italy

P-210

Unexpected discordance in 5-year OS rates between Nx colon cancer patients and those in stages II plus III

I Tonev¹, N Conev², A Petrov¹, I Donev²

¹Complex Cancer Center Plovdiv, Plovdiv, Bulgaria, ²Medical University of Varna, Varna, Bulgaria

P-211

Serum angiogenesis associated proteins and clinical outcome in metastatic colorectal cancer patients receiving bevacizumab

G Marisi¹, E Scarpi²; A Passardi², O Nanni³, F Pagan³, M Valgiusti⁴, A Casadei Gardini⁵, C Molinari², G Frassinetti², D Amadori⁴, P Ulivi¹

¹Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, ²Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, ³Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, ⁴Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, ⁵IRST-IRCCS, Meldola, Italy

P-212

CDX2 immunohistochemistry as a prognostic biomarker for colorectal cancer

A Fatimilehin¹, C Mikropoulos¹; J Summers², L Rajakumar¹, M Hill¹

¹Maidstone and Tunbridge Wells NHS Trust, Maidstone, UK, ²Maidstone & Tunbridge Wells NHS Trust, Maidstone, UK

P-213

An evaluation of the clinical utility of a panel of variants in DPYD and ENOSF1 for predicting common capecitabine related toxicities

C Palles¹, S Fotheringham², L Chegwidden³, M Lucas⁴, G Mozolowski⁵, I Tomlinson³, D Kerr⁴

¹Institute of Cancer and Genomic Sciences, Birmingham, UK, ²Oxford Cancer Biomarkers, na, Alabama, USA, ³Institute of Cancer and Genomic Sciences, Birmingham, UK, ⁴Oxford University, Oxford, UK, ⁵Oxford, Oxford, UK

P-214

Bevacizumab combined with 1st line chemotherapy in elderly patients with metastatic colorectal cancer: Are there good prognostic indicators?

C Borges¹, J Simões¹, C Lemos², C Fernandes¹, C Sarmiento³, M Damasceno³, D Almeida¹
¹Hospital S. João, Porto, Portugal, ²IPV, Viseu, Portugal, ³Hospital de S. João, Porto, Portugal

P-216

Primum non nocere: Screening patients for fluoropyrimidine-related toxicity risk: The most effective method

M Boisdron-Celle¹, J Metges², O Capitain¹, R Faroux³, C Stampfli⁴, M Ferec⁵, P Laplaige⁶, T Lecomte⁷, T Matysiak-Budnik⁸, H Senellart⁹, M Campon¹⁰, A Morel¹, E Gamelin¹

¹Institut de Cancérologie de l'Ouest Paul Papin, Angers, France, ²CHU de Brest – Hôpital Morvan, Brest, France, ³C.H.U. La Roche sur Yon, La Roche sur Yon, France, ⁴C.H. Laval, Laval, France, ⁵CHU Morlaix, Morlaix, France, ⁶Polyclinique de Blois, La Chaussée st Victor, France, ⁷Hôpital Trousseau, Tours, France, ⁸C.H.U. Hôtel Dieu, Nantes, France, ⁹Institut de Cancérologie de l'Ouest René Gauducheau, St-Herblain, France, ¹⁰Institut de Cancérologie de l'Ouest, Angers, France

P-217

ABCG2 and TOP-1 as predictive biomarkers and targets for therapy in colon cancer

N Brünnner¹, J Stenvang¹, V Popovici², E Budinska³

¹University of Copenhagen and Scandion Oncology, Copenhagen, Denmark, ²RECETOX, Faculty of Science, Masarykova Univerzita, Brno, Czech Republic, ³RECETOX, Faculty of Science, Masarykova Univerzita, Brno, Czech Republic

P-218

Biomarkers of oxidative stress in patient with colorectal cancer

H Haddouche

Université Abou-Bekr Belkaid Tlemcen, Algeria, Laboratoire de Biologie Moléculaire Appliquée et d'Immunologie, Tlemcen, Algeria

P-219

Colorectal neuroendocrine carcinoma and colorectal mixed adeno-neuroendocrine carcinoma: A population-based study of the surveillance, epidemiology, and end results registry

M Liu¹, H Zhang¹, Y Yang², X Fu¹, K Nan¹, T Tian¹

¹The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China, ²Shaanxi Provincial People's Hospital, Xi'an, China

P-220

MTHFR, TSER and DPYD gene mutation is associated with toxicity and response in pre-operative chemo-radiotherapy for local advanced rectal cancer.

*S Mancarella, O Potì, D De Giorgi, M Schirinzi
ASL Lecce, Galatina, Italy*

P-221

Regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer: The optimization of pharmacological costs

J Giuliani¹, A Bonetti²

¹Department of Oncology - Mater Salutis Hospital - Az. ULSS 9 Scaligera - Legnago (VR), Legnago, Italy, ²U.O. Oncologia - Mater Salutis Hospital - Az. ULSS 9 Scaligera - Legnago (VR), Legnago (VR), Italy

P-222

Is the PEG-G-CSF useful as the prevention for the severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab?

H Osumi¹, E Shinozaki¹, T Wakatsuki², M Suenaga¹, T Ichimura³, M Ogura⁴, Y Ota⁵, I Nakayama³, D Takahari³, K Chin¹, K Yamaguchi⁶

¹Department of Gastroenterology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Japan, ²Cancer Institute Hospital Department of Gastroenterology, Koto-ku, Japan, ³Cancer Institute Hospital, Koto-ku, Japan, ⁴Department of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Japan, ⁵Cancer Institute Hospital, Japanese Foundation of Cancer Research, Tokyo, Japan, ⁶Department of Gastroenterology Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-ku, Japan

P-223

NORTH/HGCSG1003: A phase II study evaluating the safety and efficacy of FOLFOX as adjuvant chemotherapy for patients with stage III colon cancer: Comparison with medical oncologists and surgeons

S Yuki¹, Y Komatsu², Y Kawamoto³, H Nakatsumi³, N Takahashi⁴, T Shichinohe⁵, H Okuda⁶, A Ishiguro⁷, K Harada⁸, I Iwanaga⁹, K Hatanaka¹⁰, K Oomori¹¹, M Nakamura¹², N Senmaru¹³, K Iwai¹⁴, M Koike¹⁵, T Shinohara¹⁶, K Miyashita¹⁷, Y M. Ito¹⁸, A Taketomi¹⁹, S Hirano⁵, N Sakamoto²⁰

¹Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan, ²Digestive Internal Medicine, Division of Cancer Center, Hokkaido University Hospital, Sapporo, Japan, ³Division of Cancer Center, Hokkaido University Hospital, Sapporo, Japan, ⁴Department of Surgical Center, Hokkaido University Hospital, Sapporo, Japan, ⁵Department of Gastroenterological Surgery II, Hokkaido University Hospital, Sapporo, Japan, ⁶Department of Medical Oncology, Keiyukai Sapporo Hospital, Sapporo, Japan, ⁷Department of Medical Oncology, Teine Keijinkai Hospital, Sapporo, Japan, ⁸Department of Medical Oncology, Kushiro Rosai Hospital, Kushiro, Japan, ⁹Department of Medical Oncology, Japanese Red Cross Kitami Hospital, Kitami, Japan, ¹⁰Department of Gastroenterology, Hakodate Municipal Hospital, Hakodate, Japan, ¹¹Department of Surgery, Keiwakai Ebetsu Hospital, Ebetsu, Japan, ¹²Department of Gastroenterology, Sapporo City General Hospital, Sapporo, Japan, ¹³Department of Surgery, Steel Memorial Muroran Hospital, Muroran, Japan, ¹⁴Department of Surgery, Oji General Hospital, Tomakomai, Japan, ¹⁵Department of Surgery, KKR Sapporo Medical Center, Sapporo, Japan, ¹⁶Department of Gastroenterological Surgery, Hokkaido Cancer Center, Sapporo, Japan, ¹⁷Department of Gastroenterology, Aiiku Hospital, Sapporo, Japan, ¹⁸Department of Biostatistics, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ¹⁹Department of Gastroenterological Surgery I, Hokkaido University Hospital, Sapporo, Japan, ²⁰Department of Gastroenterology and Hepatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan

P-224

Analysis of clinical outcomes of two antiEGFR antibodies, cetuximab and panitumumab, in the 1st line chemotherapy of RAS wild metastatic colorectal cancer, by neutrophil-to-lymphocyte ratio (NLR) kinetics

D Manaka¹, R Nishitai¹, S Konishi¹, T Ota¹, Y Nishikawa², R Kudo¹, K Kawaguchi¹, H An², S Hamasu¹

¹Department of Surgery, Gastrointestinal Center, Kyoto Katsura Hospital, Nishikyo-ku, Japan, ²Department of Surgery, Gastrointestinal Center, Kyoto Katsura Hospital, Nishikyo-ku, Japan

P-225

The role of maintenance therapy in the first line treatment of metastatic colorectal cancer

D Gridnev¹, A Popov¹, E Vozny¹, V Makarov¹, D Islamova¹, A Kudryavtseva², A Zheveliyuk¹, M Trandofilov¹

¹*City Hospital Named After Pletnev D.D., Moscow, Russian Federation,* ²*Engelhardt Institute of Molecular Biology RAS, Moscow, Russian Federation*

P-226

HGCSG 1301: A Multicenter, Double-Blind, Randomized control phase II trial comparing Hange-shashin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer under IRIS/Bev second-line treatment

M Nakamura¹, Y Komatsu², T Muranaka³, M Yagisawa³, Y Kawamoto³, H Nakatsumi³, S Yuki⁴, T Saiki⁵, A Ishiguro⁵, M Tateyama⁶, Y Kobayashi⁷, T Miyagishima⁸, T Takahata⁹, A Sato⁹, M Dazai¹⁰, H Okuda¹¹, K Fujikawa¹², K Eto¹³, S Muto¹⁴, K Hatanaka¹⁵, T Amano¹⁶, Y Sakata¹⁷

¹*Department of Gastroenterology, Sapporo City General Hospital, Sapporo, Japan,*

²*Digestive Internal Medicine, Division of Cancer Center, Hokkaido University Hospital, Sapporo, Japan,*

³*Division of Cancer Center, Hokkaido University Hospital, Sapporo, Japan,*

⁴*Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan,*

⁵*Department of Medical Oncology, Teine Keijinkai Hospital, Sapporo, Japan,*

⁶*Department of Internal Medicine, Tomakomai Nisshou Hospital, Tomakomai, Japan,*

⁷*Department of Medical Oncology, Kushiro Rosai Hospital, Kushiro, Japan,*

⁸*Department of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan,* ⁹*Department of Medical Oncology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan,*

¹⁰*Department of Gastroenterology, Sapporo Medical Center NTT EC, Sapporo, Japan,*

¹¹*Department of Medical Oncology, Keiyukai Sapporo Hospital, Sapporo, Japan,*

¹²*Department of Gastroenterology, Hokkaido Cancer Center, Sapporo, Japan,*

¹³*Department of Gastroenterology, Tomakomai City Hospital, Tomakomai, Japan,*

¹⁴*Department of Gastroenterology, Hokkaido Medical Center, Sapporo, Japan,*

¹⁵*Department of Gastroenterology, Hakodate Municipal Hospital, Hakodate, Japan,*

¹⁶*Clinical Research and Medical Innovation Center, Hokkaido University Hospital, Sapporo, Japan,*

¹⁷*CEO, Misawa City Hospital, Misawa, Japan*

P-227

Analysis of the benefit of the adjuvant chemotherapy in stage II colon cancer according to the presence of classic poor risk factors: Our experience in Ramon y Cajal Hospital

C Saavedra Serrano¹, M Villamayor Delgado², E Corral de la Fuente¹, A Barquín García¹, J Serrano Domingo³, R Martín Huertas¹, O Martínez Saez², F Longo Muñoz⁴, P Reguera Puertas⁵, V Pachón Olmos⁵, M Rodriguez Garrote⁵, M Vaz⁴, R Fuentes¹, A Carrato⁶, R Ferreiro Monteagudo⁵

¹*Ramón y Cajal Hospital, Madrid, Spain,* ²*Ramón y Cajal University Hospital, Madrid, Spain,*

³, ⁴*Hospital Universitario Ramón y Cajal, Madrid, Spain,* ⁵*Ramón y Cajal University Hospital, Madrid, Spain,*

⁶*IRYCIS, CIBERONC, Alcalá University, Hospital Universitario Ramón y Cajal, Madrid, Spain*

P-228

VOLTAGE: Multicenter phase Ib/II study of nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy (CRT) with capecitabine in patients with locally advanced rectal cancer (LARC)

H Bando¹, Y Tsukada², K Inamori², S Fukuoka³, T Sasaki², Y Nishizawa², M Wakabayashi⁴, M Kojima⁵, Y Togashi³, S Yuki⁶, Y Komatsu⁷, S Homma⁸, Y Hatanaka⁹, Y Matsuno¹⁰, M Uemura¹¹, T Kato¹¹, A Sato¹², H Nishikawa³, M Ito², T Yoshino¹³

¹Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan, ²Department of Colorectal Surgery, National Cancer Center Hospital East, Kashiwa, Japan, ³Division of Cancer Immunology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center Hospital East, Kashiwa, Japan, ⁴Clinical Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan, ⁵Division of Pathology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center Hospital East, Kashiwa, Japan, ⁶Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan, ⁷Digestive Internal Medicine, Division of Cancer Center, Hokkaido University Hospital, Sapporo, Japan, ⁸Department of Gastroenterological Surgery, Hokkaido University Hospital, Sapporo, Japan, ⁹Research Division of Genome Companion Diagnostics, Hokkaido University Hospital, Sapporo, Japan, ¹⁰Department of Surgical Pathology, Hokkaido University Hospital, Sapporo, Japan, ¹¹Department of Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan, ¹²Clinical Research Support Office, National Cancer Center, Kashiwa-city, Japan, ¹³National Cancer Center Hospital East, Kashiwa, Japan

P-229

Long-term clinical outcomes in large colorectal polyps with indefinite or positive resection margin after endoscopic resection

D Kang¹, H Kim¹, C Choi¹, S Park¹, S Kim¹, H Nam¹, D Ryu¹, J Ko¹, H Kim¹, B Kwon¹; K Lee², J Lee², J Lee²

¹Pusan National University Yangsan Hospital, Yangsan, Republic of Korea, ²Pusan National University Yangsan Hospital, Yangsan-si, Republic of Korea

P-230

Second line FOLFOX4 and bevacizumab for metastatic colorectal cancer: Real life efficacy and predictive factors

*T Lewandowski; R Biernacka, M Chmielowiec, M Gryziak
Maria Skłodowska-Curie Cancer Centre Institute Warsaw, Warsaw, Poland*

P-231

Clinical significance of Microsatellite instability in gender-dependent patients with right-sided colorectal cancer

J Choi¹, J Kim², S Han¹, M Park¹, S Park³

¹Kosin University, College of Medicine, Busan, Republic of Korea, ²Kosin University College of Medicine, Busan, Republic of Korea, ³Kosin University, Busan, South Korea

P-232

Efficacy of adjuvant chemotherapy for elderly patients with colon cancer

M Villamayor Delgado¹, C Saavedra Serrano², E Corral de la Fuente², A Barquín García², O Martínez Saez¹, R Martín Huertas², J Serrano Domingo³, J Molina Cerrillo⁴, F Longo Muñoz⁵, V Pachón Olmos⁴, M Rodríguez Garrote⁴, P Reguera Puertas⁴, M Vaz⁵, A Carrato⁶, R Ferreira Monteagudo⁴

¹Ramón y Cajal University Hospital, Madrid, Spain, ²Ramón y Cajal Hospital, Madrid, Spain, ³, ⁴Ramón y Cajal University Hospital, Madrid, Spain, ⁵Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁶IRYCIS, CIBERONC, Alcalá University, Hospital Universitario Ramón y Cajal, Madrid, Spain

P-233

Trifluridine/ tipiracil vs regorafenib as salvage-line treatment in patients with metastatic colorectal cancer: A multicenter retrospective study

M Kotaka¹, M Ogata², T Ogata², Y Hatachi³, H Yasui⁴, T Kato⁵, A Tsuji⁶, H Satake⁷

¹Department of Gastrointestinal Cancer Center, Sano Hospital, Kobe, Japan, ²Kobe City Medical Center General Hospital, Kobe, Japan, ³Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan, ⁴Department of Oncology, Kobe City Medical Center General Hospital, Kobe, Japan, ⁵Department of Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan, ⁶Department of Medical Oncology, Kagawa University Hospital, Kida-gun, Japan, ⁷Department of Medical Oncology, Cancer Treatment Center, Kansai Medical University Hospital, Hirakata, Japan

P-234

Phase 1b open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABT-165 plus FOLFIRI in patients with second-line (2L) colorectal cancer (CRC)

Z Wainberg¹, J Strickler², M Gordon³, M Barve⁴, L Wang⁵, H Yue⁵, M Motwani⁶, S Kasichayanula⁷, L Naumovski⁵, E Hamilton⁸

¹Ronald Reagan UCLA Medical Center, Los Angeles, California, USA, ²Duke University Medical Center, Durham, North Carolina, USA, ³Pinnacle Oncology Hematology/HonorHealth Research Institute, Scottsdale, Arizona, USA, ⁴Mary Crowley Medical Research Centers, Dallas, Texas, USA, ⁵Oncology Early Development, AbbVie Inc., Redwood City, California, USA, ⁶Oncology Early Development, AbbVie Inc., North Chicago, Illinois, USA, ⁷Clinical Pharmacology and Pharmacometrics, AbbVie Inc.,

Redwood City, California, USA, ⁸Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee, USA

P-235

Adjuvant chemotherapy for colorectal cancer using oxaliplatin induced irreversible sinusoidal obstruction syndrome

K Hara, T Yamada, M Koizumi, S Shinji, Y Yokoyama, G Takahashi, M Hotta, T Iwai, K Takeda, H Yoshida

Nippon Medical School Department of Digestive Surgery, Bunkyo-ku, Japan

P-236

Clinical and pathological features in colorectal cancer associated to Lynch syndrome

O Higuera¹, A Rodriguez², N Rodriguez-Salas³, L Ruiz-Giménez⁴, A Gallego⁴, I Ghanem⁴, A Custodio⁴, D Sanchez⁵, L Ostios⁵, J Miranda Poma⁶, J Feliu⁴

¹University Hospital La Paz, Madrid, Spain, ²Universidad Autónoma de Madrid, Madrid, Spain, ³University Hospital La Paz, Madrid, Spain, ⁴University Hospital La Paz, Madrid, Spain, ⁵University Hospital La Paz, Madrid, Spain, ⁶Hospital Universitario La Paz, Madrid, Spain

P-237

Development of a new clinical nomogram including velocity rate of disease progression to predict outcome in metastatic colorectal cancer patients treated with bevacizumab beyond progression: A subanalysis from tribe trial

E Dell'Aquila¹, F Pantano¹, D Rossini², M Stellato³, S Lonardi⁴, G Masi², M Schirripa⁴, F Marmorino², C Antoniotti², S Murgioni⁴, G Tomasello⁵, M Ronzoni⁶, P Racca⁷, B Vincenzi¹, G Allegrini⁸, F Urbano⁹, A Buonadonna¹⁰, M Banzi¹¹, G Tonini¹, C Cremolini², A Falcone¹², D Santini¹

¹Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy,

²Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy, ³Department of Medical Oncology, Campus Biomedico University of Rome, Rome, Italy, ⁴Medical Oncology Unit 1, Clinical and Experimental Oncology

Department, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy, ⁵Department of Medical Oncology, Azienda Istituti Ospitalieri di Cremona, Cremona, Italy, ⁶Department of Oncology, Istituto Scientifico San Raffaele, Milan, Italy, ⁷Medical Oncology Department, University San Giovanni Battista Istituto di Totino- Molinette, Turin, Italy, ⁸Department of Medical Oncology, Ospedale F. Lotti, Pontedera, Italy, ⁹Department of Radiological,

Oncological and Anatomopathological Sciences, Sapienza University of Rome, Rome, Italy, ¹⁰Department of Medical Oncology, Centro di Riferimento Oncologico, Aviano, Italy, ¹¹Department of Medical Oncology, Nuova Azienda Ospedaliera, Reggio Emilia, Italy, ¹²University of Pisa, Pisa, Italy

¹¹Department of Medical Oncology, Nuova Azienda Ospedaliera, Reggio Emilia, Italy, ¹²University of Pisa, Pisa, Italy

¹²University of Pisa, Pisa, Italy

¹²University of Pisa, Pisa, Italy

¹²University of Pisa, Pisa, Italy

P-238

Analysis of classical high risk factors in stage III colon cancer: Experience at University Hospital Ramon y Cajal (UHRyC)

J Serrano Domingo¹, R Martín Huertas², A Barquín García², E Corral de la Fuente², C Saavedra Serrano², M Villamayor Delgado³, O Martínez Saez³, F Longo Muñoz⁴, V Pachón Olmos⁵, M Rodríguez Garrote⁵, M Vaz⁴, P Reguera Puertas⁵, R Fuentes², A Carrato⁶, R Ferreiro Monteagudo⁵

¹, ²Ramón y Cajal Hospital, Madrid, Spain, ³Ramón y Cajal University Hospital, Madrid, Spain, ⁴Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁵Ramón y Cajal University Hospital, Madrid, Spain, ⁶IRYCIS, CIBERONC, Alcalá University, Hospital Universitario Ramón y Cajal, Madrid, Spain

P-239

Impact of adding oxaliplatin to fluoropyrimidines in the adjuvant therapy in stage II in colon cancer: Experience in Ramon y Cajal University Hospital

R Martín Huertas¹, J Serrano Domingo², E Corral de la Fuente¹, A Barquín García¹, M Villamayor Delgado³, C Saavedra Serrano¹, O Martínez Saez³, F Longo Muñoz⁴, V Pachón Olmos⁵, M Rodríguez Garrote⁵, M Vaz⁴, A Carrato⁶, P Reguera Puertas⁵, R Fuentes¹, R Ferreiro Monteagudo⁵

¹Ramón y Cajal Hospital, Madrid, Spain, ², ³Ramón y Cajal University Hospital, Madrid, Spain, ⁴Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁵Ramón y Cajal University Hospital, Madrid, Spain, ⁶IRYCIS, CIBERONC, Alcalá University, Hospital Universitario Ramón y Cajal, Madrid, Spain

P-240

Benefit of the addition of oxaliplatin to 5-FU/leucovorin or capecitabine in adjuvant therapy for stage II/III colorectal cancer in elderly patients: Experience in Ramon y Cajal University Hospital.

E Corral de la Fuente¹, C Saavedra Serrano¹, M Villamayor Delgado², A Barquín García¹, R Martín Huertas¹, J Serrano Domingo³, O Martínez Saez², V Pachón Olmos⁴, M Rodríguez Garrote⁴, F Longo Muñoz⁵, P Reguera Puertas⁴, C Guillén-Ponce⁶, A Carrato⁷, R Ferreiro Monteagudo⁴

¹Ramón y Cajal Hospital, Madrid, Spain, ²Ramón y Cajal University Hospital, Madrid, Spain, ³, ⁴Ramón y Cajal University Hospital, Madrid, Spain, ⁵Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁶H. Universitario Ramón y Cajal, IRYCIS, Madrid, Spain, ⁷IRYCIS, CIBERONC, Alcalá University, Hospital Universitario Ramón y Cajal, Madrid, Spain

P-241

Reversing colon cancer's resistance to old and standard drugs

H Bruckner¹, A Hirschfeld¹, V Nghiem¹, D Gurrell²

¹Bruckner Oncology, Bronx, New York, USA, ²University Diagnostic Imaging, Bronx, New York, USA

P-242

International prospective multi-center clinical trial with adherence to surgical and pathological quality measures: Influence of body mass index (BMI) on outcome in colon cancer

M Protic¹, A Bilchik², A Nissan³, S Usaj Knezevic⁴, B Kukic⁴, M Kresoja⁴, R Veljkovic⁵, M Zivojinov⁵, A Stojadinovic⁶

¹University of Novi Sad-Faculty of Medicine and Oncology Institute of Vojvodina, Novi Sad, Serbia, ²John Wayne Cancer Institute, Santa Monica, California, USA, ³Chaim Sheba Medical Center, Tel Hashomer, Israel, ⁴University of Novi Sad - Faculty of Medicine and Oncology Institute of Vojvodina, Novi Sad, Serbia, ⁵University of Novi Sad-Faculty of Medicine and Clinical Center of Vojvodina, Novi Sad, Serbia, ⁶Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA

P-243

Phase II study of third-line panitumumab rechallenge in patients with metastatic wild-type KRAS colorectal cancer who achieved a clinical benefit in response to first-line panitumumab plus chemotherapy

A Tsuji¹, M Nakamura², T Watanabe³, D Manaka⁴, H Matsuoka⁵, M Kataoka⁶, M Takeuchi⁷, W Ichikawa⁸, M Fujii⁹

¹Department of Medical Oncology, Kagawa University Hospital, Kida-gun, Japan, ²Aizawa Comprehensive Cancer Center, Aizawa Hospital, Matsumoto, Japan, ³Department of Surgery, Japanese Red Cross Society Himeji Hospital, Himeji, Japan, ⁴Department of Surgery, Gastrointestinal Center, Kyoto Katsura Hospital, Nishikyo-ku, Japan, ⁵Gastroenterological Surgery, Fujita Health University, Toyoake, Japan, ⁶Department of Surgery, Nagoya Medical Center, Nagoya, Japan, ⁷Department of Clinical Medicine (Biostatistics), Kitasato University School of Pharmacy, Minato-ku, Japan, ⁸Division of Medical Oncology, Showa University Fujigaoka Hospital, Yokohama, Japan, ⁹Department of Digestive Surgery, Nihon University School of Medicine, Itabashi-ku, Japan

P-244

Dose finding phase Ib study of triplet plus cetuximab for patients with wild-type RAS gene metastatic colorectal cancer (TRICETSU study)

H Satake¹, T Kotake², Y Okita², Y Hatachi², H Yasui³, M Kotaka⁴, T Kato⁵, A Tsuji²

¹Department of Medical Oncology, Cancer Treatment Center, Kansai Medical University Hospital, Hirakata, Japan, ²Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan, ³Department of Oncology, Kobe City Medical Center General Hospital, Kobe, Japan, ⁴Department of Gastrointestinal Cancer Center, Sano Hospital, Kobe, Japan, ⁵Department of Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan

P-246

Rechallenge with oxaliplatin and peripheral neuropathy in colorectal cancer patients

M Martínez-Villacampa¹, S Besora Tavera², C Santos Vivas³, C Izquierdo⁴, J Bruna⁵, R Velasco⁶

¹Department of Medical Oncology, Institut Català d'Oncologia - IDIBELL, L'Hospitalet de Llobregat, Spain, ²Bellvitge Hospital, Hospitalet, Spain, ³Translational Research Laboratory and Department of Medical Oncology, Institut Català d'Oncologia-IDIBELL, L'Hospitalet de Llobregat, Spain, ⁴Bellvitge Hospital, L'Hospitalet de Llobregat, Spain, ⁵Bellvitge Hospital, Spain, ⁶Bellvitge Hospital, Hospitalet de Llobregat, Spain

P-247

Adding oxaliplatin (OX) do neoadjuvant therapy of locally advanced rectal cancer (LARC): Still promising option?

W Rogowski¹, L Wyrwicz², V Sulzyc-Bielicka³

¹The Cardiological-Oncological Hospital Magodent, Warsaw, Poland, ²Centrum Onkologii-Instytut im. M. Skłodowskiej Curie, Warsaw, Poland, ³Pomeranian Medical University, Szczecin, Poland

P-248

G8 screening tool for treatment decision-making in elderly colorectal cancer patients

J Marín¹, G Soler², M Martínez-Villacampa³, S Vázquez⁴, C Santos Vivas⁵, N Mulet Margalef⁶, A Teule², R Salazar⁷

¹Catalan Institute of Oncology, L'Hospitalet de Llobregat, Spain, ²Department of Medical Oncology, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Spain, ³Department of Medical Oncology, Institut Català d'Oncologia - IDIBELL, L'Hospitalet de Llobregat, Spain, ⁴Servei d'Oncologia Mèdica, Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain, ⁵Translational Research Laboratory and Department of Medical Oncology, Institut Català d'Oncologia-IDIBELL, L'Hospitalet de Llobregat, Spain, ⁶Institut Català d'Oncologia de l'Hospitalet, Hospitalet de Llobregat, Spain, ⁷Translational Research Laboratory and Department of Medical Oncology, Institut Català d'Oncologia-IDIBELL, L'Hospitalet de Llobregat, Spain

P-249

A SEER analysis of increasing disparities in age-related cause specific survival (CSS) among patients with colorectal cancer

T Mehmood

Northwest General Hospital and Research Centre, Peshawar, Pakistan

P-250

Capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer: Experience of the oncology department of the university hospital of Oran, Algeria

Z Behourah¹, A Bousahba², L Djellali¹

¹University Hospital, Oran, Algeria, ²University Hospital of Oran, Oran, Algeria

P-251

The prognostic and predictive value of primary tumor sidedness in the mCRC pts

E Sezer¹, K Eser², A Onder³; B Ozturk³, V Ercolak⁴, Z Oruc⁵

¹Mersin University Medical Faculty, Department of Medical Oncology, Mersin, Turkey,

²Mersin university Medical Faculty, Department of Medical Oncology, Mersin, Turkey,

³Health Sciences University, Antalya Education and Research Hospital, Division of Medical Oncology, Antalya, Turkey, ⁴Mersin University Medical Faculty Dept. of Medical Oncology, Mersin, Turkey, ⁵Mersin City Hospital, Division of Medical Oncology, Mersin, Turkey

P-252

The evaluation of liver resection for colorectal cancer liver metastases

M Ogawa¹, K Haruki², A Horiuchi², H Shiba³, Y Mitsuyama², M Kusumoto⁴, S Eto⁴, M Ishiyama⁵, T Hasegawa⁵, K Yoshida⁵, K Yanaga⁶

¹Katsushika Medical Center, The Jikei University School of Medicine, Katsushika-ku,

Japan, ²Department of Surgery, The Jikei University of Medicine, Tokyo, Japan, ³Jikei

University School of Medicine, Minato-ku, Japan, ⁴Department of Surgery, Katsushika

Medical Center, The Jikei University of Medicine, Tokyo, Japan, ⁵Department of Surgery,

Katsushika Medical Center, The Jikei University School of Medicine, Tokyo, Japan,

⁶Department of Surgery, The Jikei University School of Medicine, Minato-ku, Japan

P-253

A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) refractory to standard chemotherapy: APOLLON study

K Yamazaki¹, H Yasui², K Yamaguchi³, Y Kagawa⁴, Y Kuboki⁵, T Yoshino⁶, M Gamoh⁷, Y Komatsu⁸, H Satake⁹, M Goto¹⁰, H Tanioka¹¹, E Oki¹², M Kotaka¹³, A Makiyama¹⁴, T Denda¹⁵, J Soeda¹⁶, K Shibuya¹⁶, M Iwata¹⁶, K Oba¹⁷, T Kato¹⁸

¹Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Sunto-gun, Japan,

²Shizuoka Cancer Center, Sunto-gun, Japan, ³Department of Gastroenterology Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-ku, Japan,

⁴Department of Gastrointestinal Surgery, Kansai Rosai Hospital, Amagasaki, Japan,

⁵National Cancer Center Hospital East, Kashiwa-city, Japan, ⁶National Cancer Center

Hospital East, Kashiwa, Japan, ⁷Department of Medical Oncology, Osaki Citizen Hospital,

Osaki-shi, Japan, ⁸Digestive Internal Medicine, Division of Cancer Center, Hokkaido

University Hospital, Sapporo, Japan, ⁹Department of Medical Oncology, Cancer Treatment

Center, Kansai Medical University Hospital, Hirakata, Japan, ¹⁰Cancer Chemotherapy

Center, Osaka Medical College Hospital, Takatsuki, JAPAN, ¹¹Department of Medical

Oncology, Okayama Rosai Hospital, Okayama, Japan, ¹²Department of Surgery, Graduate

School of Medical Sciences, Kyushu University, Higashi-ku, Japan, ¹³Department of

Gastrointestinal Cancer Center, Sano Hospital, Kobe, Japan, ¹⁴Japan Community

Healthcare Organization Kyushu Hospital, Department of Hematology/Oncology,

Kitakyushu, Japan, ¹⁵Chiba Cancer Center, Chiba, Japan, ¹⁶Takeda Pharmaceutical

Company Limited, Chuo-ku, Japan, ¹⁷Department of Biostatistics, The University of

Tokyo, Tokyo, Japan, ¹⁸Department of Surgery, National Hospital Organization Osaka

National Hospital, Osaka, Japan

P-254

Ultrasonic monitoring of liver metastasis after radiofrequency thermoablation

S Khoshimov

Tashkent Medical Academy, Tashkent, Uzbekistan

P-255

Immediate and long-term results of liver resections with metastatic lesion

S Lukmonov¹, O Usmanov¹, M Ismailov², K Madatov¹, U Kurbankulov¹, U Allazarov¹

¹Tashkent Medical Academy, Tashkent, Uzbekistan, ²Tashkent Pediatric Medical Institute,

Tashkent, Uzbekistan

P-256

Treatment efficacy and survival analysis of extremely elderly (80 years of age or older) patients with metastatic colorectal cancer: Single institute retrospective study

Y Liang¹, C Wei², J Tsai³, Y Jeng⁴, K Chen¹, A Cheng⁵, K Yeh⁶

¹Graduate Institute of Oncology, National Taiwan University; National Taiwan University Cancer Center; Department of Oncology, National Taiwan University Hospital, Taipei, Republic of Taiwan, ²Department of Oncology, National Taiwan University Hospital, Hsin-Chu Branch, Hsinchu City, Republic of Taiwan, ³Pathology, National Taiwan University Hospital, Taipei, Republic of Taiwan, ⁴Graduate Institute of Pathology, College of Medicine, National Taiwan University, Taipei, ⁵Department of Oncology and Internal Medicine, National Taiwan University Hospital, Taipei, Republic of Taiwan, ⁶National Taiwan University Hospital, Taipei, Republic of Taiwan

P-257

Improvement of metastatic colorectal cancer patient survival: Single institution experience

E Fenocchio¹, F Colombi², M Calella¹, R Filippi³, I Depetris¹, P Lombardi¹, D Marino⁴, C Cagnazzo⁴, R Ferraris⁵, M Vaira², M Aglietta⁴, F Leone¹

¹Department of Oncology, Candiolo Cancer Institute - FPO - IRCCS - University of Turin Medical School, Candiolo, Italy, ²Department of Oncology, Candiolo Cancer Institute - FPO - IRCCS, Candiolo, Italy, ³Institute for Cancer Research and Treatment, IRCCS Candiolo (TO), Candiolo, Italy, ⁴Department of Medical Oncology, University of Turin Medical School, Candiolo Cancer Institute, FPO, IRCCS, Candiolo, Italy, ⁵Department of Oncology, Candiolo Cancer Institute - FPO - IRCCS, Candiolo, Italy

P-258

HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of cases of prior regorafenib

Y Shindo¹, S Yuki², M Yagisawa³, Y Kawamoto³, Y Tsuji⁴, K Hatanaka⁵, Y Kobayashi⁶, S Kajiura⁷, A Ishiguro⁸, T Honda⁹, M Dazai¹⁰, K Eto¹¹, M Nakamura¹², M Koike¹³, S Ota¹⁴, A Sato¹⁵, K Kato¹⁶, A Ueda¹⁷, A Fukunaga¹⁸, M Sekiguchi¹⁹, Y Sakata²⁰, Y Komatsu²¹

¹Department of Gastroenterological Surgery, Nakadori General Hospital, Akita, Japan, ²Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan, ³Division of Cancer Center, Hokkaido University Hospital, Sapporo, Japan, ⁴Department of Medical Oncology, Tonan Hospital, Sapporo, Japan, ⁵Department of Gastroenterology, Hakodate Municipal Hospital, Hakodate, Japan, ⁶Department of Medical Oncology, Kushiro Rosai Hospital, Kushiro, Japan, ⁷Department of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Toyama, Japan, ⁸Department of Medical Oncology, Teine Keijinkai Hospital, Sapporo, Japan, ⁹Division of Clinical Oncology Center, Nagasaki University Hospital, Nagasaki, Japan, ¹⁰Department of Gastroenterology, Sapporo Medical Center NTT EC, Sapporo, Japan, ¹¹Department of Gastroenterology, Tomakomai City Hospital, Tomakomai, Japan, ¹²Department of Gastroenterology, Sapporo City General Hospital, Sapporo, Japan, ¹³Department of Surgery, KKR Sapporo Medical Center, Sapporo, Japan, ¹⁴Department of

Surgery, Akita City Hospital, Akita, Japan, ¹⁵Department of Medical Oncology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan, ¹⁶Department of Gastroenterology, Iwamizawa Municipal General Hospital, Iwamizawa, Japan, ¹⁷Department of Medical Oncology, Toyama Red Cross Hospital, Toyama, Japan, ¹⁸Department of Surgery, Asahikawa City Hospital, Asahikawa, Japan, ¹⁹Data Center, Hokkaido Gastrointestinal Cancer Study Group (HGCSG), Sapporo, Japan, ²⁰CEO, Misawa City Hospital, Misawa, Japan, ²¹Digestive Internal Medicine, Division of Cancer Center, Hokkaido University Hospital, Sapporo, Japan

P-259

Variability of current global practice patterns in the management of metastatic colorectal cancer

*T Bekaii-Saab¹, K Marcello², G Fisher³, S Kopetz⁴, J Strickler⁵, A Venook⁶, K Obholz²
¹Mayo Clinic Cancer Center, Scottsdale, Arizona, USA, ²Clinical Care Options, Reston, Virginia, USA, ³Stanford University School of Medicine, Palo Alto, California, USA, ⁴UT MD Anderson Cancer Center, Houston, Texas, USA, ⁵Duke University Medical Center, Durham, North Carolina, USA, ⁶University of California, San Francisco, California, USA*

P-260

Quality-of-life in patients with metastatic colorectal cancer (mCRC) treated with aflibercept and FOLFIRI: Interim results of the non-interventional AIO study QoLiTrap

*M Zahn¹, F Scholten², R von Moos³, J Thaler⁴, R Hofheinz⁵
¹Onkologie/Hämatologie Goslar, Goslar, Germany, ²Klinikum Frankfurt Hoechst GmbH, Frankfurt am Main, Germany, ³Kantonsspital Graubünden, Chur, Switzerland, ⁴Dept Internal Medicine, Wels, Austria, ⁵University Hospital Mannheim, Mannheim, Germany*

P-261

HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of GERCOR index

*K Hatanaka¹, S Yuki², S Nakano², K Sawada³, K Harada⁴, H Okuda⁵, T Ando⁶, K Ogawa⁷, K Furukawa⁸, S Minami⁹, T Saiki¹⁰, T Ohta¹¹, T Kato¹², J Nakajima¹³, T Sasaki¹⁴, S Saitoh¹⁵, Y Shindo¹⁶, M Tateyama¹⁷, S Kato¹⁸, H Nagai¹⁹, Y Sakata²⁰, Y Komatsu²¹
¹Department of Gastroenterology, Hakodate Municipal Hospital, Hakodate, Japan, ²Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan, ³Division of Cancer Center, Hokkaido University Hospital, Sapporo, Japan, ⁴Department of Medical Oncology, Kushiro Rosai Hospital, Kushiro, Japan, ⁵Department of Medical Oncology, Keiyukai Sapporo Hospital, Sapporo, Japan, ⁶Department of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Toyama, Japan, ⁷Department of Gastroenterology, Kouseiren Takaoka Hospital, Takaoka, Japan, ⁸Department of Gastroenterology, Niigata City General Hospital, Niigata, Japan, ⁹Department of Gastroenterology, Oji General Hospital, Tomakomai, Japan, ¹⁰Department of Medical Oncology, Teine Keijinkai Hospital, Sapporo, Japan, ¹¹Department of Gastroenterology, Sapporo Higashi Tokushukai Hospital, Sapporo, Japan, ¹²Department*

of Internal Medicine, Wakkanai City Hospital, Wakkanai, Japan, ¹³Department of Gastroenterology, Obihiro Kosei Hospital, Obihiro, Japan, ¹⁴Department of Internal Medicine, Hokkaido Gastroenterology Hospital, Sapporo, Japan, ¹⁵Department of Internal Medicine, Misawa City Hospital, Misawa, Japan, ¹⁶Department of Gastroenterological Surgery, Nakadori General Hospital, Akita, Japan, ¹⁷Department of Internal Medicine, Tomakomai Nisshou Hospital, Tomakomai, Japan, ¹⁸Department of Gastroenterology, Sapporo Hokuyu Hospital, Sapporo, Japan, ¹⁹Data Center, Hokkaido Gastrointestinal Cancer Study Group (HGCSG), Sapporo, Japan, ²⁰CEO, Misawa City Hospital, Misawa, Japan, ²¹Digestive Internal Medicine, Division of Cancer Center, Hokkaido University Hospital, Sapporo, Japan

P-262

Trial-level analysis of early tumor shrinkage and disease control rate as intermediate end points of first-line medical treatment in randomized studies of metastatic colorectal cancer

*G Colloca, A Venturino, D Guarneri
G. Borea Hospital, Sanremo, Italy*

P-263

Survival analysis of a multicentre, randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC)

*A Avallone¹, G Nasti², G Rosati³, C Carlomagno⁴, C Romano⁵, D Bilancia⁶, A De Stefano⁵, L Silvestro⁵, A Ottaiano⁵, A Cassata⁵, F Bianco⁵, F Izzo⁷, P Delrio⁵, E De Gennaro⁵, R Casaretti⁸, S Tafuto⁵, V Albino⁵, U Pace⁵, S Lastoria⁵, C Gallo⁹, A Budillon⁵, M Piccirillo⁵
¹Abdomen Medical Oncology, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Naples, Italy, ²Dipartimento di Oncologia Medica, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale, Naples, Italy, ³Medical Oncology, San Carlo Hospital, Potenza, Italy, ⁴Azienda Ospedaliera Universitaria Federico II, Naples, Italy, ⁵IRCCS Fondazione G. Pascale, Naples, Italy, ⁶S. Carlo Hospital, Potenza, Italy, ⁷IRCCS Fondazione G. Pascale, Naples, Italy, ⁸Istituto Tumori - Fondazione Pascale, Naples, Italy, ⁹Università Vanvitelli Napoli, Naples, Italy*

P-264

HGCSG1401: A retrospective cohort study evaluating the safety and efficacy of regorafenib in patients with metastatic colorectal cancer: Analysis of risk factors for liver dysfunction

*T Honda¹, S Yuki², T Muranaka³, H Nakatsumi³, Y Tsuji⁴, T Miyagishima⁵, S Yoshida⁶, K Hatanaka⁷, T Sasaki⁸, A Ishiguro⁹, O Muto¹⁰, H Ohnuma¹¹, S Kato¹², A Sato¹³, M Abe¹⁴, K Kato¹⁵, K Onodera¹⁶, K Eto¹⁷, M Tateyama¹⁸, T Amano¹⁹, Y Sakata²⁰, Y Komatsu²¹
¹Division of Clinical Oncology Center, Nagasaki University Hospital, Nagasaki, Japan, ²Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan, ³Division of Cancer Center, Hokkaido University Hospital, Sapporo, Japan, ⁴Department of Medical Oncology, Tonan Hospital, Sapporo, Japan, ⁵Department of*

Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan, ⁶Department of Gastroenterology, The University of Tokyo Hospital, Tokyo, Japan, ⁷Department of Gastroenterology, Hakodate Municipal Hospital, Hakodate, Japan, ⁸Department of Internal Medicine, Hokkaido Gastroenterology Hospital, Sapporo, Japan, ⁹Department of Medical Oncology, Teine Keijinkai Hospital, Sapporo, Japan, ¹⁰Department of Medical Oncology, Japanese Red Cross Akita Hospital, Akita, Japan, ¹¹Department of Medical Oncology and Hematology, Sapporo Medical University, Sapporo, Japan, ¹²Department of Gastroenterology, Sapporo Hokuyu Hospital, Sapporo, Japan, ¹³Department of Medical Oncology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan, ¹⁴Department of Medical Oncology, Sapporo-Kosei General Hospital, Sapporo, Japan, ¹⁵Department of Gastroenterology, Iwamizawa Municipal General Hospital, Iwamizawa, Japan, ¹⁶Department of Gastroenterology and Hepatology, Sapporo Medical University, Sapporo, Japan, ¹⁷Department of Gastroenterology, Tomakomai City Hospital, Tomakomai, Japan, ¹⁸Department of Internal Medicine, Tomakomai Nisshou Hospital, Tomakomai, Japan, ¹⁹Clinical Research and Medical Innovation Center, Hokkaido University Hospital, Sapporo, Japan, ²⁰CEO, Misawa City Hospital, Misawa, Japan, ²¹Digestive Internal Medicine, Division of Cancer Center, Hokkaido University Hospital, Sapporo, Japan

P-265

Treatment choices in metastatic colorectal cancer according to sidedness and RAS/BRAF status: A national survey by the Brazilian Group of Gastrointestinal Tumors (GTG)

R Peixoto¹, R Riechelmann², G Prolla³, R Weschenfelder⁴, J Rego⁵, G Dos Santos Fernandes⁶, G Pereira⁷, M de Oliveira⁸, D da Rocha Filho⁹, A Coutinho¹⁰

¹Hospital Alemão Oswaldo Cruz, São Paulo, Brazil, ²AC Camargo Cancer Center, São Paulo, Brazil, ³Hospital Mãe de Deus, Porto Alegre, Brazil, ⁴Hospital Moinhos de Vento, Porto Alegre, Brazil, ⁵Liga Contra o Câncer, Natal, Brazil, ⁶Hospital Sirio Libanês, Brasília, Brazil, ⁷Centro de Oncologia do Paraná, Curitiba, Brazil, ⁸Oncologia D'Or, Rio de Janeiro, Brazil, ⁹Fujiday, Fortaleza, Brazil, ¹⁰Clínica AMO, Salvador, Brazil

P-266

Retrospective analysis of clinical factors associated with a greater benefit with Lonsurf® in metastatic colorectal cancer

N Rodriguez-Salas¹, M Soriano Segura², A Jimenez-Gordo³, R Molina⁴, J Cámara⁵, A Lopez Alfonso⁶, B Martínez-Amores⁷; A Pertejo Fernandez⁸, G Reynoso⁹, J Miranda Poma⁸

¹University Hospital La Paz, Madrid, Spain, ²Hospital Universitario Puerta de Hierro, Madrid, Spain, ³Hospital de Getafe, Getafe, Spain, ⁴Department of Medical Oncology, Principe de Asturias University Hospital, Alcalá University, Alcalá de Henares, Alcalá de Henares, Spain, ⁵H. Universitario Fundacion Alcorcón, Alcorcón, Spain, ⁶Hospital Universitario Infanta Leonor, Madrid, Spain, ⁷Department of Medical Oncology, Principe de Asturias University Hospital, Alcalá University, Alcalá de Henares, Alcalá de Henares, Spain, ⁸Hospital Universitario La Paz, Madrid, Spain, ⁹Hospital Civil de Guadalajara, Guadalajara, Mexico

P-267

The prognostic impact of sidedness in RAS wild-type colorectal cancer

N Tavares¹, A Costa¹, D Almeida¹, S Meireles², C Fernandes¹, C Rey³, C Sarmiento², M Damasceno²

¹Hospital S. João, Porto, Portugal, ²Hospital de S. João, Porto, Portugal, ³Centro Hospitalar de São João, EPE, Porto, Portugal

P-268

Advanced colorectal cancer and risk factors for survival

D Kaidarova¹; K Smagulova², S Yesentaeva³, Y Ishkinin¹, Y Ukolova¹, A Kurmankulova¹
¹Kazakh Research Institute of Oncology and Radiology, Almaty, Kazakhstan, ²Kazakh Science Research Institute Oncology and Radiology, Almaty, Kazakhstan, ³Kazakh-Russian Medical University, Almaty, Kazakhstan

P-269

Dynamics of the monoclonal antibodies (MABs) treatment rate and mortality rate in patients with metastatic colorectal cancer (mCRC) in Russia from 2013 to 2016

M Fedyanin, H Elsnukaeva, E Polyanskaya, A Popova, I Pokataev, E Ignatova, A Bulanov, A Tryakin, S Tjulandin

N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russian Federation

P-270

Association between duration of oxaliplatin-free interval and effect of reintroduction of oxaliplatin-containing chemotherapy in patients with metastatic colorectal cancer (mCRC)

M Fedyanin, A Tryakin, A Bulanov, A Popova, E Ignatova, O Sekhina, D Chekini, E Polyanskaya, H Elsnukaeva, I Pokataev, S Tjulandin

N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russian Federation

P-271

Prognostic impact of K-RAS mutational status and primary tumour location in patients undergoing resection for colorectal cancer liver metastases: A METHEPAR analysis (multicentre study in Argentina)

J O'Connor¹, E Huertas², F Sanchez Loria², F Brancato², J Grondona³, M Fauda⁴, O Andriani⁵, P Sanchez⁶, P Barros Schelotto⁷, V Ardiles⁸, E de Santibañes⁹

¹Institute Alexander Fleming, Buenos Aires, Argentina, ²Instituto Alexander Fleming, Caba, Argentina, ³Sanatorio San Lucas, San isidro, San Isidro, Argentina, ⁴Hospital

Universitario Austral, Pilar, Argentina, ⁵Surgical Department Hospital Austral, Sanatorio Los Arcos, Caba, Argentina, ⁶Instituto A Roffo, Caba, Argentina, ⁷Fundacion Favalaro, Caba, Argentina, ⁸Hospital Italiano Buenos Aires, Caba, Argentina, ⁹Hospital italiano Buenos Aires, Caba, Argentina

P-272

Understanding of metastatic colorectal cancer (mCRC) in the real world: Initial results from a European survey on the unmet needs of patients living with metastatic colorectal cancer

Z Maravic¹, L Wyrwicz², B Karczmarek-Borowska³, E Espín Basany⁴, A Carrato⁵, A Horvath⁶, àBenedict⁷, Z Kapitány⁸

¹EuropaColon, Salisbury, UK, ²Centrum Onkologii-Instytut im. M. Skłodowskiej Curie, Warsaw, Poland, ³Center of Clinical Oncology of Provincial Hospital No. 1, Rzeszów, Poland, ⁴Hospital Valle de Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain, ⁵IRYCIS, CIBERONC, Alcalá University, Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁶Semmelweis University, Budapest, Hungary, ⁷Evidera, Budapest, Hungary, ⁸Semmelweis University Faculty of Health Sciences, Budapest, Hungary

P-273

Recruitment for a survey on the unmet needs of patients living with metastatic colorectal cancer (mCRC): Lessons from a European study

Z Maravic¹, J Stanisić Trenevski², J Bokros³, A Ruiz Casado⁴, C González de Pedro⁵, M Méndez Otero⁵, J Borràs⁶, T Ferro⁷, O Rial⁷

¹EuropaColon, Salisbury, UK, ²Dom zdravlja Voždovac, Belgrade, Serbia, ³Semmelweis University, Budapest, Hungary, ⁴Hospital Puerta de Hierro-Majadahonda, Majadahonda, Spain, ⁵Servicio de Oncología Médica, Hospital Puerta de Hierro - Majadahonda, Majadahonda (Madrid), Spain, ⁶ICO l'Hospitalet, Hospitalet de Llobregat, Spain, ⁷Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain

P-274

The clinical effectiveness and safety of re-induction oxaliplatin, irinotecan and fluorouracil (FOLFOXIRI regimen) for the treatment of metastatic colorectal cancer after two lines of chemotherapy (oxaliplatin- and irinotecan-based regimens)

E Ledin¹, A Mochalova¹; Y Zaitseva²

¹Clinical Hospital "Medsi", Moscow, Russian Federation, ²N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russian Federation

P-275

Selective internal radiation therapy (SIRT) with yttrium-90 microspheres and peri-procedural FOLFIRI/irinotecan in pre-treated colorectal liver metastases patients: An analysis of outcomes from a UK Cancer Centre between 2009 and 2017

G Wilson¹, D Bentley¹, S Mullamitha², M Braun¹, M Nasralla¹, J Bell¹, D Mullan³, J Hasan¹,

M Saunders⁴, F Marti¹, C McBain¹, N Alam¹, H Laasch³, P Najran¹, T Westwood¹, S Jeans¹, J Tipping¹, P Manoharan¹, J Lawrance¹

¹The Christie NHS Foundation Trust, Manchester, UK, ²The Christie Hospital NHS Foundation Trust, Manchester, UK, ³The Christie Hospital, Manchester, UK, ⁴Christie Hospital NHS Foundation Trust, Manchester, UK

P-276

Raltitrexed as salvage therapy for metastatic colorectal cancer: A multicenter retrospective study

I Ghanem¹, A Viudez², E García-Torrallba³, J Torres-Tenor⁴, A Carmona³, R Vera², N Rodriguez-Salas⁵, F Ayala de la Peña³, O Higuera⁶, J Feliu¹

¹University Hospital La Paz, Madrid, Spain, ²Service of Medical Oncology, Hospital de Navarra, Pamplona, Spain, ³Morales Meseguer University Hospital, Murcia, Spain, ⁴University Hospital la Paz, Madrid, Spain, ⁵University Hospital La Paz, Madrid, Spain, ⁶University Hospital La Paz, Madrid, Spain

P-277

Real world data in colorectal cancer: A retrospective analysis of overall survival in metastatic colorectal cancer patients between 2011-2015 treated in Spain, preliminary results (RWD-ACROSS study)

C Pericay¹, J Gallego², A Fernandez Montes³, H Oliveres⁴, H Asensio-Martínez⁵, J Garcia-Gómez⁶, J Fernandez-Plana⁷, M Marín-Alcalá⁸, M Ballester-Espinosa⁵, M Salgado⁹, I Macías Declara¹⁰, L Gómez-González⁵, L Iglesias-Rey⁶, I Cirera¹¹

¹Hospital de Sabadell, Corporació Sanitaria Parc Taulí-Institut Universitari, Sabadell, Spain, ²Hospital General Universitario de Elche, Elche, Spain, ³Complejo Hospitalario Universitario de Ourense, Ourense, Spain, ⁴Parc Tauli Hospital-Sabadell, Sabadell, Spain, ⁵Hospital General de Elche, Elche, Spain, ⁶Hospital de Ourense, Ourense, Spain, ⁷Hospital Mutua de Terrassa, Terrassa, Spain, ⁸Parc Tauli, Sabadell, Spain, ⁹Complejo Hospitalario Universitario de Ourense, Ourense, Spain, ¹⁰Corporació Sanitaria Parc Taulí, Sabadell, Spain, ¹¹Mutua Terrassa, Terrassa, Spain

P-278

Prognostic factors in metastatic colorectal cancer

*M Silva, I Guerreiro, S Abreu, D Marques
IPO-Porto, Porto, Portugal*

P-279

Effectiveness of TAS-102 in patients with metastatic colorectal cancer in a single comprehensive cancer center

C Sales¹, I Julião¹, A Rosinha¹, D Marques¹, F Carneiro², C Faustino³, M Machado¹, P Ferreira⁴, M Fragoso¹, N Sousa⁴

¹IPO-Porto, Porto, Portugal, ²Portuguese Institute of Oncology FG Porto, Portugal -

Medical Oncology Service, Porto, Portugal, ³Instituto Português de Oncologia do Porto, Porto, Portugal, ⁴Portuguese Institute of Oncology, Porto, Portugal

P-281

The impact of primary tumor location in patients with resected colorectal liver metastasis

V Pacheco-Barcia¹, O Donnay¹, R Mondéjar Solís¹, R Serrano², E Martín², L del Campo², J Rogado¹, B Vera², A Ballesteros³, R Colomer¹

¹Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria La Princesa, Madrid, Spain, ²Hospital Universitario La Princesa, Madrid, Spain, ³Hospital Universitario La Princesa, Madrid, Spain

P-282

RAS status in metastatic colorectal cancer: What is the relationship to epidemiological and anatomico-clinical factors?

M Haffadi¹; N Tawfiq¹, M Karkouri², Z Bouchbika¹, N Benchakroun¹, H Jouhadi¹, S Sahraoui¹, A Benider¹

¹Oncology Centre Mohammed VI for the Treatment of Cancers, University Hospital Center Ibn Rochd, Casablanca, Morocco, ²Anatomical Pathology Service, University Hospital Center Ibn Rochd, Casablanca, Morocco

P-283

Skin disorders and primary tumor location as a prognostic factor of cetuximab plus chemotherapy in the treatment of advanced colorectal cancer

T Shinya¹, S Tamotsu², K Fujikawa², T Kana³, F Yuta³, H Hiroki³, E Masayuki³, Y Takahashi²
¹National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan, ²Department of Gastroenterology, Hokkaido Cancer Center, Sapporo, Japan, ³Hokkaido Cancer Center, Sapporo, Japan

P-284

Characteristics of colorectal cancer in the elderly patients about 60 cases

H Aliane¹, S Ghomari-Bezzar², A Belhadj², N Madani³, N Charif²

¹Medical Oncology Department, CHU Tlemcen Faculte de Médecine, Laboratoire Toxicomed, Université de Tlemcen, Tlemcen, Algeria, ²Medical Oncology Department, CHU Tlemcen, Faculte de Medecine, Laboratoire Toxicomed, Université de Tlemcen, Tlemcen, Algeria, ³Medical Oncology Department, CHU Tlemcen, Faculte de Medecine, Laboratoire Toxicomed, Université de Tlemcen, Tlemcen, Algeria

P-285

Optimizing the use of EGFR antibodies across the continuum of care in mCRC: Effect of online education on clinician knowledge, competence and confidence

G Fisher¹, W Guerra¹, C Day¹; C Montagut²

¹WebMD Global, New York, New York, USA, ²Department of Medical Oncology, Hospital Universitari del Mar, Barcelona, Spain

P-286

Integrating a paradigm shift in the treatment of metastatic colorectal cancer: Effect of online CME on oncologists' knowledge and competence

T Herrmann, D Cameron,, A Carothers

Medscape Education, New York, New York, USA

P-287

Treatment based on tumor sidedness in mCRC: Effect of online education on clinician knowledge, competence and confidence

G Fisher¹, W Guerra¹, C Day¹; M Ducreux²

¹WebMD Global, New York, New York, USA, ²Gustave Roussy Cancer Campus Grand Paris, Villejuif, France

P-288

Causes of death in a cohort of early stage colorectal cancer patients at a regional centre in Australia

L Lim, W Faisal, M Wuttke, G Chong

Ballarat Regional Integrated Cancer Centre, Ballarat, Australia

P-289

Prognostic factors for early recurrences following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases

N Chandran¹, G Tan², C Chia², M Teo³

¹Duke-NUS Medical School, Singapore, ²National Cancer Centre Singapore, Singapore,

³National Cancer Centre, Singapore

P-290

Simultaneous versus staged resections of liver metastases in patients with advanced colorectal cancer

O Kolesnik¹, A Lukashenko¹, Y Ostapenko², N Chorna²

¹National Cancer Institute, Kiev, Ukraine, ²National Cancer Institute of Ukraine, Kiev, Ukraine

P-291

The DISTINCTIVE study: A biologically enriched phase II study of second-line folfiri/aflibercept in prospectively stratified, anti-EGFR resistant, metastatic colorectal cancer patients with RAS Validated wild type status

P Ziranu¹, L Demurtas¹, M Puzzone², F Loupakis³, B Daniele⁴, L Rimassa⁵, D Bilancia⁶, S Lonardi³, A Avallone⁷, N Pella⁸, D Ferrari⁹, L Frassineti¹⁰, G Beretta¹¹, A Zaniboni¹², A Santoro¹³, M Zampino¹⁴, M Sarobba¹⁵, V Zagonel¹⁶, S Barni¹⁷, G Palmieri¹⁸, R Labianca¹⁹, S Cascinu²⁰

¹Departments of Medical Oncology, University of Cagliari, University Hospital 'Dulio Casula', Cagliari, Italy, ²Departments of Medical Oncology, University of Cagliari, University Hospital 'Dulio Casula', Monserrato, Italy, ³Medical Oncology Unit 1, Clinical and Experimental Oncology Department, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy, ⁴Dipartimento di Oncologia - Ospedale Rummo, Benevento, Italy, ⁵Humanitas Research Hospital – IRCCS, Rozzano, Italy, ⁶UO Oncologia - Ospedale S. Carlo di Potenza, Potenza, Italy, ⁷Abdomen Medical Oncology, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Naples, Italy, ⁸Department of Oncology, Azienda Sanitaria Universitaria Integrata S. Maria della Misericordia, Udine, Italy, ⁹A.O. San Paolo, Milan, Italy, ¹⁰Medical Oncology Unit, "Istituto Scientifico Romagnolo", Meldola, Italy, ¹¹Humanitas Gavazzeni, Bergamo, Italy, ¹²Fondazione Poliambulanza, Brescia, Italy, ¹³Humanitas Cancer Center, Istituto Clinico Humanitas IRCCS, Rozzano, Italy, ¹⁴European Institute of Oncology, Milan, Italy, ¹⁵Medical Oncology Department, ASL Nuoro, Nuoro, Italy, ¹⁶Oncologia Medica 1, Istituto Oncologico Veneto - IRCCS, Padua, Italy, ¹⁷AO Ospedale Treviglio-Caravaggio, Treviglio, Italy, ¹⁸CNR - Unità di Genetica dei Tumori, Sassari, Sassari, Italy, ¹⁹Medical Oncology Unit ASST Papa Giovanni XXIII, Bergamo, Italy, ²⁰Azienda Ospedaliera-Università di Modena, Modena, Italy

P-292

A phase II study of dose-escalation of regorafenib for patients with previously treated metastatic colorectal cancer – DEREGULATE study

K Kawaguchi¹, R Nishitai¹, D Manaka¹, T Ota¹, Y Nishikawa², R Kudo¹, H An², S Hamasu¹, S Konishi¹

¹Department of Surgery, Gastrointestinal Center, Kyoto Katsura Hospital, Nishikyo-ku, Japan, ²Department of Surgery, Gastrointestinal Center, Kyoto Katsura Hospital, Nishikyo-ku, Japan

P-293

Comorbidities (CM) and potential impact in outcomes of advanced colorectal cancer patients (ACC) in Argentina: EVIREPRO real life program

A Schmilovich¹, F Ramello², M Malicki³, N Colombo Berra⁴, S Rojo⁵, G Davila⁶, V Binner⁷, H Barrionuevo⁸, J Capria⁹, M Poggio⁷, R Arca¹⁰, D Tabares¹¹, D Vicente¹², D Santillan¹³, J Burre¹¹, M Vazquez¹¹

¹Grupo Biotoscana, Buenos Aires, Argentina, ²Private Practice, Gualeguaychu, Argentina, ³Private Practice, Lanus, Argentina, ⁴Private Practice, Rosario, Argentina, ⁵Private Practice, La Calera, Argentina, ⁶Private Practice, Villa Maria, Argentina, ⁷Private Practice, San Nicolas, Argentina, ⁸Private Practice, Santa Fe, Argentina, ⁹Fundacion Investigar, Pilar, Argentina, ¹⁰Private Practice, Caba, Argentina, ¹¹Private Practice, La Plata, Argentina, ¹²Private Practice, Rosario, Argentina, ¹³Private Practice, Lomas de Zamora, Argentina

P-294

Multicenter phase Ib/ II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study)

T Kato¹, H Satake², K Oba³, Y Kagawa⁴, H Yasui⁵, M Nakamura⁶, T Watanabe⁷, T Matsumoto⁸, K Hirata⁹, K Muro¹⁰, Y Komatsu¹¹, T Yoshino¹², K Yamazaki¹³, H Mishima¹⁴, M Kotaka¹⁵, A Tsuji¹⁶, Y Kakeji¹⁷, E Oki¹⁸, N Nagata¹⁹, J Sakamoto²⁰

¹Department of Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan, ²Department of Medical Oncology, Cancer Treatment Center, Kansai Medical University Hospital, Hirakata, Japan, ³Department of Biostatistics, The University of Tokyo, Tokyo, Japan, ⁴Department of Gastrointestinal Surgery, Kansai Rosai Hospital, Amagasaki, Japan, ⁵Department of Oncology, Kobe City Medical Center General Hospital, Kobe, Japan, ⁶Aizawa Comprehensive Cancer Center, Aizawa Hospital, Matsumoto, Japan, ⁷Department of Surgery, Japanese Red Cross Society Himeji Hospital, Himeji, Japan, ⁸Department of Internal Medicine, Japanese Red Cross Society Himeji Hospital, Himeji, Japan, ⁹Department of Surgery I, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁰Department of Clinical Oncology and Outpatient Treatment Center, Aichi Cancer Center Hospital, Chikusa-Ku, Nagoya, Japan, ¹¹Digestive Internal Medicine, Division of Cancer Center, Hokkaido University Hospital, Sapporo, Japan, ¹²National Cancer Center Hospital East, Kashiwa, Japan, ¹³Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Sunto-gun, Japan, ¹⁴Division of Cancer Center, Aichi Medical University, Nagakute, Japan, ¹⁵Department of Gastrointestinal Cancer Center, Sano Hospital, Kobe, Japan, ¹⁶Department of Medical Oncology, Kagawa University Hospital, Kida-gun, Japan, ¹⁷Division of Gastrointestinal Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, ¹⁸Department of Surgery, Graduate School of Medical Sciences, Kyushu University, Higashi-ku, Japan, ¹⁹Department of Surgery, Kitakyushu General Hospital, Kitakyushu, Japan, ²⁰Tokai Central Hospital, Kakamigahara, Japan

P-295

A multicenter, multicohort, phase 2 study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing metastatic colorectal cancer

T Yoshino¹, S Siena², R Dalal³, Y Okuda⁴, E Yamamoto⁵, A Grothey⁶
¹National Cancer Center Hospital East, Kashiwa, Japan, ²Niguarda Cancer Center, Università degli Studi di Milano, Milan, Italy, ³Daiichi Sankyo, Inc., Basking Ridge, New Jersey, USA, ⁴Daiichi Sankyo Co., Ltd, Tokyo, Japan, ⁵Daiichi Sankyo Co., Ltd, Chuo-ku, Japan, ⁶Mayo Clinic, Rochester, Minnesota, USA

P-296

ABT-165 plus FOLFIRI vs bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bevacizumab

Z Wainberg¹, L Wang², H Yue², M Motwani³, S Kasichayanula⁴, M Blaney², L Naumovski², J Strickler⁵

¹Ronald Reagan UCLA Medical Center, Los Angeles, California, USA, ²Oncology Early Development, AbbVie Inc., Redwood City, California, USA, ³Oncology Early Development, AbbVie Inc., North Chicago, Illinois, USA, ⁴Clinical Pharmacology and Pharmacometrics, AbbVie Inc., Redwood City, California, USA, ⁵Duke University Medical Center, Durham, North Carolina, USA

P-297

CanStem303C trial: A Phase 3 Study of napabucasin (NAPA) in combination with 5-fluorouracil (5-FU), leucovorin, and irinotecan (FOLFIRI) in adult patients (pts) with previously treated metastatic colorectal cancer (mCRC)

M Shah¹, A Grothey², N Tebbutt³, R Xu⁴, T Yoshino⁵, A Cervantes⁶, J Tabernero⁷, J Taieb⁸, A Falcone⁹, B Xu¹⁰, M Fontaine¹¹, L Borodyansky¹¹, E Van Cutsem¹²

¹Weill Cornell Medical College and New York Presbyterian Hospital, New York, New York, USA, ²Mayo Clinic, Rochester, Minnesota, USA, ³Olivia Newton-John Cancer & Wellness Centre, Austin Health, Melbourne, Australia, ⁴Sun Yat-Sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China, ⁵National Cancer Center Hospital East, Kashiwa, Japan, ⁶University Hospital of Valencia, Valencia, Spain, ⁷Vall d'Hebron University Hospital, Barcelona, Spain, ⁸Sorbonne Paris Cité, Paris Descartes University, Georges Pompidou European Hospital, Paris, France, ⁹University of Pisa, Pisa, Italy, ¹⁰The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, China, ¹¹Boston Biomedical, Cambridge, Massachusetts, USA, ¹²UZ Leuven-Campus Gasthuisberg, Leuven, Belgium

P-298

A phase II study of avelumab in MSI-H metastatic colorectal cancer patients

D Proszynski¹, M Winiarek², K Marcisz-Grzanka³, J Krynski⁴, J Zwolinski⁴, J Palucki⁵, A Cencelewicz-Lesikow¹, K Kokoszynska¹, L Wyrwicz⁶

¹M Skłodowska-Curie Memorial Cancer Center, Warsaw, Poland, ²Dept of Gastrointestinal Oncology, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland, ³Mria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland, ⁴Department of Gastrointestinal Oncology, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland, ⁵Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland, ⁶Centrum Onkologii-Instytut im. M. Skłodowskiej Curie, Warsaw, Poland

P-299

Predictive factors of complete pathological response in operated patients with locally advanced rectal cancer after chemoradiotherapy neoadjuvant treatment in Peru

R Motta, P Ybazeta, O Cordova, S Quiroz, A Figueroa, C Aliaga, R Salas, J Geronimo Edgardo Rebagliati Hospital, Lima, Peru

P-300

Predictive value of circulating tumor-derived DNA (ctDNA) in patients with locally advanced rectal cancer (LARC) treated with neoadjuvant chemoradiotherapy (CT-RT): Preliminary results

P Ravenda¹, G Gregato¹, M Rotundo¹, S Frassoni², V Dell'Acqua¹, C Trovato¹, W Petz¹, P Rafaniello Raviele¹, V Bagnardi², F Bertolini¹, M Zampino¹
¹European Institute of Oncology, Milan, Italy, ²University of Milan, Bicocca, Milan, Italy

P-301

CRP / albumin ratio can be a predictor of response to neoadjuvant chemoradiotherapy (CRT) in rectal cancer

T Yetisyigit¹, S Seber¹, A Yolcu²
¹Namik Kemal University Hospital, Tekirdag, Turkey, ²Tekirdag State Hospital, Tekirdag, Turkey

P-302

Pathological complete response after chemoradiotherapy in locally advanced rectal cancer: Capecitabine or 5-fluorouracil? Which is better?

X Hernández-Yagüe¹, E Canals-Subirats¹, G Mateu Esquerda², C Auñón Sanz¹, A Maroto Genover³, D Julià Bergkvist², N Gómez Romeu², M Osorio Fernández³, P Planellas Gine², B Queralt⁴, R Farrés-Coll⁵
¹Catalan Institute of Oncology Girona, Girona, Spain, ²Hospital Dr. Josep Trueta de Girona - Institut Català de la Salut, Girona, Spain, ³Institut Diagnòstic per la Imatge (IDI)-Hospital Dr. Trueta de Girona, Girona, Spain, ⁴Institut Català d'Oncologia Girona, Gerona, Spain, ⁵Hospital Dr. Josep Trueta de Girona- Institut Català de la Salut, Girona, Spain

P-303

Food intake and nutritional status of colorectal cancer patients undergoing radio-chemotherapy in Sardjito hospital

M Purba, H Winarti, R Pangastuti
Nutrition Department Sardjito Hospital, Jogjakarta, Indonesia

P-304

Preoperative chemoradiation in locally advanced rectal cancer: A single center experience

L Oliveira¹, A Rolo¹, C Carvalho¹, I Faustino¹, C Alpoim², C Calçada³, A Costa³, G Fonseca³, J Conde³, A Teixeira¹, C Fardilha³, P Costa³, C Coutinho¹

¹Department of Oncology, Hospital Senhora da Oliveira, Guimarães, Portugal,

²Department of General Surgery, Hospital da Senhora da Oliveira, Guimarães, Portugal,

³Department of Radiation Oncology, Hospital de Braga, Braga, Portugal

P-305

The role of adjuvant chemotherapy according to the status of surgical margin in rectal cancer patients who received preoperative chemoradiation and total mesorectal excision

S Sung¹, J Lee², S Kim², J Lee²

¹Department of Radiation Oncology, St. Vincent`s Hospital, College of Medicine, The Catholic University of Korea, SuWon, Republic of Korea, ²St. Vincent`s Hospital, College of Medicine, The Catholic University of Korea, Suwon, Republic of Korea

P-306

The relationship between primary tumor regression grade and lymph nodes status in local advanced rectal cancer after neoadjuvant chemoradiation therapy

H Ju¹, L Liu², W Wu¹, Y Cai¹, X Lu¹

¹Zhejiang Cancer Hospital, Hangzhou, China, ²Zhejiang cancer hospital, Zhejiang, China

P-307

Preoperative predictors for pathologic response and prognosis of rectal cancer after neoadjuvant chemoradiation

G Yoo¹, J Yu², H Park², D Choi², W Cho², Y Park³, J Park², H Lim⁴, W Kang², H Kim⁵, K Song¹

¹Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ²Samsung Medical Center, Seoul, Republic of Korea, ³Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Seoul, Republic of Korea, ⁴ Samsung Medical Center, Seoul, Republic of Korea, ⁵Department of General Surgery, Seoul, Republic of Korea

P-308

Comparison of incidence and survival outcomes in mucinous and signet-ring cell colorectal cancers with classical adenocarcinoma: A SEER analysis

T Mehmood

Northwest General Hospital and Research Centre, Peshawar, Pakistan

P-309

Quality improvement in the management of rectal cancer in a large healthcare system in the United States

W Sause

Intermountain Healthcare, Murray, Utah, USA

P-310

Diagnosis and selection of method of combined treatment of local-distributed cancer of the rectum with invasion into organs of the genitals

S Lukmonov¹, O Usmanov¹, K Madatov¹, U Allazarov¹, U Kurbankulov¹, M Ismailov²

¹Tashkent Medical Academy, Tashkent, Uzbekistan, ²Tashkent Pediatric Medical Institute, Tashkent, Uzbekistan

P-311

Comparison between the toxicity profile of fluorouracil versus capecitabine concomitant with radiotherapy in patients with non-metastatic rectal cancer

A Lotfy¹, M Yassin², G Rashwan³; A Nagy¹

¹Ain Shams University, Cairo, Egypt, ²Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt, ³Nasser Institute, Cairo, Egypt

P-312

Role of consolidative radiation therapy after surgery in patients with stage IV rectal cancer

T Mehmood

Northwest General Hospital and Research Centre, Peshawar, Pakistan

P-313

Nonstandard hypofraction radiotherapy in neoadjuvant chemo-radiation therapy of locally advanced rectal cancer

A Abdujapparov¹, S Tkachev², F Djuraev³, Y Ten¹

¹National Cancer Research Center, Tashkent, Uzbekistan, ²National Cancer Research Center, Moscow, Russian Federation, ³Tashkent Medical Academy, Tashkent, Uzbekistan

P-314

Prone vs supine position in patients with rectal cancer treated with volumetric arc therapy and concurrent chemotherapy

L Diaz Gomez¹, A Seguro Fernandez², P Ramirez Daffos³, J Tisairé⁴, J Jaen Olasolo¹

¹HU Jerez , Jerez de la Fra, Spain, ²H. Jerez, Jerez de la Fra, Spain, ³HU Puerta del Mar, Cadiz, Spain, ⁴Hospital de Jerez, Jerez de la Fra, Spain

P-315

The role of palliative re-irradiation in management of rectal cancer

T Janjua¹; M Hingorani², R Cooper³, P Hatfield³, N Casanova³, M Williams¹, M Teo³, D Sebag-Montefiore⁴

¹St James University Hospitals, Leeds, UK, ²St James University Teaching Hospitals , Leeds, UK, ³St James University Hospital , Leeds, UK, ⁴University of Leeds, Leeds, UK

P-316

Is there any association of dose received by pelvic bone marrow in preoperative radiotherapy in rectal cancer with hematological toxicity of subsequent oxaliplatin-based chemotherapy?

M Spalek¹, W Michalski², K Bujko³, L Wyrwicz⁴

¹M Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland, ²Laboratory of Bioinformatics and Biostatistics, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland, ³Dept of Radiotherapy, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland, ⁴Centrum Onkologii-Institut im. M. Sklodowskiej Curie, Warsaw, Poland

P-317

A single centre experience of in-field recurrence following pre-operative radio(chemo)therapy in patients with rectal cancer

O Coen¹, L Karsera¹, N Tambe¹; R Roy²

¹Hull & East Yorkshire NHS Trust, Cottingham, UK, ²Queen's Centre of Oncology & Haematology, Hull, UK

P-318

Laparoscopic technologies in the treatment of patients with locally advanced rectal cancer: The possibilities and prospects

S Khoshimov

Tashkent Medical Academy, Tashkent, Uzbekistan

P-319

Long term efficacy results from the phase II CRAB trial: Neoadjuvant bevacizumab, capecitabine and radiotherapy in locally advanced rectal cancer

V Velenik¹, M Omejc², J Ocvirk¹, I Edhemović¹, F Anderluh¹, I Oblak¹, J But-Hadžić¹

¹Institute of Oncology, Ljubljana, Slovenia, ²University Medical Centre , Ljubljana, Slovenia

P-320

Pilot trial of YIV-906 with neoadjuvant chemoradiotherapy (CRT) in patients with locally advanced rectal cancer

K Johung¹, B Kann¹, J Lacy², S Stein³, J Kortmansky¹, W Zaheer¹, Y Cheng¹, W Lam¹, S Liu¹, R Decker¹, H Hochster⁴, S Higgins¹

¹Yale University School of Medicine, New Haven, Connecticut, USA, ²Yale Cancer Center, New Haven, Connecticut, USA, ³Yale University Cancer Center, New Haven, Connecticut, USA, ⁴Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA

P-321

Profile of neurotoxicity of oxaliplatin in young versus elderly patients treated for colorectal carcinoma

H Aliane¹, S Ghomari-Bezzar²

¹Medical Oncology Department, CHU Tlemcen Faculte de Médecine, Laboratoire Toxicomed, Université de Tlemcen, Tlemcen , Algeria, ²Medical Oncology Department, CHU Tlemcen, Faculte de Medecine, Laboratoire Toxicomed, Universite de Tlemcen, Tlemcen, Algeria

P-322

First study in North Africa: Screening colorectal cancer

C Mazouzi¹; K Bouzid²

¹CHU Bejaia, Bejaia, Algeria, ²CPMC Algiers Algeria, Algiers, Algeria

P-323

Perioperative treatment of gastric cancer: FLOT or not

F Djuraev¹, A Abdujapparov², N Atakhanova¹

¹Tashkent Medical Academy, Tashkent, Uzbekistan, ²National Cancer Research Center, Tashkent, Uzbekistan